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Drug discovery
Today, most drugs are small molecule drugs, as exempliied by pain killers such as paracetamol 
and aspirin, but also by antibiotics, antidepressants and many others. The active substance of 
these drugs can be easily formulated into tablets for oral administration. Once the tablet reaches 
the gastrointestinal tract, the tablet disintegrates and the active substance is released and taken 
up from the intestine into the bloodstream from where it can circulate to the site of action.
Especially in the past, many drugs were discovered by serendipity instead of a rational design. 
When for a certain compound a therapeutic effect was observed, the compound was chemically 
modiied in such a way that the side effects were reduced leading for example to the development 
of paracetamol [1, 2]. 
With an increasing understanding of molecular processes, in the late 1990s a transition took place 
towards a target-oriented drug discovery. After the identiication and validation of a therapeutic 
target, a small molecule that interferes with the function of this target, a so-called “hit”, is 
identiied by high-throughput screens and is then chemically optimized to increase activity, reduce 
potential side-effects and enable formulation as an orally available drug. 
Even more than the serendipity-based approach, also this target-oriented search has been guided 
by rules on certain physico-chemical characteristics to enable oral bioavailability. Characteristics 
such as having a molecular weight of less than 500 Dalton and a certain degree of lipophilicity 
which enables the circulation through the blood as well as passive diffusion into cells deine these 
molecules as “drug-like” [3]. These basic requirements for a drug are still the starting point for 
drug discovery in the area of small molecules, though many small molecule drugs on the market 
violate these rules. 
Protein therapeutics
Since proteins are major players in numerous essential processes in our body, this class of molecules 
comprises most therapeutic targets. Targeting proteins with small molecules is, however, 
sometimes dificult because the small molecules are, due to their small surface area, only able 
to interact with high afinity by binding into speciic hydrophobic pockets of a protein [4]. Since 
many protein interactions occur via large and lat molecular surfaces, these are therefore dificult 
to disrupt with small molecules. Therefore, for many potential therapeutic targets alternatives for 
small molecules are required.
An alternative to small molecule drugs are protein and peptide therapeutics. These therapeutics 
belong to the group of the so-called “biologics” or “therapeutic biological applications” (BLA). 
According to the federal drug administration (FDA), a biologic is deined as a “virus, therapeutic 
serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or 
analogous product, … applicable to the prevention, treatment, or cure of a disease or condition 
of human beings” [5]. However, whereas small molecules are able to target extracellular as well 
as intracellular targets, protein therapeutics are restricted to extracellular targets because they are 
usually not able to cross the plasma membrane. 
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The number of biologics has increased enormously: in 2013 four of the top 10-best selling drugs 
were biologics among which the most successful one was Humira, a monoclonal antibody against 
tumor necrosis factor (TNF) receptor, for the treatment of rheumatoid arthritis [6]. Monoclonal 
antibodies such as Herceptin for breast cancer which are targeting receptors being overexpressed 
in cancer cells belong to the best-selling drugs as well [7].
When directly comparing protein therapeutics with small molecules, there are several advantages 
of protein therapeutics [8]. The fact that protein therapeutics, in particular antibodies, can have 
a 300 times larger molecular weight than small molecules implies the possibility for a much more 
extended interaction surface of protein therapeutics compared to small molecules (Figure 1). As 
a consequence, protein therapeutics can better mimic the naturally occurring interaction which 
reduces the non-speciic off-target effects. 
A further advantage of antibodies is that they have a longer half-life in the blood since they are too 
large to be cleared by the kidney leading to monthly doses of antibody therapeutics as compared 
to daily doses of most small molecule drugs [9]. The biggest problem with protein therapeutics is 
that they have to be injected which is much less convenient for the patient compared to taking 
pills.
8 
 
therapeutics c n better mimic the naturally occurring interaction which reduces the non-specific off-target 
effects. 
A further advantage of antib dies is that they have a longer h lf-life in the blood since they are too large 
t  be cleared by the kidney leading to monthly doses of antibody therapeutics as compared to daily doses 
of most small molecule drug  [9]. The biggest problem with protein therapeutics is that they have to be 
injected which is much less convenient for the patient compared to taking pills. 
 
 
Figure 1: Herceptin Fab fragment (PDB file: 1N8Z) versus paracetamol (4A9J). Image was prepared with 
Yasara [10]. For the Fab fragment the peptide backbone is displayed as a ribbon with the secondary structure 
elements β-strands and α-helices displayed in red and blue, respectively. 
 
Although some successful small molecule inhibitors of protein-protein interactions have been described 
[11], protein therapeutics often work more efficiently in this area of application. One example is the direct 
comparison of the small molecule inhibitor nutlin [12, 13] and the peptide inhibitor ATSP-7041 [14, 15] 
(Figure 2). ATSP-7041 is a so-called “stapled peptide”. By stapling the peptide, the α-helical secondary 
structure, that mimics the surface of the protein-protein interaction domain, is conformationally 
constrained which is entropically favorable for the interaction. The targets of this stapled peptide are the 
proteins MDM2 and MDMX which inhibit the tumor suppressor p53. p53 is an important player in the 
development of cancer [16, 17]. When disrupting the interaction between p53 and these proteins, p53 can 
be reactivated. However, whereas the nutlins can only bind to MDM2 [12, 13], the stapled peptide ATSP-
7041 binds to both proteins with higher affinities resulting in a more efficient inhibition of tumor growth. 
Figure 1: Herceptin Fab fragment (PDB ile: 1N8Z) versus parac tamol (4A9J). Image w s prepared 
with Yasara [10]. For the Fab fragment the peptide backbone is displayed as a ribbon with the secondary 
structure elements β-strands and α-helices displayed in red and blue, respectively.
Although some successful small molecule inhibitors of protein-protein interactions have been 
described [11], protein therapeutics often work more eficiently in this area of application. 
One example is the direct comparison of the small molecule inhibitor nutlin [12, 13] and the 
peptide inhibitor ATSP-7041 [14, 15] (Figure 2). ATSP-7041 is a so-called “stapled peptide”. By 
stapling the peptide, the α-helical secondary structure, that mimics the surface of the protein-
protein interaction domain, is conformationally constrained which is entropically favorable for 
General introduction  |  13
1
the interaction. The targets of this stapled peptide are the proteins MDM2 and MDMX which 
inhibit the tumor suppressor p53. p53 is an important player in the development of cancer [16, 
17]. When disrupting the interaction between p53 and these proteins, p53 can be reactivated. 
However, whereas the nutlins can only bind to MDM2 [12, 13], the stapled peptide ATSP-7041 
binds to both proteins with higher afinities resulting in a more eficient inhibition of tumor 
growth.
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Figure 2: Structures of Nutlin-3a [13] and the stapled peptide ATSP-7041 [14]. 
 
 
Drug delivery vectors  
In the past years, intensive research has been directed towards drug delivery which aims at increasing the 
efficiency of drugs. Drug delivery encompasses several levels: protecting the drug from degradation, 
targeting it to the site of action and increasing uptake into the target cells. Depending on the drug and its 
target, a drug delivery vector may incorporate only one or several of these functionalities. 
Nanoparticles composed of lipids (liposomes) and/or polymers such as poly(lactic-co-glycolic acid) 
(PLGA) are promising vehicles for targeted drug delivery. PLGA is frequently used as drug delivery 
vector because it is biodegradable, can protect the drug from degradation, the physicochemical 
characteristics can be tuned by changing the relative amounts of lactic and glycolic acid enabling the 
encapsulation of various drugs, a sustained release of the drug is possible and it is already approved by 
the FDA [18]. Some PLGA-based drugs are already used in the clinics; the applications range from 
bipolar disorders (Risperdal Consta) to diabetes (Bydueron) and protstate cancer (Lupron Depot). In 
particular, by using nanoparticles the targeting to tumors can be increased because of a longer circulation 
time and the enhanced permeability and retention (EPR) effect of tumors [19], which is caused by the 
leaky endothelial vasculature of the tumor tissue. For instance, the chemotherapeutic drug doxorubicin 
was formulated into pegylated liposomes, thereby reducing toxicity and achieving tumor accumulation 
[20, 21]. Another advantage of using nanoparticles for drug delivery is the potential for a custom-made 
functionalization of the drug-encapsulating particles; the nanoparticles can be decorated with molecules 
such as receptor ligands or antibodies to achieve tissue- or cell-specific targeting. 
The preferred route of drug delivery is oral administration with the major challenge of the passage of the 
oral or intestinal epithelial barrier. As one example for the implementation of an oral drug delivery 
strategy for a biologic, in 2013, insulin-containing nanoparticles targeting the neonatal Fc receptor were 
shown to cross the barrier more efficiently than nanoparticles without Fc fragments [22] leading to a 
stronger hypoglycemic effect in mice.  
If the therapeutic targets reside inside the cells, as it is the case for therapeutic oligonucleotides, siRNA 
and for the application of proteins and peptides against intracellular targets, the delivery poses a 
Figure 2: Structures of Nutlin-3a [13] and the stapled peptide ATSP-7041 [14].
r  livery vectors 
In the past years, intensive research has been directed towards drug delivery which aims at 
increasing the eficiency of drugs. Drug delivery encompasses several levels: protecting the drug 
from degradation, targeting it to the site of action and increasing uptake into the target cells. 
Depending on the drug and its target, a drug delivery vector may incorporate only one or several 
of these functi nalities.
Nanoparticles composed of lipids (liposomes) and/or polymers such as poly(lactic-co-glycolic acid) 
(PLGA) are promising vehicles for targeted drug delivery. PLGA is frequently used as drug delivery 
vector because it is biodegradable, can protect the drug from degradation, the physicochemical 
characteristics can be tuned by ch nging th  relative amounts of lactic and glycolic acid enabling 
the enc psulation of various drugs, a sustained release of the drug is possible nd it is already 
approved by the FDA [18]. Some PLGA-based drugs are already used in the clinics; the applications 
range from bipolar disorders (Risperdal Consta) to diabetes (Bydueron) and protstate cancer 
(Lupron Depot). In particular, by using nanoparticles the targeting to tumors can be increased 
because of a longer circ lation time a d the enhanced permeability and retention (EPR) effect 
of tumors [19], which is cause  by the l aky endothelial vascula ure of the tumor tissue. For 
14  |  Chapter 1
instance, the chemotherapeutic drug doxorubicin was formulated into pegylated liposomes, 
thereby reducing toxicity and achieving tumor accumulation [20, 21]. Another advantage of 
using nanoparticles for drug delivery is the potential for a custom-made functionalization of the 
drug-encapsulating particles; the nanoparticles can be decorated with molecules such as receptor 
ligands or antibodies to achieve tissue- or cell-speciic targeting.
The preferred route of drug delivery is oral administration with the major challenge of the 
passage of the oral or intestinal epithelial barrier. As one example for the implementation of an 
oral drug delivery strategy for a biologic, in 2013, insulin-containing nanoparticles targeting the 
neonatal Fc receptor were shown to cross the barrier more eficiently than nanoparticles without 
Fc fragments [22] leading to a stronger hypoglycemic effect in mice. 
If the therapeutic targets reside inside the cells, as it is the case for therapeutic oligonucleotides, 
siRNA and for the application of proteins and peptides against intracellular targets, the delivery 
poses a considerable challenge since the biologics are not able to cross the plasma membrane. 
One possibility to improve the cellular uptake of biologics is the use of cell-penetrating peptides 
(CPPs) which can be coupled to drug-encapsulating nanoparticles or the drug itself. 
Cell-penetrating peptides
The discovery of CPPs was rather by coincidence than by a hypothesis-based approach. Alan 
Frankel was developing an assay in order to measure the activity of the Tat-protein of the human 
immumodeiciency virus (HIV) which is a transcription factor [23]. He made transient small holes 
into the plasma membrane by “scrape-loading” to deliver the protein into the cells since proteins 
are normally by themselves not able to be internalized by cells. To his very surprise the damaging 
of the membrane was not required to deliver the protein. Tat could enter the cells by itself. Almost 
at the same time, a different research group found that the antennapedia protein of Drosophila 
melanogaster [24] was also internalized by cells. The minimal sequences of these proteins being 
essential for eficient internalization were identiied and then became the irst CPPs, namely 
penetratin [25] and Tat [26]. In 1999, it was shown that the conjugation of the Tat peptide to a 
protein resulted in eficient protein delivery into cells also in vivo [27]. Since then, the number 
of CPPs has been increasing enormously. As one line of investigation, the CPP research became 
inspired by viruses and toxins which exert their activity inside cells and thus evolved ways to 
overcome the plasma membrane. CPPs which have a viral origin are for example a Vpr-derived 
peptide [28] and the aforementioned Tat peptide [26] from HIV and Erns which is derived from a 
pestivirus [29]. The most prominent example of the toxins is maurocalcine [30] which is derived 
from a scorpion venom. In addition, cationic antimicrobial peptides also have cell-penetrating 
activity like lactoferricin [31, 32] and buforin [33]. 
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Table 1: Sequences of the cell-penetrating peptides used in this thesis [34]
peptide sequence class origin
hLF KCFQWQRNMRKVRGPPVSCIKR-NH
2
cationic Human lactoferrin 
[31]
penetratin RQIKIWFQNRRMKWKK-NH
2
cationic,
amphipathic
Antennapedia homeodomain [25]
R9 RRRRRRRRR-NH
2
cationic,
Arginine-rich
synthetic 
[35]
TP10 AGYLLGKINLKALAALAKKIL-NH
2
cationic,
amphipathic
Galanin and mastoparan [36]
1All peptides were N-terminally labeled with luorescein and the C-terminus was amidated. 
Table 2: CPP-conjugates in clinical trials [38]. Table was adapted from [39, 40].
Company & 
Compound
CPP target disease status
ClinicalTrials.
gov identiier
Xigen  
XG-102a Tat JNK inhibitor
Inlammation
Pain
Cataract
III recruiting NCT02235272
AM-111b Tat JNK inhibitor Hearing loss II completed NCT00802425
XG-104 Tat JNK inhibitor Dry eye II recruiting NCT02235259
Capstone Therapeutics      
AZX100c PTD4 
TGF-β-induced expression of 
connective tissue growth factor
Scar prevention/
reduction
II completed NCT00825916
KAI Pharmaceuticals      
KAI-9803d Tat PKCδ inhibitor Myocardial 
infarction
II completed NCT00093197
KAI-1678e Tat PKCε inhibitor Pain II completed
NCT01106716 
NCT01135108 
NCT01015235
KAI-1455 Tat PKCε inhibitor Ischemia I N/A
Revance Therapeutics      
RT001f Tat
blocks neuromuscular 
transmission
Transdermal 
delivery of 
botulinum toxin
II completed NCT00907387
RT001 Tat Sweat glands Hyperhidrosis I completed N/A
CDG Therapeutics        
p28g p28 Inhibitor of p53 ubiquitination
Refractory solid 
tumors
I completed NCT00914914
a[41], b[42-44], c[45], PTD4 is an alanine-rich variant of Tat [46], d[47], e[48, 49], f[50], 
gp28 is a peptide derived from the redox protein azurin [51]
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There is not one speciic deinition of a CPP but in general these peptides may be considered as 
peptides of eight to thirty amino acids. Most CPPs are cationic or cationic and amphipathic (Table 
1). In a recent review, CPPs were categorized into three different groups based on their physico-
chemical characteristics: hydrophobic, amphipathic and cationic peptides [37]; the majority of all 
groups have a net positive charge (83%). 
Some CPP-conjugates are already in clinical trials (Table 2). In particular, a Tat-JNK-inhibitor for the 
treatment of pain, inlammation and cataract is promising since it is entering phase 3. 
Interactions with the cell surface
The internalization eficiency of drug delivery vehicles is always a function of the interaction of 
the vehicle with the components of the cell surface and the reaction of the cell towards this 
interaction. Molecular components of the cell surface are the lipids of the plasma membrane, 
the glycocalyx and receptors. In general, the plasma membrane consists of phospholipids; the 
major lipids are phosphatidylcholine, -ethanolamine and sphingomyelin in the outer lealet and 
phosphatidylserine, -ethanolamine and –inositol in the inner lealet and cholesterol which is 
present in both layers [52] (Figure 3). Proteins such as receptors, glycoproteins, and glycolipids are 
embedded into or associated with the lipid bilayer. Since the lipids are not attached to a certain 
scaffold, they are able to laterally diffuse within the lipid bilayer resulting in fast local changes 
of the lipid composition and providing a basis for protein clustering. The lipids and proteins 
are organized into small microdomains, such as lipid rafts, which are more rigid cholesterol-rich 
structures being enriched in sphingomyelin [52] (Figure 3). Lipid rafts are involved in cellular 
signaling processes which is due to the fact that the local enrichment of certain proteins and 
lipids in these rafts is associated with the activation of signaling processes, for example receptor 
tyrosine kinase signaling [52]. 
So far, there is only limited knowledge about the structural requirements of the membrane for 
the eficient internalization of drug delivery vectors. Especially, insights into the requirements 
on the lipid level are scarce. We demonstrated that ceramide, which is formed by hydrolysis 
of sphingomyelin, provides entry points for a highly eficient internalization of CPPs [53]. In 
another study, it was shown that amphipathic cell-penetrating peptides bind preferably to anionic 
lipids [54]. Considerable research has been performed on the involvement of the glycocalyx, in 
particular glycosaminoglycans, in the internalization of drug delivery vectors which is reviewed 
in chapter 2 [55]. The only proteins which were described to be involved in the internalization 
of cell-penetrating peptides are scavenger receptors for complexes composed of CPPs and 
oligonucleotides [56] and the chemokine receptor CXCR4 [57].
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Figure 3: Structure of the the plasma membrane. The plasma membrane is permeable for small lipophilic 
molecules, but not for large polar macromolecules, like proteins and oligonucleotides. The distribution of 
phospholipids is asymmetric for both lipid layers. In particular, phosphatidylserine is only present in the intracellular 
leaflet. Transmembrane proteins are embedded in the lipid bilayer.  
 
 
Structural requirements of CPPs 
Numerous analyses of structure-activity relationships have been performed resulting in a good 
understanding of general structural features of cell-penetrating peptides. The most important one is the 
requirement for basic amino acids, like arginine and lysine. Even though some negatively charged CPPs 
have been reported [58, 59], in the published work these peptides showed activity only at much higher 
concentrations than the standard positively charged CPPs and thus their relevance may be questioned. 
Several studies have described that arginine-rich peptides are more effective CPPs than the lysine-rich 
variants which was explained by the possibility of the guanidinium-group of arginine to form bidentate 
bonds with the anionic components of the plasma membrane, such as the glycosaminoglycans of the 
glycocalyx, phosphate-groups of the polar lipid head groups and aspartic and glutamic acid side chains of 
proteins [60-62]. Based on these findings, new CPPs were designed, among which the polyarginine 
peptides are one of the most prominent and efficient CPPs containing at least six arginine residues.  
Furthermore, arginine was shown to be not only involved in electrostatic but also hydrophobic 
interactions which contribute to uptake [63]. How the conformational orientation, for example cyclization 
of arginine is influencing the uptake efficiency will be described in detail in chapters 5 and 6. Next to 
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r s lys s of structure-activity relationships have be n performed resulting in a good 
understanding of general structural features of cell-penetrating peptides. The most important one 
is the requirement for basic amino acids, like arginine and lysine. Even though some negatively 
charged CPPs have been reported [58, 59], in the published work these peptides showed activity 
only at m ch high r concentrations than the standard positiv ly charg d CPPs d thus their 
relevance may be questioned. Several studies have described that arginine-rich peptides are 
more effective CPPs than the lysine-rich variants which was explained by the possibility of the 
guanidinium-group of arginine to form bidentate bonds with the anionic components of the 
plasma membrane, such as the glycosaminoglycans of the glycocalyx, phosphate-groups of the 
polar lipid head groups and aspartic and glu amic acid sid  chains of proteins [60-62]. Based on 
these indings, new CPPs were designed, among which the polyarginine peptides re one of the 
most prominent and eficient CPPs containing at least six arginine residues. 
Furthermore, arginine was shown to be not only involved in electrostatic but also hydrophobic 
interactions which contribute to uptake [63]. How the conformational orientation, for example 
cyclization of arginine is inluencing the uptake eficiency will be described in detail in chapters 
5 and 6. Next to basic amino acids, the hydrophobic amino acid tryptophan was shown to have 
a positive effect on uptake [64] since it can engage in hydrophobic interactions with the plasma 
membrane and destabilize the membrane by intercalating into the lipid bilayer [65]. 
Mechanism of uptake
In general, the route of uptake of a CPP is a function of the identity of the peptide, cell type, 
concentration and the (drug) molecule it is conjugated to [66-69]. Three different routes of 
internalization have been described for the entrance of arginine-rich CPPs which were reviewed 
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recently [70]. In HeLa cells at peptide concentrations lower than 2 µM, peptides passively 
diffuse across the plasma membrane, whereas at concentrations ranging from 2 to 10 µM, 
glycosaminoglycan-dependent endocytosis occurs [71]. The involvement of glycosaminoglycans 
was long regarded as an essential requirement for the internalization of cationic CPPs since 
these are the irst molecules the CPPs can electrostatically interact with when approaching a cell. 
However, stimulatory as well as inhibitory effects of glycosaminoglycans on the internalization 
eficiencies of CPPs were described, depending on the characteristics of CPPs which are reviewed 
in chapter 2. 
The bottleneck of uptake via endoytosis in the cytoplasmic delivery of molecules is the entrapment 
in endosomal vesicles requiring endosomal escape in order to reach the cytoplasm [72]. Therefore, 
various approaches to enhance endosomal release have been explored. One strategy to promote 
the endosomal release of CPPs is the insertion of histidine residues into the peptide which become 
protonated at the low pH in the endosomes and lysosomes resulting eventually in the rupture of 
the endosomes and the release of the contents into the cytosol through a phenomenon described 
as the proton sponge effect [73]. 
At higher peptide concentrations, for some cell lines uptake occurs via a mechanism, either 
referred to as transduction or nucleation zones [69, 74, 75]. Here, the peptide is accumulating 
at certain areas at the plasma membrane (nucleation zones) resulting in a rapid uptake into the 
whole cell. This mechanism is characterized by the presence of ceramide-rich platforms at the 
sites of the nucleation zones, which are formed by acid sphingomyelinase [53]. This mechanism is, 
however, restricted to low molecular weight molecules [69]. Better insights into the mechanistic 
details of this pathway, in particular the activation of acid sphingomyelinase, would enable 
the development of new peptides or other compounds which speciically trigger this pathway, 
thereby circumventing the problem of endosomal entrapment. 
Given the fact that the lipid bilayer is very hydrophobic, the question remains how the cationic 
peptides cross the plasma membrane. Molecular dynamics simulations for the Tat peptide 
showed that the strong electrostatic interactions between arginine and lysine residues with the 
phosphate groups lead to a deformation of the membrane with subsequent pore formation [76]. 
The relevance of this model for uptake via nucleation zones was not investigated yet and it is also 
not clear how relevant this model is for the uptake of CPPs in general, as in most cases uptake 
via endocytosis occurs.
Aims and outline of the thesis
The aim of this thesis was to better understand the structural features of cell-penetrating peptides 
and the plasma membrane that govern the initial interaction and subsequent internalization into 
cells. Next to contributing to the fundamental understanding of how these molecules achieve 
uptake, these insights will help in the development of cell- or tissue-speciic targeting of peptides 
and drugs.
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In chapter 2, the role of glycosaminoglycans in the uptake of cationic drug delivery vectors is 
reviewed. So far, the research on the uptake mechanism of cell-penetrating peptides on the 
one hand and complexes of lipids or polymers with oligonucleotides (lipoplexes and polyplexes) 
on the other hand has been two different lines of research. By critically reviewing the available 
data, we were able to identify common characteristics for the involvement of the anionic 
glycosaminoglycans in the entrance mechanisms of both types of delivery vehicles. By comparing 
these characteristics with the role of glycosaminoglycans in the uptake of viruses, the review 
strongly suggests that glycosaminoglycans alone are not suficient for triggering the uptake of 
cationic drug delivery vectors but that other components of the plasma membrane are probably 
involved as well. 
Chapters 3 and 4 focus on cell-penetrating peptides and show that the role of glycosaminoglycans 
in the uptake mechanism strongly depends on the type of CPP. In chapter 3, for an arginine-rich 
CPP, a positive effect of the glycosaminoglycans on the uptake eficiency is described. By means 
of a detailed thermodynamic analysis of the CPP-glycosaminoglycan interaction, a negative 
correlation between stoichiometry of binding and the uptake eficiency was revealed indicating 
that the clustering of glycosaminoglycans is a trigger for uptake. Chapter 4 demonstrates that 
this correlation is not a general concept in the uptake mechanisms of CPPs. Here, structural 
variants of an amphipathic CPP were compared and it was revealed that in this case clustering 
of glycosaminoglycans did not correlate with uptake eficiency. Instead, the glycosaminoglycan 
clusters could be considered as aggregates which were too large to be internalized. 
In chapter 5 more insight is gained into the uptake mechanism of arginine-rich cell-penetrating 
peptides. By comparing two different cell lines, we show that for cells with a low sphingomyelin 
content, direct membrane permeation occurs while for cells with a high content of sphingomyelin, 
direct penetration across the plasma membrane depends on the conversion of sphingomyelin 
into ceramide. 
In chapter 6, an analysis of a structure-activity relationship elucidates structural principles of 
bicyclic peptides as cell-penetrating peptides. By introducing arginine residues into a bicyclic 
scaffold, the peptides entered cells eficiently and had the advantage of being more stable than 
the linear counterparts. 
Chapter 7 describes a strategy for the activation of short oligoarginine peptides which by 
themselves are inactive as cell-penetrating peptides. In this application, the short oligoarginines 
contain a terminal cystein residue and are rendered cell-permeable by dimerization via disulide 
bridge formation. 
In chapter 8, the indings are summarized and future directions are provided.
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ABSTRACT
The implementation of eficient strategies for cellular delivery is the most signiicant hurdle in 
the development of oligonucleotide and protein-based nanomedicines. Unlike small molecule 
drugs that enter cells by virtue of hydrophobicity or by being substrates of transporters, these 
macromolecules lack the capacity to cross the plasma membrane in a non-disruptive way, 
therefore requiring the combination with carriers that mediate entry. Remarkably, for the major 
part, these carriers lack distinct structural features except for a high density of positive charge. 
Uptake has been attributed to the ability to engage in electrostatic interactions with the lipid 
bilayer and negatively charged glycosaminoglycans (GAGs) of the cellular glycocalyx. However, 
conlicting evidence has been obtained to which degree the interaction with GAGs contributes 
to uptake and the molecular mechanisms involved in uptake. Also, it is not clear to which extent 
the same molecular mechanisms apply for the different types of cationic delivery vectors. Here, 
we review the available data for cationic delivery vectors, including lipoplexes, polyplexes and cell-
penetrating peptides (CPPs). We show that in spite of their different molecular size and degree 
of positive charge, all types of vectors share major characteristics with respect to the suggested 
role of GAGs in uptake. Moreover, by a comparison with the role of heparan sulfates in viral 
uptake we propose new avenues in the search for molecular mechanisms that trigger uptake of 
drug delivery vehicles and discuss how these insights may translate into new design principles for 
nanomedicines.
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INTRODUCTION
The lipid bilayer of the plasma membrane forms the boundary between the inside and the outside 
of a cell. However, molecules approaching a cell will irst encounter a layer of oligosaccharides 
that can take the form of a dense glycocalyx as thick as 2 – 4.5 µm for capillary endothelial cells 
[1]. This glycocalyx is formed by the N- and O-linked glycosylation of the extracellular domains of 
transmembrane and membrane-associated proteins in which the terminal structures can contain 
the negatively charged sialic acid and sulfated sugars [2, 3]. In particular, the proteoglycans carry 
large O-linked oligosaccharides consisting of highly negatively charged repeating disaccharide 
units, the glycosaminoglycans (GAGs), such as the heparan sulfates (HS). 
The glycocalyx fulils numerous functions ranging from an impact on the elastic behavior of 
the plasma membrane and the cell in its tissue context to the modulation of the local ionic 
environment through binding of water and counter ions [4, 5]. Next to these non-speciic 
functions, the glycocalyx also provides binding sites for growth factors and thus inluences the 
cellular microenvironment with respect to cell proliferation and differentiation. Basic ibroblast 
growth factor 2 may be considered the paradigmatic example for a role of the glycocalyx in 
growth factor function, as activity of this growth factor towards its receptor depends on the 
simultaneous binding to HS [6]. 
Next to growth factors, the glycocalyx has also been associated with the cellular binding and 
uptake of several viruses. In this context, the question has been addressed to which extent 
binding of these pathogens to the glycocalyx by itself triggers intracellular signaling leading to 
uptake or whether binding to the glycocalyx promotes uptake by inducing proximity to receptors 
involved in uptake [7-10]. 
Also for polycationic nanoparticles and cationic cell-penetrating peptides (CPPs), binding to GAGs 
has been linked to uptake [11]. Nanoparticulate delivery systems share with viruses the size and 
capacity to engage in multivalent interactions. Yet, they lack speciic domains for cell surface 
receptors that control cell tropism and triggering of uptake for most viruses. A comparison 
of viruses and nanoparticles should therefore help to reveal functions that GAGs can exert by 
themselves and point towards molecular mechanisms that so far have been overlooked in the 
uptake of nanoparticles. 
CPPs, which are peptides of about 8 to 30 amino acids in size [12], do not interact with speciic 
receptors. The current mechanistic framework for induction of uptake comprises cross-linking of 
heparan sulfates which then induces activation of small GTPases that lead to actin reorganization 
followed by endocytosis [13]. In spite of its appeal, evidence to support this model is still 
fragmentary and a number of observations do not it into this concept. Moreover, one should 
note that whenever a reduction of uptake by heparan sulfates has been reported, this reduction 
varied between only 20 and 80 % [14, 15]. 
The current state of knowledge therefore warrants a critical evaluation of the available data and 
concepts of the role of GAGs. In fact, the available data supports three different hypotheses 
for the role of GAGs in uptake: (i) GAGs cluster upon ligand binding which then drives uptake, 
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(ii) GAGs bind the ligand and then cocluster with (a) receptor(s) and (iii) GAGs are involved as 
coreceptors of unknown receptor(s) binding the ligand at the surface and bringing it in close 
proximity to the receptor. 
In this article, we review the latest indings in the light of any of these three hypotheses. 
Following an overview of the structure and function of GAGs and associated proteins, we will 
review the evidence that links GAG binding to uptake of CPPs and polyplexes. We will then 
provide a synthesis of the individual concepts to identify commonalities but also aim to stimulate 
a cross-validation by motivating experiments that test concepts across types of vectors. We will 
also discuss the GAG dependence of virus uptake as it may stimulate new avenues for research 
on the uptake mechanisms of the drug delivery vectors. 
A better understanding of the role of GAGs in uptake will be instrumental in the rational 
development of delivery vectors with higher eficacy and also a preference for certain cell types. 
Also, a clear understanding of the dependence of GAG binding and proteins involved in delivery 
may enable a prediction of the tissue tropism of delivery vectors. Based on such insight decisions 
on the incorporation of further targeting modalities, for example directed against certain cell 
surface receptors, can be made.
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Figure 1: Schematic representation of the disaccharide composition of different GAGs (heparan sulfate (HS), 
chondroitin sulfate (CS) and dermatan sulfate (DS)) linked to syndecan (SDC) and glypican, (GPC). These 
GAGs comprise a uniform tetrasaccharide core (Xylose-Galactose-Galactose-Glucoronic acid), covalently bound to 
a Ser/Thr residue of the core protein [20]. HS comprises an N-acetyl-glucosamine (GlcNAc) and a uronic acid (UA) 
residue and undergoes modification reactions via epimerization of some glucoronic acid units to iduronic acid. 
Furthermore, sulfation can occur at different positions within the polymer, including N-deacetylation and N- and O-
sulfation of the N-acetylglucosamine units (GlcNAc) [21]. These modifications generate various domain structures, 
e.g. for binding of FGF [22, 23]. CS and DS consist of repeating disaccharide units of N-acetyl-D-galactosamine 
(GalNAc) and D-glucuronic acid (GlcA) [24]. Also CS and DS can be modified by partial epimerization, sulfation 
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major groups of cell-associated HS proteoglycans which differ from each other in their core protein: the 
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possess any intracellular domain and by virtue of their membrane-proximal positioning of GAG chains, 
they are considered to work exclusively as co-receptors, as for fibroblast growth factor-2 (FGF-2), and as 
‘fine tuners’ of cell signaling [27, 28]. SDCs are transmembrane proteins and in human and other 
mammals four different SDCs have been described that differ in the nature of coupled oligosaccharides, 
structure of intracellular signaling domains and tissue distribution. In general, SDCs carry three to five 
HS chains and SDC-1 and -3 may also contain some CS/DS chains [29]. While SDC-4 is ubiquitously 
expressed, the other SDCs are only expressed on certain cell types: SDC-1 on epithelial and plasma cells 
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as cell adhesion and migration [29]. They have also been broadly associated with endocytosis of 
nanoparticulate systems and CPPs as recently reviewed by Belting [11]. Given their temporally and 
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Heparan sulfate proteoglycans – molecular structure and roles in cellular signaling and 
initiation of endocytosis
Heparan sulfate proteoglycans (HSPGs) comprise a diverse group of proteins that contain at 
least one covalently bound heparan sulfate (HS) glycosaminoglycan (GAG) chain and can carry 
chondroitin sulfate (CS) and dermatan sulfate (DS) (Figure 1) [16]. GAGs can consist of more 
than 150 repeating disaccharide units and the number of GAG chains attached to a protein 
core (10 kDa - 500 kDa) varies from one to more than 100, depending on the type of HSPG 
[17, 18]. The typical density of HS proteoglycans on the cell surface as measured in various cell 
culture systems are in the range of 105 to 106 molecules per cell [19]. The large number of further 
structural modiications, such as sulfation and acetylation, provides the possibility to create a 
large structural diversity and the basis for generating speciic domain structures which can be 
utilized for biological recognition of proteins [16]. 
With respect to a potential role as cellular attachment sites for CPPs, polyplexes and viruses, 
there are two major groups of cell-associated HS proteoglycans which differ from each other 
in their core protein: the glypicans (GPCs) and the syndecans (SDCs) (Figure 1). In contrast to 
syndecans, glypicans do not possess any intracellular domain and by virtue of their membrane-
proximal positioning of GAG chains, they are considered to work exclusively as co-receptors, 
as for ibroblast growth factor-2 (FGF-2), and as ‘ine tuners’ of cell signaling [27, 28]. SDCs 
are transmembrane proteins and in human and other mammals four different SDCs have been 
described that differ in the nature of coupled oligosaccharides, structure of intracellular signaling 
domains and tissue distribution. In general, SDCs carry three to ive HS chains and SDC-1 and 
-3 may also contain some CS/DS chains [29]. While SDC-4 is ubiquitously expressed, the other 
SDCs are only expressed on certain cell types: SDC-1 on epithelial and plasma cells and SDC-2 
on endothelial cells and ibroblasts [29]. SDCs are involved in various cellular processes, such as 
cell adhesion and migration [29]. They have also been broadly associated with endocytosis of 
nanoparticulate systems and CPPs as recently reviewed by Belting [11]. Given their temporally and 
spatially controlled expression patterns and the phenotypes of knock-downs, it is clear that SDCs 
exert important functions in development and tissue organization. However, it is dificult to deine 
whether the SDCs exert these functions in isolation or if they act as co-receptors through a local 
enrichment of growth factors via their GAG chains and signaling mediated by their C-terminal 
intracellular domain. This domain can serve as a scaffold for the organization and molecular 
interaction with signal transduction proteins that have an impact on cytoskeletal organization 
and initiation of endocytosis (Figure 2) [11, 29, 30]. A prominent feature of the intracellular 
domains of all SDCs is the presence of a C-terminal PDZ motif that binds to PDZ domain 
containing proteins [31]. Also for the other intracellular and transmembrane domains a variety 
of interactions has been reported [30]. Nevertheless, many of the reported interactions may be 
indirect. The most obvious link to autonomous signaling so far is the activation of protein kinase 
C by SDC-4 [32-34] leading to the activation of the small GTPases Rac, RhoA and Cdc42 which 
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are all involved in actin reorganization and thereby can induce the internalization of this HSPG. 
However, input from integrins may be required [35, 36]. Given that SDCs functionally synergize 
with other cell surface receptors, as for example integrins, the extent to which syndecans can be 
understood as true autonomous receptors capable of driving actin reorganization and uptake 
awaits further clariication.
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Figure 2: Syndecans as coreceptors in signaling. a) Link of HS chains on HSPGs and cytoskeletal reorganization 
as exemplified for FGF-2-dependent signaling by syndecans [6]. The HS chains of syndecan-1-4 HSPGs play an 
essential role in fibroblast growth factor (FGF) signaling via direct interaction of the GAGs with FGF and its 
receptor FGFR-1 [6, 37-39]. This interaction facilitates the formation of a ternary complex on the cell surface and 
consequent PLCγ and myosin II-mediated actin reorganization [40-43]. b) The presence of the extracellular matrix 
component fibronectin facilitates the coreceptor function of SDC-4 in fibronectin-induced integrin signaling. The 
cytoplasmic part of SDCs is divided into three domains: the conserved domains 1 and 2 (C1 and C2) and a variable 
(V) domain [44]. These domains contain recognition sites in C1, as for the ERM protein family, tubulin and 
cortactin. The C2 domain comprises a binding site for PDZ domain-containing proteins, e.g. syntenin, synectin, 
synbindin, and calcium/calmodulin- dependent serine protein kinase. The function of the V domain in SDC-1,-2,-3 
is largely unknown, whereas for SDC-4 a binding site for phosphatidylinositol-4,5-bisphosphate (PIP2) within the V 
domain was found to be responsible for binding of SDC-4 to PI-4,5-bisphosphate (PIP2) and protein kinase C-α 
(PKCα). This interaction activates PKCα, which in turn phosphorylates cytoplasmic proteins involved in focal 
adhesion formation and thereby links SDC-4 to the actin cytoskeleton and consequent reorganization [45-47]. 
 
Figure 2: Syndecans as coreceptors in signaling. a) Link of HS chains on HSPGs and cytoskeletal 
reorganization as exempliied for FGF-2-dependent signaling by syndecans [6]. The HS chains of syndecan-1-4 
HSPGs play an essential role in ibroblast growth factor (FGF) signaling via direct interaction of the GAGs with 
FGF and its receptor FGFR-1 [6, 37-39]. This interaction facilitates the formation of a ternary complex on the 
cell surface and consequent PLCγ and myosin II-mediated actin reorganization [40-43]. b) The presence of the 
extracellular matrix component ibronectin facilitates the coreceptor function of SDC-4 in ibronectin-induced 
integrin signaling. The cytoplasmic part of SDCs is divided into three domains: the conserved domains 1 
and 2 (C1 and C2) and a variable (V) domain [44]. These domains contain recognition sites in C1, as for 
the ERM protein family, tubulin and cortactin. The C2 domain comprises a binding site for PDZ domain-
containing proteins, e.g. syntenin, synectin, synbindin, and calcium/calmodulin- dependent serine protein 
kinase. The function of the V domain in SDC-1,-2,-3 is largely unknown, whereas for SDC-4 a binding site for 
phosphatidylinositol-4,5-bisphosphate (PIP2) within the V domain was found to be responsible for binding of 
SDC-4 to PI-4,5-bisphosphate (PIP2) and protein kinase C-α (PKCα). This interaction activates PKCα, which in 
turn phosphorylates cytoplasmic proteins i volved in f cal adhesion formation and thereby links SDC-4 to the 
actin cytoskeleton and con equent re ga ization [45-47].
Heparan sulfate proteoglycans in the uptake of CPPs
Structural determinants for HS binding. 
In spite of the evidence linking GAGs to uptake these molecules have never been considered 
as CPP receptors in the classical sense. To a large part, this notion may still be attributed to 
observations that were initially described as key characteristics of CPP uptake such as energy and 
chirality independence, and absence of saturation [48, 49]. However, in the meantime a large 
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body of evidence has been compiled that refutes each of these initial concepts. Importantly, 
GAGs have been associated with energy-dependent endocytosis (see below). Also the fact that 
oligoarginines bind to heparan sulfates with binding constants in the upper nanomolar range 
[50-52], suggests that GAGs may in fact be considered as CPP receptors raising the question 
whether speciic structural determinants for binding and induction of uptake exist.
For the interaction of cationic CPPs with GAGs, the number of positive charges and the number 
of arginines, in particular, were shown to be critical [15]. Studies conducted on the interaction 
of the Tat peptide with heavily sulfated saccharides (heparin, heparan sulfates and chondroitin 
sulfate) demonstrated that the number of binding sites per unit of molecular weight differed for 
the different types of GAGs and correlated roughly with the degree of sulfation [53]. Electrostatic 
forces between positively charged amino acid residues and negatively charged sulfates drive 
the peptide-sugar interaction, as demonstrated by a detailed analysis of the thermodynamics 
of binding of nonaarginine [51]. The dependence of the stoichiometry of binding on the degree 
of sulfation suggested charge neutralization as a molecular principle for binding; moreover, the 
authors hypothesized that nonaarginines can cluster HS. Along with electrostatic forces, hydrogen-
bonding and/or hydrophobic interactions were also reported to be involved in the interaction: 
for two penetratin variants, differing in the numbers of arginines and lysines, hydrophobic 
interactions were critical in the binding of the arginine-containing analog with heparin, while 
binding of the lysine-containing variant was mainly mediated by electrostatic interactions [54]. 
Moreover, for a series of penetratin analogs that differed in the number of tryptophans, there was 
a strong positive correlation between the number of tryptophan residues and afinity [55]. GAG 
binding led to the formation of aggregates in a tryptophan content-dependent manner and the 
degree of binding correlated with uptake. 
Remarkably, none of the studies investigating the interaction of CPPs with GAGs addressed 
the requirement for a speciic sequence motif. In comparison, in 1989, Cardin and Weintraub 
performed a screening of 21 HS-binding molecules and found that they all contained [XBBXBX] 
as a consensus sequence, with B corresponding to a basic amino acid and X corresponding to 
an arbitrary (or hydrophobic) amino acid [56]. For a CPP derived from human lactoferrin [52] 
this motif is present but not essential [57]. In fact, due to the high density of positively charged 
residues most cationic CPPs will more or less conform to this motif.
The role of HS in CPP uptake
The reduction in uptake upon enzymatic removal of heparan sulfate chains, and the poor 
internalization of CPPs in mutant Chinese hamster ovary (CHO) cell lines lacking either all GAGs 
or only HS [14, 15, 52, 57-59] support the notion that proteoglycans play a central role in the 
uptake of CPPs. However, it cannot be excluded that the GAG-deicient cell lines might also be 
defective in functions other than GAG synthesis which might affect uptake. Furthermore, the 
GAG-deiciency may have induced compensatory adaptations that may affect the results.
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Competition with dextran sulfates or heparin has also been employed to address the importance 
of the capacity of CPPs to interact with cell-surface heparan sulfates for uptake. Coincubation of 
cells with dextran sulfate or heparin decreased uptake eficiency [60]. However, this was also the 
case for Jurkat cells that are poor in HS [61]. Therefore, these experiments rather show that CPPs 
possess the capacity to bind to HS and that this binding reduces their uptake activity but do not 
reveal whether HS are essential for uptake.
Evidence has been presented that the role of GAGs is concentration dependent. Jiao and 
coworkers showed for penetratin and arginine-rich peptides that at low concentrations (1 µM), 
GAGs are by-passed, whereas at higher peptide concentrations, GAG-dependent endocytosis 
occurs [62]. 
In spite of this evidence in favor of a role of GAGs in uptake, there are also studies describing an 
inhibitory effect of GAGs [63] or sialic acid [64] in peptide uptake indicating that sequestering 
of peptides by GAGs or sialic acid may impede uptake. At this point, the basis for the reported 
discrepancies is not clear. 
The role of CPP-induced GAG clustering for uptake
CPPs possess the capacity to trigger endocytosis and clustering of HS has been associated with 
this activity [65, 66]. Even though the exact mechanism of HS clustering is still not understood, 
the general idea is that charge neutralization between the cationic peptides and the anionic GAGs 
leads to the formation of neutral nanoparticulate complexes which are internalized [15, 67-69]. 
However, controversy exists to which degree clustering is directly related to uptake. For variants 
of a CPP derived from the human protein lactoferrin [52], there was a strong negative correlation 
between the stoichiometry of binding and uptake eficiency [57] (Figure 3a). However, uptake did 
not correlate with the capacity of these peptides to cluster HS in solution. Variants of penetratin 
containing lysines and arginines engage HS and internalization is correlated with the arginine 
content and the clustering eficiency [54] (Figure 3b). However, the arginine-containing variant 
is also internalized more eficiently in the absence of HS indicating that the ultimate trigger for 
uptake is not directly related to HS, an observation that is consistent with our observation that 
L- and D-variants of arginine-rich peptides bind to HS with similar afinity, yet the latter are less 
eficient in triggering uptake [50] (Figure 3c).
A PEGylated version of an arginine-tryptophan peptide that failed to cluster HS due to the steric 
hindrance imposed by the PEG chain entered cells via endocytosis also questioning the role of HS 
clustering in the induction of endocytosis [67]. Our group recently showed that for analogs of 
the amphiphilic CPP TP10 there was no correlation between GAG clustering and internalization 
[61] (Figure 3d).
A more differentiated view was proposed by Rullo and coworkers who suggested that the 
formation of tight and stable complexes, as observed for penetratin with isolated components in 
a cell-free system, can be translated into endocytic import, while loosely bound peptides such as 
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Tat are likely to enter the cell via direct translocation [70]. In spite of its appeal, this idea is dificult 
to reconcile with the observation for the PEGylated CPP and the fact that D-peptide analogs 
are less effective in inducing endocytosis in spite of having the same afinity for HS as their 
L-counterparts [50]. Since the heparan sulfates themselves do not show a chiral discrimination of 
CPPs, additional factors, as for example receptors, must be involved in the triggering of uptake 
as indicated above. 
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Figure 3: Proposed models for the internalization of CPPs. a) The internalization of arginine-rich CPPs occurs in 
a stoichiometry-dependent way pointing towards an autonomous role of GAGs for the internalization of CPPs [57]. 
b) For CPPs containing the hydrophobic amino acid tryptophan it was shown that, next to interactions with GAGs, 
direct binding to the membrane is promoting uptake [54]. c) D-CPPs are internalized less efficiently than the L-
counterpart despite of having the same HS affinity. This observation suggests the involvement of a stereospecific, 
yet unknown, trigger [50]. d) Amphipathic peptides were shown to form clusters with GAGs, which are, probably 
due to their size, not internalized [61].  
 
Signaling processes involved in peptide internalization 
Except for those situations in which CPPs were shown to passively enter cells by direct crossing of the 
plasma membrane [62, 71, 72], the interaction of the CPP with the cell initiates processes that lead to 
uptake either via endocytosis [65, 66] or by activation of acid sphingomyelinase [73].  
Concepts on how this interaction is coupled to the activation of endocytosis are vague. Two lines of 
evidence are being followed. One line addresses the potential of the CPPs to autonomously induce 
membrane curvature and actin reorganization [74-76]. However, so far this research has been limited to 
cell-free model systems and the validation of the physiological relevance is hampered by the difficulty to 
study these mechanisms in cells in isolation. To this point, none of these models has incorporated GAGs 
as potential binding sites.  
A second line of evidence links the clustering of heparan sulfates to the induction of actin rearrangement 
leading to endocytosis. This model is based on the observation that exposure of cells to CPPs leads to 
lamellipodia formation in a Rac-dependent manner [13]. However, while this latter publication 
demonstrated the abolishment of lamellipodia formation in the presence of dominant negative Rac1, it 
lacks the final evidence which would be inhibition of CPP uptake. Imamura and coworkers performed 
elegant single particle tracking experiments with Tat-conjugated quantum dots. Interestingly, only 
exposure of cells to multivalent, but not to bivalent quantum dots led to Rac1-dependent local actin 
reorganization and uptake [77].  
GAGs, and syndecans were placed into this model by showing that the overexpression of syndecan-2 [15] 
or -4 [78] resulted in increased peptide uptake. The link to syndecan-4 was further supported by 
demonstrating that the protein kinase C inhibitor Gö6976 also reduced uptake.  
In contrast, the observation that preincubation with exogenous dextran sulfate can restore the uptake of 
short cationic peptides in GAG-deficient cells suggests that induction of uptake is independent of the core 
protein [79]. This latter evidence also raises the possibility that heparan sulfate proteoglycans only act as 
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Imamura and coworkers performed elegant single particle tracking experiments with Tat-
conjugated quantum dots. Interestingly, only exposure of cells to multivalent, but not to bivalent 
quantum dots led to Rac1-dependent local actin reorganization and uptake [77]. 
GAGs, and syndecans were placed into this model by showing that the overexpression of 
syndecan-2 [15] or -4 [78] resulted in increased peptide uptake. The link to syndecan-4 was 
further supported by demonstrating that the protein kinase C inhibitor Gö6976 also reduced 
uptake. 
In contrast, the observation that preincubation with exogenous dextran sulfate can restore the 
uptake of short cationic peptides in GAG-deicient cells suggests that induction of uptake is 
independent of the core protein [79]. This latter evidence also raises the possibility that heparan 
sulfate proteoglycans only act as auxiliary receptors. This concept is exempliied by the interplay 
of HS and the low-density lipoprotein receptor-related protein (LRP) for the uptake of lipoproteins 
[80]. Here, HS serve as attachment sites of remnant lipoproteins which are then passed to the LRP 
which acts as the receptor mediating uptake. Also, for the full length HIV-Tat protein on neuronal 
cells, the interaction of the Tat core domain with LRP was linked to endocytosis while the initial 
cellular attachment occurred through interaction of the Tat basic domain with HS [81]. 
Heparan sulfate proteoglycans in the uptake of nanoparticulate systems
Glycosaminoglycans have been recognized as a determinant also for the internalization and 
intracellular activity of nano- and microparticulate drug delivery systems. Since most delivery 
vectors are polycationic, the charge-driven interaction of cationic particulate systems with 
heparan sulfates has been considered common sense. However, the recent observation that in 
serum, polyplexes assume a negative zeta-potential and that uptake may occur via scavenger 
receptors also stresses the importance for further research in this ield [82, 83]. Also, the question 
arises to which extent differences in the interpretation of results may be the consequence of 
the use of serum-free versus serum-containing media. While for CPPs the presence of serum 
only reduces uptake eficiency [84] for polyplexes, the impact of serum and as a consequence 
change of zeta potential may lead to qualitatively different uptake mechanisms. Furthermore, 
for polyplexes, heparan sulfates may also play a role in the decomplexation and intracellular fate 
of the complexes. The intracellular traficking of polyplexes is an area of research on its own. 
Therefore, here we will exclusively focus on uptake.
The role of HS in the cell attachment and uptake of poly- and lipoplexes
Evidence of the involvement of GAGs in the uptake of polyplexes was reported irst during the 
late 1990s. Mislick suggested that GAGs can act as receptors for gene delivery complexes both, 
in vitro and in vivo and that this interaction is responsible for the cellular entry of the complexes 
[85]. Moreover, these pioneering studies concluded that electrostatic interactions are required 
for triggering internalization of the complexes. This hypothesis is also supported by more recent 
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studies, demonstrating that positively charged DNA carriers with very different molecular structure, 
including PEI [86-88], cyclodextrins [89], poly(amido amines) [90] and poly(glycoamidoamines) 
[91] engage GAGs before being internalized (Figure 4a).
Most studies have focused on the impact of heparan sulfates using GAG-deicient cell lines 
or enzymatic cleavage. While this may provide general insights into the role of cell-bound 
polyanions for uptake, further insights can be obtained by a discrimination of speciic structural 
determinants, as exempliied by the analysis of the cellular uptake of poly(glycoamidoamines) 
[91]. Upon desulfation of GAGs, which reduces the negative charges on these molecules, only a 
modest reduction in cellular uptake of PEI polyplexes but a dramatic reduction of internalization of 
poly(glycoamidoamines) was observed. Since desulfation had little effect on uptake of PEI, these 
authors suggested that other GAGs such as CS and DS can provide the required functionalities. 
One may comment, however, that CS and DS should also be desulfated as a consequence of the 
treatment, questioning the validity of this interpretation. An analysis of the interaction of the 
polyplexes with various GAGs suggested that next to electrostatic interactions, other interaction 
forces are also involved. 
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overall HSPG level. This study also demonstrated, that the use of different clones of one cell line may 
introduce substantial experimental variability between laboratories. 
Decomplexation of polyplexes by GAGs may be a confounding factor in analyzing the role of cellular 
GAGs in uptake [92]. DNA can be released prematurely from cationic poly- or lipoplexes through 
interaction with anionic HS and this interaction strongly depends on the nature of the oligoplexes and the 
kind of GAG expressed on the cell surface [90] (Figure 4b) [91]. The fact th t HS removal can even 
increase ptake of PAMAM polyplexes [93] can be expl ined by an inc ased mai tena ce of polyplex 
integrity on the cell surface. 
In spite of this strong evidence supporting a role of HS in uptake, it is important to keep in mind that upon 
HS removal uptake is never fully eliminated but only reduced by amounts similar to the ones described 
for CPPs. Nevertheless, to this point most data supports a positive role of HS in internalization raising the 
question whether HS do so by acting as mere attachments sites, or whether binding of HS triggers uptake. 
 
 
Figure 4: Suggested models for the uptake of nanoparticulate complexes. a) GAGs are inducing the 
internalization of nanoparticulate complexes [86]. b) Binding to GAGs leads to the decomplexation preventing 
uptake [92]. c) Serum proteins may bind to the cationic polymers which are encapsulating the nucleic acids. The 
internalization of these particles with the protein corona may occur through the scavenger receptor [83]. 
 
Endocytosis of cationic nanoparticulate systems 
Following binding to the cell surface, the consensus is that gene delivery systems enter the cells by 
endocytosis or phagocytosis. In a number of studies, it has been demonstrated that internalization of 
polyplexes has an impact on growth factor signaling, providing evidence that similar to CPPs polyplexes 
induce endocytosis and do not just “piggy back” on constitutive membrane turnover [94]. The absence of 
any specific structural requirement of polyplexes except for cationicity for uptake, leaves the induction of 
HS clustering as the most obvious molecular mechanism triggering uptake. So the questions are, whether 
clustering is indeed sufficient as a mechanistic concept and what are the factors that trigger internalization 
of DNA complexes.  
Mounkes [95] observed that ipoplexes were in ernalized to a high extent by cells (o er)expressing SDC-
1; furthermore, heparinase exposure decreased transfection also in vivo. SDC-1 was also shown to be 
important for the internalization of polyplexes [88, 96, 97]. Nevertheless, these studies proposed different 
mechanisms to explain the role of syndecans in internalization:  
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The internalization of these particles with the protein corona may occur through the scavenger receptor [83].
By studying different CHO cell clones, Thompson and coworkers showed that a high density of 
HS promoted uptake [87]. However, one clone also showed high binding but low internalization, 
suggesting that uptake is a function of the relative abundance of different GAG-carrying proteins 
rather than the overall HSPG level. This study also demonstrated, that the use of different clones 
of one cell line may introduce substantial experimental variability between laboratories.
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Decomplexation of polyplexes by GAGs may be a confounding factor in analyzing the role of 
cellular GAGs in uptake [92]. DNA can be released prematurely from cationic poly- or lipoplexes 
through interaction with anionic HS and this interaction strongly depends on the nature of the 
oligoplexes and the kind of GAG expressed on the cell surface [90] (Figure 4b) [91]. The fact that 
HS removal can even increase uptake of PAMAM polyplexes [93] can be explained by an increased 
maintenance of polyplex integrity on the cell surface.
In spite of this strong evidence supporting a role of HS in uptake, it is important to keep in mind 
that upon HS removal uptake is never fully eliminated but only reduced by amounts similar to 
the ones described for CPPs. Nevertheless, to this point most data supports a positive role of HS 
in internalization raising the question whether HS do so by acting as mere attachments sites, or 
whether binding of HS triggers uptake.
Endocytosis of cationic nanoparticulate systems
Following binding to the cell surface, the consensus is that gene delivery systems enter the 
cells by endocytosis or phagocytosis. In a number of studies, it has been demonstrated that 
internalization of polyplexes has an impact on growth factor signaling, providing evidence that 
similar to CPPs polyplexes induce endocytosis and do not just “piggy back” on constitutive 
membrane turnover [94]. The absence of any speciic structural requirement of polyplexes except 
for cationicity for uptake, leaves the induction of HS clustering as the most obvious molecular 
mechanism triggering uptake. So the questions are, whether clustering is indeed suficient as 
a mechanistic concept and what are the factors that trigger internalization of DNA complexes. 
Mounkes [95] observed that lipoplexes were internalized to a high extent by cells (over)expressing 
SDC-1; furthermore, heparinase exposure decreased transfection also in vivo. SDC-1 was also 
shown to be important for the internalization of polyplexes [88, 96, 97]. Nevertheless, these 
studies proposed different mechanisms to explain the role of syndecans in internalization: 
Kopatz and coworkers [96] proposed a detailed sequence of events that were deined as HS-
dependent phagocytosis. According to their model, after initial binding, a gradual electrostatic 
engulfment of the plasma membrane around the particle occurs and this zippering is sustained 
by the clustering of SDC-1 in cholesterol-rich rafts. This clustering in turn triggers PKC activity and 
causes the linking of actin binding to the cytoplasmic tail of the syndecan. The resulting tension 
then pulls the particle into the cells. However, this model seems to apply only to large particles 
(200-500 nm), as well as to bacteria and viruses. 
An expansion of this model was proposed by Paris and coworkers [97]. These researchers showed 
that SDC-1 is involved in the recognition and binding of the complexes, while SDC-2 acts as 
an accessory molecule. Upon binding of the polyplexes, clusters of SDC-1 and -2 are formed. 
However, only clustering of SDC-1 seems to be involved in the internalization of the complexes 
as 1 h after incubation, mostly SDC-1/polyplex complexes were internalized and localized in the 
proximity of the nucleus, while SDC-2 clusters were still located at the plasma membrane in 
Glycosaminoglycans in the cellular uptake of drug delivery vectors – bystanders or active players?  |  37
2
association with polyplexes. Interestingly, upon co-expression of both syndecans, SDC-2 exerted 
a dominant negative effect on transfection since in this case syndecan/polyplexes remained at the 
cell surface even after 6 h.
By studying the events that occur prior to endocytosis, Rehman and coworkers showed that 
polyplexes and lipoplexes attach via, both, SDC-1 and -2, leading to syndecan clustering and 
induction of actin polymerization, which then causes retrograde transport of the syndecan-ligand 
complex along ilopodia [88]. Inhibition of ilopodia movement highly reduced transfection 
eficiency. However, it was not shown whether this was only due to a lack of transport of 
complexes to the cell bodies or whether endocytosis of complexes was also compromised.
With respect to other proteins involved in uptake, it was demonstrated that dynamin is required for 
the internalization of proteoglycan-binding ligands through a caveolin- and clathrin independent 
but lotillin and dynamin-dependent mechanism [86]; along with dynamin, the presence of 
lotillin-1, a component of lipid rafts, promoted the internalization of polyplexes in agreement 
with results obtained for poly(amido amine) polyplexes.
In spite of this evidence linking SDCs to uptake, as for CPPs also for polyplexes a scarcity of 
knowledge exists in how heparan sulfate engagement is coupled to the induction of endocytosis. 
Moreover, the recent demonstration of an involvement of scavenger receptors in the uptake 
of polyplexes demonstrates that there is room for radically new concepts [83]. In the presence 
of serum, an inversion of the zeta-potential at least for polyplexes consisting of CPP and 
oligonucleotides occurs likely due to formation of a protein corona (Figure 4c) [82, 83, 98, 99]. 
These observations question the general view of an interaction driven primarily by electrostatics.
Heparan sulfates in viral infections
Even though the entry of viruses is typically associated with more classical receptor ligand 
interactions, syndecans have also been associated with viral uptake (Figure 5). Heparan sulfates 
have been implicated as attachment molecules in the infection of herpes simplex virus (HSV), 
[100] and a mechanism of HS-mediated “suring” along ilopodia, similar to the one described for 
polyplexes, has been observed [101]. For HSV-1, down regulation of the syndecans or blockage 
by antibodies resulted in a decreased infection and less entry into the cells. Furthermore, upon 
infection, expression levels of syndecan-1 and syndecan-2 are increased [102]. 
As irst shown for HeLa cells [103], and lately for physiological target cells lacking CD4, such as 
macrophages [104] and dendritic cells [105], attachment of HIV to cells is mediated by syndecans. 
On dendritic cells, HIV seems to engage syndecan-3 [105] via a polybasic stretch in glycoprotein 
gp120, the classic ligand on the HIV surface [106]. However, this interaction does not lead to 
uptake. Instead, on dendritic cells the virus forms a reservoir for infection of CD4-positive T-helper 
cells [105].
For human papillomavirus (HPV), that infect terminally differentiated epithelial cells, SDC-1 serves 
as the initial receptor through binding to lysine residues in the capsid proteins. This binding 
38  |  Chapter 2
induces conformational changes in the capsid proteins required for cell entry [107]. However, 
these conformational changes do not require HS [7]. Also here, the transport of virions along 
actin-rich protrusions bears remarkable similarity to the one shown for PEI particles [88]. Evidence 
suggests that a further, yet unknown receptor, is associated with viral entry and subsequent 
infection [7]. Surviladze and coworkers proposed a model in which uptake is induced by growth 
factors associated with soluble HS bound to the virus particles [108].
HS have also been considered as attachment factors in the infection of Dengue virus, through 
binding of the envelope glycoprotein E. Glycoprotein E has several binding sites for HS that 
promote both, attachment and cell entry [109]. For a particular dengue virus strain syndecan-2 
was identiied as a receptor [110]. Bound particles laterally diffuse in the plasma membrane until 
they are captured by preformed clathrin-coated pits which then serve as the sites of viral entry 
[8]. Nevertheless, binding of HS, although necessary, may not be the only factor required for 
internalization of the viral particle. Intracellular signaling mediated by G protein-coupled receptor 
kinase 2 seems to be implicated in the triggering of endocytosis [9]. 
Syndecans are also involved in the irst step of hepatitis E virus (HEV) infection. In particular, SDC-
1 mediates viral attachment to host cells, as its removal dramatically decreases HEV binding [111]. 
Uptake of HEV was shown to occur via clathrin-dependent endocytosis [112]. Researchers posit 
that a receptor for HEV has to exist, indicating that SDC-1 acts as an accessory molecule or as a 
co-receptor.
For human T-cell leukemia virus type I (HTLV-1) syndecans bearing short-chain heparan sulfates 
contribute to uptake. This publication stresses the requirement for the short-chain nature of the 
HS chains leading to the concept that these short-chain HS position the virus close to the plasma 
membrane [10]. This activity acts in concert with the glucose transporter 1 and neuropilin-1 for 
induction of uptake. 
Overall, for viral entry HS act as accessory molecules and uptake has been linked to the induction 
of down-stream processes linked to the primary receptor molecules rather than the proteoglycans.
Bystanders or active players?
With regard to our initial question – are GAGs bystanders or active players, the current state-of-
knowledge reveals that this answer very much depends on the type of delivery system. As such, 
differences in the answer to this question may also rather be a consequence of the conceptional 
framework of the respective research area than true mechanistic differences. 
Viral entry has historically been correlated to interactions with speciic receptors, which eventually 
trigger a series of processes leading to internalization of the viral particles. In this scenario, GAGs 
were relegated to a secondary role as bystanders or coreceptors that support association of virus 
particles with the cell surface and at best contribute to uptake. 
In contrast, studies carried out on CPPs and nanoparticulate systems have provided ample 
evidence that GAGs can act as autonomous receptors and therefore be the main actors in the 
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internalization of such molecular entities. However, very clearly, in the complex context of the 
plasma membrane, it will never be possible to address the role of GAGs in isolation and to exclude 
an involvement of other receptor molecules. In fact, a considerable body of data supports the idea 
that the GAGs themselves are not suficient to trigger the import of CPPs, questioning their role 
as the main active players. As one possibility, clustering of GAGs may induce co-clustering with 
a receptor that elicits import, probably via clustering-dependent activation of signaling processes 
(Figure 5). Finally, binding to GAGs may bring the vector into the vicinity of a coreceptor. While 
this latter possibility may provide an explanation for the chirality dependence of endocytosis 
induction it is dificult to reconcile with the structural diversity of CPP sequences. 
In the following section we will point out future lines of research that may resolve the question, 
whether for viruses and artiicial delivery systems fundamental conceptional differences exist or 
whether major aspects in the uptake mechanisms of artiicial vectors have been overlooked so far.
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Figure 5: Proposed models for the involvement of glycosaminoglycans in the uptake of viruses, proteins and 
CPPs/nanoparticulate systems. For viruses and LDL receptor-related protein (LRP) HS bound to transmembrane 
proteins and in particular the syndecans were shown to act as coreceptors or auxiliary receptors. In contrast, for 
CPPs and other nanoparticulate complexes next to the current concept of GAG clustering we propose two more 
concepts in analogy to viruses and LRP: GAGs may act as a coreceptor for an unknown receptor or vice versa (as 
for LRP), or GAGs form clusters with the unknown receptor promoting uptake or complex formation of GAGs itself 
is already triggering the uptake.  
 
Future directions in the research of HS and uptake 
So far, research on CPPs and polyplexes has been surprisingly separate. A potential reason may be that 
the CPP field had its origin in the area of transcription factors and membrane active peptides, while 
polyplexes are a result of pharmaceutical polymer research. Very clearly, with the formation of CPP-
based polyplexes, both areas overlap. Furthermore, also for free CPPs as shown above, in spite of the fact 
that polyplexes are much larger and polyvalent in nature, at present there seem to be more commonalities 
for CPPs and polyplexes than differences.  
Very clearly, for CPPs, polyplexes, and viruses alike there is a strong link of HS engagement and uptake. 
However, conflicting data exist, and especially for CPPs and polyplexes the molecular events that link HS 
binding to the induction of uptake are sketchy. A direct visualization of the dynamics of vector, GAGs 
and candidate signaling proteins in living cells will be key to obtain such an understanding. However, the 
approaches used for GAG labeling so far are confronted with major shortcomings. For fusion to 
fluorescent proteins the structure of the syndecans and glypicans imposes major limitations. For the 
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events that link HS binding to the induction of uptake are sketchy. A direct visualization of the 
dynamics of vector, GAGs and candidate signaling proteins in living cells will be key to obtain 
such an understanding. However, the approaches used for GAG labeling so far are confronted 
with major shortcomings. For fusion to luorescent proteins the structure of the syndecans 
and glypicans imposes major limitations. For the syndecans, a C-terminal fusion abrogates the 
functionality of the PDZ motif. Very interestingly, the publications that employed C-terminal GFP 
fusions of syndecan-1 did not include any mentioning of this point. Probably, the PDZ motif 
has little relevance as for C-terminal GFP fusions only after removal of intracellular domains 
delivery of PEI polyplexes was reduced [97]. Insertion of luorescent proteins into the membrane 
proximal region of the extracellular domain [78] of syndecans and glypicans alike will change the 
positioning of oligosaccharides relative to the plasma membrane and as a consequence potentially 
impede with protein traficking in the secretory pathway and protein-protein interactions at the 
cell surface.
Labeling with heparan sulfate-speciic antibodies has been employed on living cells [113]. 
However, these reagents compete with the binding of vectors. For example, binding of the 
lactoferrin-derived CPP [52] could be inhibited completely by the HS-binding single chain antibody 
HS4C3 [114] (own unpublished results). Furthermore, secondary antibodies may artiicially 
enhance crosslinking. Instead, metabolic labeling of sugars may present a highly powerful, yet 
little explored option for labeling of glycosaminoglycans [61, 115, 116].
As described for HIV, heparan sulfate-bound virus may even serve as a long-lived reservoir for 
infectious particles on the cell surface demonstrating that multivalent binding of heparan sulfates 
by nanoparticles does not necessarily lead to uptake. More research is therefore needed to 
understand the molecular basis for these differences. One possibility could be that viruses bind to 
heparan sulfates with a lower total positive charge density and that only this latter is associated 
with the triggering of delivery pathways of nanoparticles.
Given their role as accessory receptors in viral uptake, it could well be that the function of 
syndecans and glypicans in mediating uptake is context-speciic, such as requiring the presence 
of further transmembrane proteins/receptors that ultimately trigger the uptake machinery (Figure 
1). Considering the fact that the local accumulation of many growth-factor receptors can trigger 
endocytosis, this concept would be fully compatible with the independence of uptake of a speciic 
growth factor receptor that is a hallmark of uptake for CPP and polyplexes. The mechanisms 
triggering uptake of CPP and polyplexes would then be even more reminiscent of those triggering 
viral uptake or of LRP ligands [117].
Finally, more research is needed to elucidate the basis for the remarkable similarities in the uptake 
mechanisms of CPP and nanoparticulate systems. Two possibilities can explain this circumstance: 
First, relevant differences may have been overlooked. Second, the observed coalescence of 
CPP-HS complexes into nanoparticulate structures on the cell surface may eliminate differences 
between both types of delivery vectors. 
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Potential implications for the design of nanomedicines 
So far, the rationale for detailed molecular analyses in the cellular association and uptake of CPPs 
and polyplexes has been that if only uptake was understood in detail, then more eficient and less 
toxic delivery vehicles with ideal cell type speciicity could also be generated. 
For individual CPPs, signiicant effort has been invested into the analysis of structure-activity 
relationships of heparan sulfate binding and uptake. The question is, to which extent this insight 
can beneit the further development of pharmaceutical polymers. For example are differences, 
observed for penetratin and hLF variants [54, 57] maintained if such a peptide is grafted onto a 
nanoparticle or does multivalency override these structural aspects? For cationic polymers and 
lipids further research is needed to elucidate whether the addition of a CPP beneits the delivery 
and which component controls uptake and intracellular traficking. 
Ultimately, the question remains, whether also with a GAG-centered approach, as currently 
followed for CPPs and polyplexes, an increased delivery eficiency in combination with cell type 
speciicity and reduced toxicity can be reached. As summarized above, for proteins such as the 
LRP and its ligands and the Tat protein as well as for viruses, GAGs exert their physiological 
function in concert with other receptors through which cell-type tropism is attained. Except 
for those situations in which a targeting based on heparan sulfate density in the target organ 
confers suficient speciicity for therapeutic beneit, as is the case for siRNA targeting to the 
liver [118, 119], research on CPPs and polyplexes could beneit from a consideration of GAGs 
as only auxiliary receptors. A deep investigation of the speciic tissue distribution and relative 
abundance of syndecans and other heparan sulfate-carrying proteins may constitute a irst step in 
this direction. Following such a strategy, it must be possible to rationally predict tissue preference 
of delivery systems and deine the requirement for further targeting modalities.
Even more fundamental questions remain with respect to molecular determinants and mechanisms 
underlying cellular uptake of nanoparticulate systems. Very clearly, positive charge is a common 
denominator of delivery vectors. However, the observation that polyplexes assume a negative 
zeta-potential in the presence of serum adds another layer of complexity. The association of 
proteins with nanoparticles, leading to the so-called protein corona is an emerging area in 
nanoparticle research [98, 99]. Still, a positive charge of the particle itself seems to be decisive 
for uptake [120], suggesting that the protein corona disassembles once a particle approaches 
the cell surface. Nevertheless, it is an intriguing concept that nanoparticles dynamically recruit 
factors contributing to their uptake, similar to what has been described for HPV [108]. In this 
case, research on nanomedicines needs to understand to which extent the protein corona is a 
function of the drug delivery vehicle and a consideration of the structure-activity-relationship 
of the drug delivery vehicle alone may be misleading. So far evidence of genome-wide gene 
expression analyses has indicated that nanoparticles enter without induction of gene expression 
changes [121] disfavoring an engagement of growth factor receptors. However, transferrin is also 
present in serum and, if absorbed to particles, could induce uptake without induction of growth 
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factor dependent signaling. It remains to be shown, whether this dynamic self-organization 
of nanoparticles may be exploited to tailor organ tropism and targeting or whether ultimately, 
delivery strategies will focus on stealth strategies such as pegylation in combination with targeting 
moieties [122]. 
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ABSTRACT
Binding to negatively charged heparan sulfates (HS) at the cell surface is considered the irst 
step in the internalization of cationic cell-penetrating peptides (CPPs). However, little is known 
about the relation of the characteristics of the HS-CPP interaction such as afinity, stoichiometry 
and clustering with uptake. In this study, we investigated a collection of mutants of a cyclic CPP 
derived from human lactoferrin with respect to HS binding and uptake. The thermodynamic 
parameters of HS binding were determined by isothermal titration calorimetry, clustering of HS 
was investigated by dynamic light scattering, and cellular uptake by low cytometry and confocal 
microscopy. Whereas mutations of non-arginine amino acids that are conserved across lactoferrins 
of different mammalia only had a minor effect on uptake eficiency, changes in the number of 
arginine residues inluenced the uptake signiicantly. In general, introduction of arginine residues 
and cyclization improved the HS afinity and the ability to cluster HS. In particular, there was a 
strong negative correlation between stoichiometry and uptake indicating that crosslinking of 
HS is the driving force for the uptake of arginine-rich CPPs. Using glycan microarrays presenting 
a collection of synthetic HS we show that a minimal chain length of HS is required for peptide 
binding.
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INTRODUCTION
Cell-penetrating peptides (CPPs) are a promising class of cellular delivery vehicles for therapeutic 
agents such as oligonucleotides, siRNA and proteins [1]. Structurally, CPPs are divided into 
multiple classes depending on their cationicity and/or amphipathicity [2]. A prominent group 
of the cationic CPPs are the arginine-rich peptides. In general, arginine-containing CPPs are 
internalized more eficiently than their lysine-containing counterparts [3]. This observation has 
been explained by the ability of the guanidino group to form bidentate hydrogen bonds with 
negatively charged heparan sulfates (HS), with acidic groups of the lipid bilayer, and furthermore 
by the capacity of these complexes to partition into hydrophobic environments [4,5].
More recently, CPPs containing one or more conformational constraints through cyclization have 
been an interesting addition to the ield. This group of peptides includes toxin-derived peptides 
such as maurocalcine [6], crotamine [7], the crotamine-derived CyloP [8], as well as the CPP 
derived from the N-terminal antimicrobial domain of human lactoferrin, hLF [9]. For hLF and CyloP, 
the presence of the disulide bridge was shown to be essential for eficient uptake. Interestingly, 
also for linear CPPs, cyclization has been shown to enhance uptake [10,11]. 
For the hLF-derived CPP, the cyclization-dependent uptake activity was accompanied by a strong 
increase in the afinity for HS. HS are negatively charged, protein-linked oligosaccharides that 
form part of the glycocalyx [12]. For arginine-rich CPPs in more general, but also for related 
guanidino-rich β-peptides, binding to HS has been associated with uptake [13-16]. However, as 
we showed recently, the afinity of binding to HS is not a suficient criterion for eficient uptake, 
as arginine-rich CPP consisting of D-amino acids internalized less effectively than their L-amino 
acid counterparts, despite comparable HS binding constants [17]. 
Several studies have described the importance of glycosaminoglycan (GAG) clustering for eficient 
uptake of CPPs [18-20]. Penetratin analogs with arginine residues showed stronger membrane 
binding than their lysine analogs which correlated with a higher ability to cluster HS and an 
improved uptake [20]. Ziegler et al. showed that PEGylation of the CPP WR9 that is only taken 
up via endocytosis and not via direct translocation in contrast to the non-PEGylated variant, did 
not affect HS afinity but compromised HS clustering [19]. However, while in the cited work HS 
clustering was described as a factor promoting uptake, for analogs of the amphipathic CPP TP10 
we showed that the size of the peptide-HS clusters could be a limiting factor for eficient uptake 
[21]. 
At present, the combination of results obtained for different peptides is a major shortcoming for 
generating a comprehensive picture on the involvement of HS in uptake. Here, we addressed 
the structure-activity-relationship for HS-binding, clustering and cellular uptake for variants of 
the hLF-derived CPP. We consider this CPP an ideal tool for this purpose as the requirement for 
a cyclic structure suggests the presence of structural determinants for eficient HS binding. Since 
lactoferrins are conserved across mammalia the question arose whether conserved residues next 
to arginines contribute to the recognition of HS. Furthermore, by the generation of mutants 
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that varied in the number and position of arginine residues, and in the presence and nature of 
the disulide bridge the role of these structural features could be addressed without completely 
changing the structural context. Uptake was assessed for HS-positive cells, also after enzymatic 
removal of the glycocalyx, and for cells that show only little HS expression. The afinity and 
stoichiometry of binding to HS were determined by isothermal titration calorimetry (ITC), the 
capacity to cluster HS by dynamic light scattering (DLS). 
The results demonstrate that cyclization primarily serves the generation of a suficiently high local 
arginine density. Remarkably, for HS-positive cells, only the stoichiometry of binding showed a 
strong negative correlation with uptake which indicates the requirement of HS cross-linking for 
inducing the uptake of arginine containing CPPs. Consistent with this hypothesis, this correlation 
was not present on HS-poor cells and was abolished after enzymatic removal of the glycocalyx. 
Finally, to identify particular structural features relevant for the interaction of HS and the hLF CPP 
we acquired interaction proiles to microarrays presenting a collection of synthetic GAGs.
MATERIALS AND METHODS
Cell culture 
HeLa and Jurkat E6.1 leukemia cells were cultured in RPMI 1640 (Pan Biotech, Aidenbach, 
Germany) containing 10% fetal calf serum (FCS). Ovcar-3 cells were cultured in RPMI containing 
20% FCS and Caco-2 cells in MEM supplemented with 20% FCS, 1% sodium pyruvate and 1% 
nonessential amino acids (all from Invitrogen, Eugene, USA). Cells were cultured in a humidiied 
atmosphere, 5 % CO2 at 37 °C and passaged every 2 or 3 days. HBS buffer pH 7.4 (10 mM 
HEPES, 135 mM NaCl, 5 mM KCl, 5 mM MgCl
2
, 1.8 mM CaCl
2
) was used for washing. All cells 
were originally obtained from the American Type Culture Collection (Rockville, MD, USA). 
Peptides 
Peptides were purchased from EMC microcollections (Tübingen, Germany). All peptides were 
N-terminally labeled with carboxyluorescein and C-terminally amidated. The identity and purity 
of the peptides was determined by mass spectrometry and reversed-phase high-performance 
liquid chromatography. For formation of the intramolecular disulide bridge, the peptides were 
dissolved in 50 mM Hepes buffer (pH 8) to a concentration of 1-2 mM and incubated for 2 h at 
37 °C. Disulide bridge formation was conirmed using the Ellman’s test [22]. A stock solution 
of [5,50-dithiobis-(2-nitrobenzoic acid)](DTNB) (Sigma Aldrich, St. Louis, USA) was prepared 
containing 2 mM DTNB and 50 mM sodium acetate in milli-Q. For the test solution, 50 µL DTNB 
solution was mixed with 100 µL of a 1 M Tris solution (pH 8), 840 µL milli-Q and 10 µL peptide 
solution (1 – 2 mM). After incubating 5 min at RT, the absorption was measured at 412 nm using 
a Novaspec II visible spectrophotometer (Pharmacia, New York, USA). Peptides without a disulide 
bridge were dissolved in milli-Q water. Peptide concentrations were determined by measuring 
the absorption of luorescein at 492 nm assuming an extinction coeficient of 75,000 M-1cm-1. 
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Flow cytometry 
HeLa or Caco-2 cells were seeded in 24-well plates at a density of 80,000 cells (1 day) or 40,000 
cells (2 days) per well prior to the experiment. 100,000 Ovcar-3 cells were seeded 1 day before 
the experiment. Cells were incubated with the different peptides at the indicated concentrations 
for 30 min at 37 °C in serum-containing medium. After washing the cells with RPMI containing 
10% FCS, cells were detached by trypsinization for 5 min at 37 °C and washed with medium 
by centrifugation. After resuspension, the cell-associated luorescence was measured using a 
FACSCalibur low cytometer (BD Biosciences, Erembodegem, Belgium). Analysis of 10,000 gated 
cells was performed using the Summit software 4.3 (Dako,Fort Collins, USA). For Jurkat E6.1 
cells, a similar protocol was used with 300,000 cells per sample in a total volume of 200 µL, also 
including a trypsin wash step to remove membrane-bound peptides. 
Confocal laser scanning microscopy
HeLa cells were seeded in chambered coverslips (Nunc, Wiesbaden, Germany) at a density of 
40,000 cells (1 day) or 20,000 cells (2 days) prior to the experiment. Cells were incubated with 
peptides at the indicated concentrations in RPMI supplemented with 10 % FCS for 30 min and 
washed with RPMI containing 10 % FCS. For Jurkat cells, a cell suspension containing 300,000 
cells was mixed with the peptide solution in a inal volume of 200 µL and washed by centrifugation. 
Confocal laser scanning microscopy was performed on a TCS SP5 confocal microscope (Leica 
Microsystems, Mannheim, Germany) equipped with an HCX PL APO 63x1.2 water immersion 
lens. The 488 nm line of the argon ion laser was used for excitation of luorescein and emission 
was collected between 500 and 550 nm. 
Isothermal Titration Calorimetry 
Peptide and HS (average molecular weight 13.6 kDa, Celsus, Cincinnati, OH, USA) solutions were 
diluted with HBS to yield physiological salt concentrations. ITC experiments were performed with 
an ITC200 Microcal (Microcal, Northampton, USA) at 25 °C. After washing the measurement cell 
with the peptide to coat the walls of the cell, 38 times 1 µL HS were injected into the peptide 
solution (220 µL). Peptide (20-60 µM) and HS (40-90 µM) concentrations were adapted for the 
different hLF variants in order to ensure a high signal-to-noise ratio. To correct for background 
heat changes, the heat changes of the ive last injections which were assumed to represent 
exclusively dilution effects were averaged. Data were analyzed using the ITC200 Microcal software 
employing a one-site binding model. 
Dynamic light scattering 
DLS experiments were performed on a Zetasizer Nano S (Malvern Instruments, Malvern, UK) 
with a He-Ne laser (633 nm) and an avalanche photodiode detector at an angle of 173°. 2 µL 
of the different peptide solutions (50 µM) were titrated into 100 µL of a 10 µM HS solution in 
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a ZEN0040 disposable cuvette. After mixing the sample, incubation for 3 min at 37 °C, and an 
additional mixing step, 3x12 measurements were performed. HS and peptide solutions were 
diluted using iltered HBS. The attenuator was set at 8 for all measurements. 
Removal of the glycocalyx
Prior to peptide incubation, HS only, or the complete set of glycosaminoglycans (GAGs), including 
HS, chondroitin sulfate (CS), dermatan sulfate (DS), and hyaluronic acid (HA), and additionally 
the glycan sialic acid (SA) were removed by incubating cells for 1.5 h at 37°C with RPMI + 1% 
FCS containing 10 mU/mL heparinase III (Seikagaku, Tokyo, Japan) alone or in a cocktail with 
275-550 U/mL hyaluronidase (Sigma Aldrich, St. Louis, USA), 100 mU/mL chondroitinase ABC 
(Sigma Aldrich, St. Louis, USA) and 100 mU/mL sialidase (Sigma Aldrich, St. Louis, USA). After the 
incubation, cells were washed twice with PBS and the peptide incubation was started.
Microarray binding studies
Glycan microarrays containing synthetic HS/heparin oligosaccharides and 5 kDa natural heparin 
were prepared from N-hydroxy-succinimidyl ester-activated CodeLink slides as described 
previously [23-26]. After spotting of glycans, the slides were incubated overnight in a humid 
chamber, then quenched at 50°C for 1 h in 50 mM aminoethanol solution, pH 9, and blocked at 
room temperature for 1 h with 1% (w/v) BSA in 6 mM HEPES, pH 7.4. Slides were then washed 
three times with 6 mM HEPES, pH 7.4 and dried by centrifugation (5 min, 200 x g). For acquisition 
of peptide binding proiles, slides were incubated at 4°C overnight with 10 μg/mL of luorescent 
peptides (hLF WT: 3.25 µM, hLF Hcy: 3.22 µM, hLF +4R: 3.07 µM) in 1% (w/v) BSA in 6 mM 
HEPES, pH 7.4 with 0.01% (v/v) Tween-20 in a humid chamber. Then, slides were washed three 
times with 6 mM HEPES, pH 7.4 with 0.1% (v/v) Tween-20, rinsed once with water and dried 
by centrifugation. Slides were scanned with a GenePix 4300A microarray scanner (Molecular 
Devices). Fluorescein was excited at 488 nm and luorescence intensities were determined with 
the GenePix Pro 7 software (Molecular Devices). 
RESULTS
Impact of mutations of highly conserved amino acids on uptake eficiency
So far, the investigation of structural characteristics of the CPP hLF that relate to eficient 
internalization had focused on the role of the disulide bridge. Uptake strongly depends on the 
presence of the bridge, as does the capacity to bind to HS [9]. These observations suggested a 
requirement for a particular conformational arrangement of the peptide backbone and/or amino 
acid side chains for the interaction with HS and possibly also for the induction of uptake. In order 
to further deine whether this was indeed the case, several mutant peptides with single and 
multiple amino acid exchanges were designed. In particular, we wanted to investigate whether 
HS binding and uptake eficiency shared the same structure-activity relationship.
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In a irst set of peptides, amino acid positions that are highly conserved in lactoferrins among 
various species were exchanged for alanine residues (hLF W5A, hLF Q6A, hLF M9A, hLF P15A) 
(Table 1, Supplemental table 1). With these mutants, we wanted to learn whether the evolutionary 
constraint that limited the variability of these residues was associated with uptake eficiency. 
Table 1 Sequences of tested hLF variants.
Name Group Sequence
hLF WT Fluo-KCFQWQRNMRKVRGPPVSCIKR-NH
2
1
hLF W5A conserved residues Fluo-KCFQAQRNMRKVRGPPVSCIKR-NH
2
hLF Q6A Fluo-KCFQWARNMRKVRGPPVSCIKR-NH
2
hLF M9A Fluo-KCFQWQRNARKVRGPPVSCIKR-NH
2
hLF P15A Fluo-KCFQWQRNMRKVRGAPVSCIKR-NH
2
hLF V12R arginine displacement Fluo-KCFQWQRNMRKRRGPPVSCIKR-NH
2
hLF R7A Fluo-KCFQWQANMRKVRGPPVSCIKR-NH
2
hLF R13A Fluo-KCFQWQRNMRKVAGPPVSCIKR-NH
2
hLF R7A/V12R Fluo-KCFQWQANMRKRRGPPVSCIKR-NH
2
hLF R13A/P15R Fluo-KCFQWQRNMRKVAGRPVSCIKR-NH
2
hLF +4R arginine density Fluo-KCFRWQRNRRKVRGRPVRCIKR-NH
2
hLF lin+4R Fluo-KRFRWQRNMRKVRGRPVRSIKR-NH
2
hLF R7 Fluo-RCFQWQRNMRRVRGPPVSCIRR-NH
2
hLF K7 Fluo-KCFQWQKNMKKVKGPPVSCIKK-NH
2
hLF Hcy bridge structure Fluo-K-Hcy-FQWQRNMRKVRGPPVS-Hcy-IKR-NH
2
2
1Mutated residues are indicated in bold letters. Fluo indicates N-terminally labeled luorescein, NH
2
 amidated 
C-termini.
2Hcy refers to homocysteine in which the side chain is one methylene group longer than in cysteine
For the hLF WT peptide, we previously determined that the uptake at a concentration of 5 µM 
depends on endocytosis, whereas the uptake at peptide concentrations higher than 20 µM 
also takes place via the acid sphingomyelinase-dependent induction of nucleation zones (NZ) 
[9,27,28]. These two entry mechanisms can be distinguished by confocal microscopy and by 
low cytometry. In confocal microscopy, uptake via endocytosis can be identiied by punctate 
structures, whereas uptake via NZ leads to an intense and homogenous luorescence throughout 
the cytosol and nucleus. In low cytometry, uptake via endocytosis corresponds to a symmetric 
peak. Entry via NZ is relected by a tailing of the peak towards a higher intensity. The uptake 
eficiencies and subcellular distributions of the hLF variants were quantiied by low cytometry 
and visualized by confocal microscopy, respectively (Figure 1, Supplementary Figure S1). When 
exchanging highly conserved amino acids for alanine, the uptake eficiency was decreased by a 
maximum of 50 % compared to hLF WT, and for all peptides the reduction was more pronounced 
at 5 µM as compared to 20 µM (Figure 1a-b). Exchange of tryptophan reduced uptake by about 
50% at both concentrations, whereas exchange of methionine led to a 50 % reduction at 5 
µM and a slighter reduction at 20 µM. Replacement of glutamine and also proline was without 
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signiicant effect. The importance of tryptophan for the uptake of hLF is not unique for hLF but 
is reminiscent of the importance of this residue for the uptake of other CPPs [29-31]. Overall, 
the data demonstrate no particular importance of the highly conserved non-arginine residues for 
uptake.
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Figure 1: Flow cytometry and confocal microscopy of hLF variants. HeLa cells were incubated with 5 µM (a) or 
20 µM (b) of the indicated peptides for 30 min at 37 °C and then washed and analyzed by flow cytometry. (a,b) 
Median fluorescence of the hLF variants was normalized to hLF WT. Bars indicate the average of the normalized 
median of at least two independent experiments. Error bars denote the standard error of the mean (SEM). 
Significance of different uptake efficiencies compared to WT at p< 0.1 (*) or p< 0.05 (**) was assessed using an 
independent t-test in SPSS with test-value 100 reflecting the uptake of hLF WT. (c) Confocal microscopy images 
after 30 min incubation with the indicated peptides (5 µM). The scale bar denotes 10 µm. 
 
Effects of the number and position of arginine residues and the presence and nature of the disulfide 
bridge  
Given their prominent role in cellular delivery vectors, we designed a second set of mutants with 
variations in the number and position of arginine residues. In total, hLF WT contains seven positively 
charged residues, four of which are arginines. One of the synthetic mutants contained an additional 
arginine residue (hLF V12R), two variants had one arginine residue less (hLF R7A, hLF R13A), and in 
two mutants an arginine position was shifted (hLF R7A/V12R, hLF R13A/P15R) (Table 1). It is notable 
that two hLF mutants (hLF R13A and hLF R13A/P15R) were synthesized with a disrupted Cardin-
Weintraub motif. This motif has been reported as a GAG binding motif [XBBXBX], with B 
corresponding to a basic amino acid and X corresponding to an arbitrary amino acid [32].  
 
All modifications in which the number and/or position of the arginine residues were changed slightly 
decreased uptake efficiency via endocytosis (Figure 1a, Supplementary Figure S1, S2). However, this 
decreased uptake was only statistically significant for hLF R7A and hLF R13A/P15R, for which the 
median uptake efficiency was reduced by about 40% at 5 µM. In contrast, for efficient internalization via 
NZ at 20 µM, merely a minimum number of arginine residues were required. In particular, the deletion of 
one arginine residue (hLF R7A, hLF R13A) significantly decreased the uptake via NZ compared to hLF 
WT (Figure 1b), whereas the addition of one arginine (hLF V12R) did not improve the uptake at 20 µM. 
Disruption of the Cardin-Weintraub motif had little impact on uptake which may be explained by the 
overall arginine content of the peptide which provides chemical groups for interaction (Figure 1). 
Figure 1: Flow cytometry and confocal microscopy of hLF variants. HeLa cells were incubated with 5 
µM (a) or 20 µM (b) of the indicated peptides for 30 min at 37 °C and then washed and analyzed by low 
cytometry. (a,b) Median luorescence of the hLF vari nts was normalized to hLF WT. Bars indicat  the average 
of the norm liz d median of at leas two ind pendent experiments. Error bars denote the standard error 
of the mean (SEM). Signiicance o  differ nt uptak  eficiencies compared to WT at p< 0.1 (*) or p< 0.05 
(**) was assessed using an independent t-test in SPSS with test-value 100 relecting the uptake of hLF WT. 
(c) Confocal microscopy images after 30 min incubation with the indicated peptides (5 µM). The scale bar 
denotes 10 µm.
Effects of the number and position of arginine residues and the presence and nature of 
the disulide bridge 
Given their prominent ole in cellular delivery vectors, we designed a second set of mutants 
with variations in the number and position of arginine residues. In total, hLF WT contains seven 
positively charged residues, four of which are arginines. One of the synthetic mutants contained 
an additional arginine residue (hLF V12R), two variants had one arginine residue less (hLF R7A, 
hLF R13A), and in two mutants an arginine position was shifted (hLF R7A/V12R, hLF R13A/P15R) 
(Table 1). It is notable that two hLF mutants (hLF R13A and hLF R13A/P15R) were synthesized 
with a disrupted Cardin-Weintraub motif. This motif has been reported as a GAG binding motif 
[XBBXBX], with B corresponding to a basic amino acid and X corresponding to an arbitrary amino 
acid [32]. 
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All modiications in which the number and/or position of the arginine residues were changed 
slightly decreased uptake eficiency via endocytosis (Figure 1a, Supplementary Figure S1, S2). 
However, this decreased uptake was only statistically signiicant for hLF R7A and hLF R13A/P15R, 
for which the median uptake eficiency was reduced by about 40% at 5 μM. In contrast, for 
eficient internalization via NZ at 20 µM, merely a minimum number of arginine residues were 
required. In particular, the deletion of one arginine residue (hLF R7A, hLF R13A) signiicantly 
decreased the uptake via NZ compared to hLF WT (Figure 1b), whereas the addition of one 
arginine (hLF V12R) did not improve the uptake at 20 µM. Disruption of the Cardin-Weintraub 
motif had little impact on uptake which may be explained by the overall arginine content of the 
peptide which provides chemical groups for interaction (Figure 1).
Previously, we had shown that a linear hLF analog without the disulide bridge was not taken up 
at all nor showed binding to HS [9]. To test the hypothesis that cyclization promotes uptake by 
achieving an increase in local arginine density for a peptide with a rather low arginine density in 
the primary structure, four additional arginine residues were introduced into the linear variant 
(hLF lin+4R, Table 1). In addition, we also designed a cyclic counterpart with four additional 
arginine residues (hLF +4R). Indeed, the uptake eficiency at 5 µM of hLF lin+4R in HeLa cells 
was comparable to the one of hLF WT (Figure 1a, Supplementary Figure S1, S2), indicating that 
a loss of a conformation-dependent local accumulation of arginines can be compensated by 
an increase in arginine density in the primary peptide structure. Interestingly, at concentrations 
at which uptake via NZ is dominant (20 µM), the uptake of hLF lin+4R was highly improved in 
comparison to hLF WT (Figure 1b). The two uptake mechanisms, endocytosis and uptake via NZ, 
were visible in the low cytometry histograms, as a symmetrical peak and a shoulder, respectively 
(Supplementary Figure S1). When comparing hLF lin+4R with hLF +4R that is comparing the 
effect of extra arginines in the absence/presence of cyclization, hLF +4R was taken up even 
more eficiently than hLF and hLF lin+4R at low and high concentrations (Figure 1). These results 
indicate that neither hLF WT nor hLF lin+4R had incorporated the maximum capacity to trigger 
uptake but that only the combination of high arginine density and cyclization did. Although 
arginine density plays an important role in uptake via endocytosis, to our surprise, replacement of 
all lysines in the sequence by arginine (hLF R7, Table 1) signiicantly reduced the uptake eficiency 
at 5 and 20 µM (Figure 1). An explanation for this inding is presented below. As expected, 
replacing all arginines by lysine residues (hLF K7) severely decreased the uptake even more than 
hLF R7 (Figure 1). 
After having shown that the uptake of the linear hLF could be restored by the introduction of 
arginine residues, we inally wanted to get a deeper insight into the importance of the geometry 
of the disulide bridge for uptake. For this purpose, the cysteine residues were replaced by 
homocysteine (hLF Hcy). Homocysteine is a cysteine analog where the side chain is extended 
with one methylene group. At 5 µM, hLF Hcy showed a slightly reduced uptake eficiency in 
comparison to WT (Figure 1a).
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Dependence of uptake eficiency on HS binding
Having established a structure-activity relationship with regard to amino acid sequence and 
structural requirements for eficient uptake, the next step was to test whether there was a 
correlation between the uptake eficiencies and binding to HS chains. ITC, using soluble HS, 
was used for this purpose. In addition to the dissociation constant, ITC also provides information 
about stoichiometry, enthalpy and entropy of binding, thereby giving a detailed view of the 
binding characteristics. For ITC, we focused on those arginine-rich variants that showed clear 
differences in the uptake eficiencies compared to hLF WT (hLF lin+4R, +4R and R7). Furthermore, 
we focused on hLF Hcy to obtain more insight into the role of the disulide bridge in HS binding 
(Figure 2a-e, table 2). The two variants with four extra arginine residues had a higher afinity 
for HS by a factor of 2.5-5; however, there was no general correlation between the number of 
arginines, afinity and internalization capacity. For example, R7 had the same afinity as hLF WT 
but showed a clearly decreased uptake (Figure 2f), and even though hLF Hcy had a similar uptake 
eficiency as hLF WT, the KD was clearly higher than that of hLF WT. However, a strong negative 
correlation was observed for the stoichiometry of binding and uptake at 5 µM (Figure 2g). The 
stoichiometry varied by a factor of up to 3.5. While for hLF R7 up to 14 peptides bound per HS 
chain, for hLF +4R these were only 4. The fewer peptides bound per HS, the higher the uptake 
eficiency. 
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 Arginines (N) 
Sites per HS 
(N) 
KD 
(µM) 
Enth lpy 
(kcal-1mol-1) 
Entropy 
(cal-1mol-1deg-1) 
Enthalpy 
(per hLF) 
Enth lpy 
(per Arg) 
hLF WT31 4 9 ± 12 0.64 ± 0.07 -31 ± 5 -75 ± 15 -3 ± 1 -0.78 ± 0.22 
lin+4R4 8 6 ± 1 0.24 ± 0.04 -41 ± 15 -106 ± 4 -7 ± 1 -0.93 ± 0.17 
+4R2 8 4 ± 1 0.12 ± 0.01 -35 ± 3 -84 ± 11 -9 ± 3 -1.11 ± 0.32 
R73 7 14 ± 0.4 0.53 ± 0.07 -84 ± 12 -254 ± 44 -6 ± 1 -0.88 ± 0.13 
Hcy2 4 10 ± 2 1.17 ± 0.10 -35 ± 2 -91 ± 7 -4 ± 0.4 -0.92 ± 0.10 
1The number of measurements is indicated as subscript behind the peptide name.  
2Errors denote standard deviations. 
 
 
Figure 2: ITC measurements for the interaction of hLF variants with HS. (a-e) Upper panels: raw ITC data 
showing the heat changes over the time course of a single experiment. One peak corresponds to one injection of HS 
into the cell with peptide. Lower panels: integrated heats per HS injection as a function of the molar ratio of 
HS/peptide. Correlations between binding constant (f) and stoichiometry (g) with the uptake efficiency at 5 µM in 
HeLa cells. Each point represents the mean of at least two experiments. Error ranges are shown in Table 2. 
 
Since not only HS binding but also the ability to cluster HS had been shown to contribute to the efficiency 
of endocytosis of CPPs [18,13], the capacity of the peptides to form complexes with HS was measured by 
dynamic light scattering (DLS) (Figure 3, Supplementary Figure S3). All peptides had the ability to 
cluster HS in a concentration-dependent manner except hLF K7, which did not form a significant number 
of clusters at all as deduced from the intensity of the scattered light (Figure 3a). Interestingly, hLF lin+4R 
that s owed a good uptake and had few binding sites was poor in clustering HS, whereas R7, that was 
poorly taken up, had the same capacity to cluster HS as hLF +4R. Clusters for all peptides had a 
comparable size (Figure 3b), indicating that the scattering intensity provided valid information on the 
number of clusters.  
 
Figure 2: ITC measurements for the interaction of hLF variants with HS. (a-e) Upper panels: raw ITC 
data showing the heat changes over the time course of a single experiment. One peak corresponds to one 
injection of HS into the cell with peptide. Lower panels: integrated heats per HS injection as a function of the 
molar ratio of HS/peptide. Correlations between binding constant (f) and stoichiometry (g) with the uptake 
eficiency at 5 µM in HeLa cells. Each point represents the mean of at least two experiments. Error ranges are 
shown in Table 2.
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Table 2 Thermodynamic parameters derived from ITC binding studies between hLF variants and HS
Arginines
(N)
Sites per 
HS
(N)
K
D
(µM)
Enthalpy
(kcal-1mol-1)
Entropy
(cal-1mol-1deg-1)
Enthalpy
(per hLF)
Enthalpy
(per Arg)
hLF WT
3
1 4 9 ± 12 0.64 ± 0.07 -31 ± 5 -75 ± 15 -3 ± 1 -0.78 ± 0.22
lin+4R
4
8 6 ± 1 0.24 ± 0.04 -41 ± 15 -106 ± 4 -7 ± 1 -0.93 ± 0.17
+4R
2
8 4 ± 1 0.12 ± 0.01 -35 ± 3 -84 ± 11 -9 ± 3 -1.11 ± 0.32
R7
3
7 14 ± 0.4 0.53 ± 0.07 -84 ± 12 -254 ± 44 -6 ± 1 -0.88 ± 0.13
Hcy
2
4 10 ± 2 1.17 ± 0.10 -35 ± 2 -91 ± 7 -4 ± 0.4 -0.92 ± 0.10
1The number of measurements is indicated as subscript behind the peptide name. 
2Errors denote standard deviations.
Since not only HS binding but also the ability to cluster HS had been shown to contribute to the 
eficiency of endocytosis of CPPs [18,13], the capacity of the peptides to form complexes with HS 
was measured by dynamic light scattering (DLS) (Figure 3, Supplementary Figure S3). All peptides 
had the ability to cluster HS in a concentration-dependent manner except hLF K7, which did not 
form a signiicant number of clusters at all as deduced from the intensity of the scattered light 
(Figure 3a). Interestingly, hLF lin+4R that showed a good uptake and had few binding sites was 
poor in clustering HS, whereas R7, that was poorly taken up, had the same capacity to cluster 
HS as hLF +4R. Clusters for all peptides had a comparable size (Figure 3b), indicating that the 
scattering intensity provided valid information on the number of clusters. 
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Figure 3: Determination of complex formation by dynamic light scattering. The indicated concentrations of the 
peptides were titrated into 50 µM HS and the count rate and sizes of complexes were measured; (a) count rate, (b) 
cluster size. The capacity to cluster HS is inferred from the count rate of scattered light measured in HBS at 37°C. 
Error bars denote standard errors of the mean of at least two independent experiments. (c) Correlation between count 
rate (at a peptide concentration of 2 µM) and uptake efficiency at 5 µM in HeLa cells. 
 
Impact of glycocalyx removal on uptake efficiency 
The negative correlation of uptake and stoichiometry revealed a clearly defined impact of the glycocalyx 
on peptide uptake. Furthermore, the differences in stoichiometry demonstrated that the peptides differed 
in their capacity to engage the glycocalyx. We therefore hypothesized that removal of the glycocalyx 
should affect peptide uptake in a non-uniform manner. Two hypotheses are conceivable: First, for 
peptides with a high stoichiometry, the glycocalyx may act as a buffer, leading to an enhancement of 
uptake upon GAG removal for those peptides in particular. Second, a low stoichiometry may promote 
uptake, because these peptides are efficiently cross-linking the glycocalyx. Then, removal of the 
glycocalyx should lead to reduced uptake of these peptides. In order to address these hypotheses, HS was 
removed by a heparinase treatment. Surprisingly, HS removal did not have any effect on the uptake of 
any of the tested peptides (Supplementary Figure S4). We have already shown earlier that heparinase 
treatment greatly reduced membrane binding of hLF but had only little effect on uptake [9]. Since the 
glycocalyx is not only composed of HS but also of other negatively charged sugars, such as the GAGs, 
CS and DS as well as HA and SA, we completely digested the glycocalyx of HeLa cells using an enzyme 
cocktail. The efficiency of removal of the sugars was confirmed by staining the specific epitopes with 
antibodies (Supplementary Figure S5). The membrane integrity was not affected by the GAG removal, as 
was confirmed by the absence of an increased propidium iodide staining in comparison to the untreated 
control (Supplementary Figure S5). Complete digestion of the whole glycocalyx decreased uptake of hLF 
+4R and hLF lin+4R by about 50 % and 30 % at 5µM, respectively (Figure 4, Supplementary Figure S6). 
In contrast, uptake of the wild-type peptide, and the R7 and Hcy variants remained unaffected, supporting 
an uptake-promoting role of the glycocalyx for the peptides with a low stoichiometry and refuting the 
hypothesis of a buffering effect.  
 
Figure 3: Determination of complex formation by dynamic light scattering. The indicated 
concentrations of the peptides were titrated into 50 µM HS and the count rate and sizes of complexes were 
measured; (a) count rate, (b) cluster size. The capacity to cluster HS is inferred from the count rate of scattered 
light measured in HBS at 37°C. Error bars denote standard errors of the ean of at least two independent 
experiments. (c) Correlation between count rate (at a peptide concentration of 2 μM) and uptake eficiency 
at 5 μM in HeLa cells.
Impact of glycoc lyx removal on uptake ficiency
The negative correlation of uptake and stoichiometry revealed a clearly deined impact of the 
glycocalyx on peptide uptake. Furthermore, the differences in stoichiometry demonstrated that 
the peptides differed in their capacity to engage the glycocalyx. We therefore hypothesized that 
removal of the glycocalyx should affect pept de uptake in a non-uniform manner. Two hy othes s 
are conceivable: First, for peptides with a high stoichiometry, the glycocalyx may act as a buffer, 
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leading to an enhancement of uptake upon GAG removal for those peptides in particular. 
Second, a low stoichiometry may promote uptake, because these peptides are eficiently cross-
linking the glycocalyx. Then, removal of the glycocalyx should lead to reduced uptake of these 
peptides. In order to address these hypotheses, HS was removed by a heparinase treatment. 
Surprisingly, HS removal did not have any effect on the uptake of any of the tested peptides 
(Supplementary Figure S4). We have already shown earlier that heparinase treatment greatly 
reduced membrane binding of hLF but had only little effect on uptake [9]. Since the glycocalyx 
is not only composed of HS but also of other negatively charged sugars, such as the GAGs, CS 
and DS as well as HA and SA, we completely digested the glycocalyx of HeLa cells using an 
enzyme cocktail. The eficiency of removal of the sugars was conirmed by staining the speciic 
epitopes with antibodies (Supplementary Figure S5). The membrane integrity was not affected 
by the GAG removal, as was conirmed by the absence of an increased propidium iodide staining 
in comparison to the untreated control (Supplementary Figure S5). Complete digestion of the 
whole glycocalyx decreased uptake of hLF +4R and hLF lin+4R by about 50 % and 30 % at 5μM, 
respectively (Figure 4, Supplementary Figure S6). In contrast, uptake of the wild-type peptide, 
and the R7 and Hcy variants remained unaffected, supporting an uptake-promoting role of the 
glycocalyx for the peptides with a low stoichiometry and refuting the hypothesis of a buffering 
effect. 
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Figure 4: Peptide uptake at 5 µM after full digestion of the glycocalyx. After removal of HS, CS, DS, HA and 
SA for 1.5 h, the uptake of the indicated peptide variants was quantified by flow cytometry. (a) Comparison of 
fluorescence with and without digestion. (b) Degree of reduction after digestion compared to non-treated cells. Error 
bars denote SEM (n=2). 
 
Cell line dependence of the uptake of hLF variants 
The negative correlation of stoichiometry of binding with uptake and the effect of GAG removal 
indicated that efficient cross-linking of HS chains promotes rather than compromises uptake. In order to 
exclude that this correlation is a particular characteristic of HeLa cells, we compared uptake in HeLa cells 
with two cells lines positive for HS (Caco-2 [33,34] and Ovcar-3 cells [35,36]). In addition, we also 
included Jurkat cells in our analysis as this cell line carries only a few GAGs [17,21]. For these cells, 
uptake efficiency should be independent of stoichiometry, similar to HeLa cells after enzymatic GAG 
removal. Because Jurkat cells are more sensitive to peptide uptake both in the induction of NZ-dependent 
uptake and toxicity, peptide concentrations were adjusted to 1 and 5 µM. The relative uptake efficiencies 
in the HS-expressing cell lines Caco-2 and Ovcar-3 were very similar to the ones of HeLa cells 
(Supplementary Figure S9). Primarily, for all GAG-positive cells, the +4R variants showed a strongly 
increased uptake in comparison to the other variants and the uptake of R7 and K7 was lower than the one 
of the hLF WT peptide. 
In contrast, in Jurkat cells the uptake of hLF lin+4R and hLF +4R relative to hLF WT was decreased at 
low concentrations (1 µM), whereas the uptake of hLF R7 and hLF K7 was reduced to a much smaller 
extent compared to HeLa cells (Figure 5, Supplemental Figure S7, S8). Therefore, consistent with our 
hypothesis, for Jurkat cells the relative uptake efficiencies were more similar to the GAG-digested HeLa 
cells than to the untreated HeLa cells. At 5 µM, the uptake pattern was more similar to that in HeLa cells 
except that the uptake of hLF +4R was as efficient as hLF WT, consistent with the fact that at this higher 
concentration endocytosis-independent uptake via NZ is triggered. 
 
Figure 4: Peptide uptake at 5 μM aft r full diges ion of the glycocalyx. After removal of HS, CS, DS,
HA and SA for 1.5 h, the uptake of the indicated peptide variants was quantiied by low cytometry. (a) 
Comparison of luorescence with and without digestion. (b) Degree of reduction after digestion compared to 
non-treated cells. Error bars denote SEM (n=2).
Cell line dependence of the uptak  of hLF variants
The negative correlation of stoichiometry of bi ding with uptak  and the effect of GAG removal 
indicated that eficient cross-linking of HS chains promotes rather tha  compromises uptake. 
In order to exclude that this correlation is a particular chara teristi  of HeLa cells, we compared 
uptake in HeLa cells with two c lls lines positive for HS (Caco-2 [33,34] and Ovcar-3 cells [35,36]). 
In addition, we also included Jurkat cells in our analysis as this cell line carries only a few GAGs 
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[17,21]. For these cells, uptake eficiency should be independent of stoichiometry, similar to HeLa 
cells after enzymatic GAG removal. Because Jurkat cells are more sensitive to peptide uptake both 
in the induction of NZ-dependent uptake and toxicity, peptide concentrations were adjusted to 1 
and 5 µM. The relative uptake eficiencies in the HS-expressing cell lines Caco-2 and Ovcar-3 were 
very similar to the ones of HeLa cells (Supplementary Figure S9). Primarily, for all GAG-positive 
cells, the +4R variants showed a strongly increased uptake in comparison to the other variants 
and the uptake of R7 and K7 was lower than the one of the hLF WT peptide.
In contrast, in Jurkat cells the uptake of hLF lin+4R and hLF +4R relative to hLF WT was decreased 
at low concentrations (1 µM), whereas the uptake of hLF R7 and hLF K7 was reduced to a 
much smaller extent compared to HeLa cells (Figure 5, Supplemental Figure S7, S8). Therefore, 
consistent with our hypothesis, for Jurkat cells the relative uptake eficiencies were more similar 
to the GAG-digested HeLa cells than to the untreated HeLa cells. At 5 µM, the uptake pattern 
was more similar to that in HeLa cells except that the uptake of hLF +4R was as eficient as hLF 
WT, consistent with the fact that at this higher concentration endocytosis-independent uptake 
via NZ is triggered.
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Figure 5: Uptake of hLF variants in Jurkat cells. Jurkat cells were incubated with 1 µM (a) or 5 µM (b) of the 
indicated peptides for 30 min at 37 °C, washed and analyzed by flow cytometry. (a-b) Median fluorescence of the 
hLF variants was normalized to hLF WT. Bars indicate the average of the median of at least three independent 
experiments. Error bars denote the standard error of the mean (SEM). (c) Confocal microscopy images of 1 µM of 
the peptides incubated for 30 min at 37 °C. 
 
Definition of structural determinants in HS binding 
After the determination of the HS binding characteristics by ITC and DLS, two broadly used techniques 
to characterize HS binding in the field of CPPs, we wanted to take the analysis of the peptide-HS 
interaction a step further and determine whether there are structural determinants of HS itself that lead to 
binding preferences for all or individual peptides. For this purpose, the HS binding of hLF WT, hLF Hcy 
and hLF +4R which differ in uptake efficiency and stoichiometry was measured using microarrays 
carrying a collection of synthetic glycans of various length and degree of sulfation (Figure 6a) [23-26]. 
All peptides bound to 5 kDa natural heparin (Figure 6 b-d). When comparing the intensities of the signals, 
the binding patterns for the three hLF variants showed clearly distinct binding profiles. hLF WT and hLF 
Hcy bound to all structures. The binding of hLF Hcy was weaker than that of hLF WT which is in 
agreement with the lower binding affinity for HS compared to hLF WT (Table 2). To our surprise, hLF 
+4R could only be detected on structures 5 and 9 at very low intensities and on the control 5 kDa heparin 
in spite of its high affinity for HS. For the other signals, no clear correlation could be found between 
structural characteristics and binding intensities except that structures with N-sulfation showed stronger 
binding than the N-acetylated variants (eg. structure 3 vs. 4). In addition, whereas 2-O-sulfation promotes 
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Deinition of structural determinants in HS binding
After the determination of the HS binding characteristics by ITC and DLS, two broadly used 
techniques to characterize HS binding in the ield of CPPs, we wanted to take the analysis of the 
peptide-HS interaction a step further and determine whether there are structural determinants of 
HS itself that lead to binding preferences for all or individual peptides. For this purpose, the HS 
binding of hLF WT, hLF Hcy and hLF +4R which differ in uptake eficiency and stoichiometry was 
measured using microarrays carrying a collection of synthetic glycans of various length and degree 
of sulfation (Figure 6a) [23-26]. All peptides bound to 5 kDa natural heparin (Figure 6 b-d). When 
comparing the intensities of the signals, the binding patterns for the three hLF variants showed 
clearly distinct binding proiles. hLF WT and hLF Hcy bound to all structures. The binding of hLF 
Hcy was weaker than that of hLF WT which is in agreement with the lower binding afinity for 
HS compared to hLF WT (Table 2). To our surprise, hLF +4R could only be detected on structures 
5 and 9 at very low intensities and on the control 5 kDa heparin in spite of its high afinity for 
HS. For the other signals, no clear correlation could be found between structural characteristics 
and binding intensities except that structures with N-sulfation showed stronger binding than the 
N-acetylated variants (eg. structure 3 vs. 4). In addition, whereas 2-O-sulfation promotes binding 
(e.g. structure 6), 6-O-sulfation is disadvantageous (e.g. structure 2 vs. 6). Very clearly, charge 
alone is insuficient to explain binding preferences. 
DISCUSSION
Binding of CPPs to HS has been described to support eficient internalization via endocytosis 
[13-16]. However, there is still no consistent picture on the relationships of HS binding and CPP 
internalization. In order to gain more insight into the interdependence of the HS interaction 
and internalization, we designed a set of hLF-derivatives varying in the number and position of 
arginine residues. 
Using ITC for a subset of variants, we obtained a comprehensive analysis of the thermodynamics 
and stoichiometry of HS binding. Very interestingly, even though binding constants differed by 
up to one order of magnitude, there was no clear correlation of afinity for HS and uptake. This 
inding is in line with our previous results for L-peptides and their D-counterpart [17] which, in 
spite of identical afinities, showed a strongly reduced uptake of the D-peptides, indicative of 
a chirality-sensitive trigger. Here, we found in addition to the chirality-sensitive trigger a strong 
negative correlation between the stoichiometry of HS binding and endocytic uptake (Figure 2). 
We considered two different hypotheses as the basis for this observation. First, the glycocalyx 
could act as a buffer, sequestering those peptides with a high stoichiometry and thus reducing 
their uptake. Second, peptides with a low stoichiometry could have a stronger capacity to cross-
link HS thus leading to eficient internalization (Figure 7). The fact that removal of the glycocalyx 
reduced the uptake of the low stoichiometry peptides while not affecting the uptake of the high 
stoichiometry peptides strongly favors the second hypothesis. 
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Figure 6: Binding of hLF variants to glycan microarrays. (a) Molecular structures, (b) microarray layout 
and peptide binding shown for hLF WT, (c) binding speciicities of the three tested peptides. Fluorescence 
intensity values (excitation wavelength 488 nm) were determined using the GenePix Pro 7 software (Molecular 
Devices). Mean values ± S.E.M. of n=20 spots at the highest concentrations of two independent microarrays 
are plotted. 
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Cross-linking of the glycocalyx by hLF lin+4R and hLF +4R contributes to the high uptake of 
these peptides, while contributing less to the uptake of hLF R7. This model is also supported by 
the similarity of uptake proiles for HS-positive cells and the reduced uptake of hLF lin+4R and 
hLF +4R in HS-poor Jurkat cells. Neither for GAG-digested HeLa cells, nor for Jurkat cells was 
a correlation between uptake and stoichiometry present (Supplementary Figure S10). It will be 
interesting to explore to which extent this correlation also holds for D-peptides, which showed a 
reduced capacity to induce endocytosis. Such experiments should answer the question whether 
GAG cross-linking and the elusive chirality-dependent trigger are part of the same molecular 
mechanism.
Remarkably, the capacity to cluster HS, as measured by DLS, did neither correlate with the binding 
stoichiometry nor with uptake eficiency. This observation adds a shade to the more general 
concept that associates the capacity to cluster HS to uptake [18], a concept that is also violated 
for variants of the CPP TP10 [21]. Very clearly, cross-linking of HS on the cell surface depends to 
a larger extent on the stoichiometry of binding than clustering in solution.
Interestingly, Ziegler and Seelig showed that the CPP WR9 that was able to induce GAG clustering 
showed uptake via endocytosis and NZ, while a PEGylated variant that failed to cluster GAG was 
taken up by endocytosis only [19]. These results are in agreement with our indings that hLF +4R 
being the most eficient in clustering HS, was also the only peptide showing uptake via NZ at 5 
µM (Figure 1). However, our data also supports a positive effect of GAG clustering on induction 
of endocytosis which was also shown for other guanidinium-rich transporters and polyplexes 
[37,38]. As an alternative explanation for an induction of NZ-dependent uptake via HS clustering 
it may be possible that when fewer peptide molecules are sequestered by HS a higher amount of 
peptide is still available that may be taken up via NZ.
Despite the strong negative correlation of stoichiometry and uptake, we did not arrive at a 
consistent structural model to explain the differences in stoichiometry. Of those peptides that 
showed good uptake eficiencies and contained more arginine residues (e.g. lin+4R, +4R) fewer 
peptide molecules were bound to one HS molecule (Table 2), consistent with charge neutralization 
as the underlying principle [18, 39]. Remarkably, hLF +4R, having the best capability of clustering 
HS, showed a binding stoichiometry that was the closest to charge neutralization compared to 
the other peptides tested. This estimate is based on the sulfur content of 5.4 % of the HS used 
in ITC which can be translated into 23 sulfonic acid groups. These sulfonic acid groups are co-
occurring with ~ 23 carboxyl groups leading to 46 charges in total and as hLF +4R has 11 positive 
charges and four hLF +4R are binding per HS, roughly all charges are neutralized. However, the 
importance of arginine residues for binding HS and the occurrence of charge neutralization was 
violated by hLF R7 for which replacement of all lysine residues by arginines resulted in a much 
higher stoichiometry and also had a negative impact on the uptake eficiency. 
The stoichiometry of peptide-heparan sulfate binding as a determinant of uptake efficiency of CPPs  |  67
3
58 
 
 
Figure 7: Schematic of the proposed stoichiometry-dependence of uptake. With a higher binding stoichiometry, 
peptides have a limited capacity to cross-link HS. In contrast, peptides with a low stoichiometry, effectively cross-
link HS leading to proteoglycan clustering and internalization. 
 
Remarkably, the capacity to cluster HS, as measured by DLS, did neither correlate with the binding 
stoichiometry nor with uptake efficiency. This observation adds a shade to the more general concept that 
associates the capacity to cluster HS to uptake [18], a concept that is also violated for variants of the CPP 
TP10 [21]. Very clearly, cross-linking of HS on the cell surface depends to a larger extent on the 
stoichiometry of binding than clustering in solution. 
Interestingly, Ziegler and Seelig showed that the CPP WR9 that was able to induce GAG clustering 
showed uptake via endocytosis and NZ, while a PEGylated variant that failed to cluster GAG was taken 
up by endocytosis only [19]. These results are in agreement with our findings that hLF +4R being the 
most efficient in clustering HS, was also the only peptide showing uptake via NZ at 5 µM (Figure 1). 
However, our data also supports a positive effect of GAG clustering on induction of endocytosis which 
was also shown for other guanidinium-rich transporters and polyplexes [37,38]. As an alternative 
explanation for an induction of NZ-dependent uptake via HS clustering it may be possible that when 
fewer peptide molecules are sequestered by HS a higher amount of peptide is still available that may be 
taken up via NZ. 
Despite the strong negative correlation of stoichiometry and uptake, we did not arrive at a consistent 
structural model to explain the differences in stoichiometry. Of those peptides that showed good uptake 
efficiencies and contained more arginine residues (e.g. lin+4R, +4R) fewer peptide molecules were bound 
to one HS molecule (Table 2), consistent with charge neutralization as the underlying principle [18, 39]. 
Remarkably, hLF +4R, having the best capability of clustering HS, showed a binding stoichiometry that 
was the closest to charge neutralization compared to the other peptides tested. This estimate is based on 
the sulfur content of 5.4 % of the HS used in ITC which can be translated into 23 sulfonic acid groups. 
These sulfonic acid groups are co-occurring with ~ 23 carboxyl groups leading to 46 charges in total and 
Figure 7: Schematic of the proposed stoichiometry-dependence of uptake. With a higher binding 
stoichiometry, peptides have a limited capacity to cross-link HS. In contrast, peptides with a low stoichiometry, 
effectively cross-link HS leading to proteoglycan clustering and internalization.
Us ng ic oarrays carrying HS structures with different length and degre  of sulfation, most 
strikingly, hLF +4R that had the lowest binding stoichiometry showed the poorest interaction with 
the microarrays. This observation can be explained by the fact that the synthetic oligosaccharides 
were too short to provide binding sites for all arginine residues in the peptide. Consistent with 
t is consideration, with a molecular weight of the HS used in ITC o  13.63 kDa and on average 55 
sugars per chain, hLF WT and hLF Hcy engage six sugar units, which matches the lengths of the 
strongly bound HS on the microarrays. The lower binding afinities for hLF Hcy compared to hLF 
WT can be explained by the lower binding afinity measured by ITC. In contrast, hLF +4R requires 
14 sugar molecules (3.04 kDa) for binding which on the array was only provided y the natural 
15 kDa heparin. It is important to note that in nature, the HS chain length is much longer than 
the synthetic HS structures: HS vary between 5 and 70 kDa corresponding to 15-230 times larger 
than the HS structures on the microarray [40]. 
When testing the biological effect of HS removal on HeLa cells, only a weak and poorly reproducible 
reduction of uptake was observed. However, when he wh le glycocalyx including other GAGs 
like CS, DS and also HA and SA were removed, a strong reduction in uptake was observed for 
hLF +4R (Figure 4) being most eficient in clustering HS. These results indicate that not only HS 
are involved in the uptake of arginine-rich CPP but also the other sugars of the glycocalyx. So far, 
the focus on GAG involvement for CPP uptake has mostly been on HS. Recently, the involvement 
of SA and other GAGs was studied for CPP but a clear picture about the structural requirements 
for eficient CPP binding and internalization is still missing and should be investigated in more 
detail [41,42].
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In conclusion, by performing a detailed analysis of uptake, binding constants and stoichiometry 
for a set of variants of the lactoferrin-derived CPP, we established a well-deined structure-
activity relationship for HS binding and uptake where stoichiometry was the decisive factor. This 
inding sheds more light on the mechanism of uptake of arginine-rich CPP but more importantly, 
indicates that in the further development of CPP, even with the same number of positively 
charged residues, well deined functional characteristics exist that control uptake activity. We 
expect our observations to hold for other members of the class of arginine rich peptides. Even 
though not addressed yet, it is reasonable to speculate that stoichiometry may also contribute 
to the dependence of uptake on peptide length for oligoarginines [43]. Nevertheless, we have 
already shown before, that this observation does not hold for other classes of CPP [21]. Such 
knowledge may be decisive when considering future in vivo applications to avoid sequestration 
in the glycocalyx, but instead achieve eficient cellular delivery.
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Table S1 Homology of the human lactoferrin-derived CPP with the corresponding amino acid sequences of 
lactoferrins of other mammalia. 
origin sequence
Human KCFQWQRNMR-KVRGPPVSCIKR1
Chimpanzee KCFRWQRNMR-RVRGPPVSCIKR
Dromedary KCAQWQRRMK-KVRGPSVTCVKK
Horse KCAKFQRNMK-KVRGPSVSCIKR
Goat KCYQWQRRMR-KLGAPSITCVRR
Sheep KCYQWQRRMR-KLGAPSITCVRR
Water buffalo KCHRWQWRMK-KLGAPSITCVRR
Bovine KCRRWQWRMK-KLGAPSITCVRR
Wild Yak KCRRWQWRMK-KLGAPSITCVRR
Pig KCRQWQSKIR-RTN-P-IFCIRR
Mouse KCLRWQNEMR-KVGGPPLSCVKK
Rat KCFMWQ-EMLNKAGVPKLRCARK
1 Highly conserved residues are underlined.
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Figure S1 Flow cytometry histograms of hLF variants in HeLa cells after a 30 min incubation at 37°C. (a-e) 5 µM, 
(f-j) 20 µM of the indicated peptides. 
Figure S1 Flow cytometry histograms of hLF variants in HeLa cells after a 30 min incubation at 37°C. (a-e) 5 
µM, (f-j) 20 µM of th  indicated peptides.
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 Figure S2 Confocal microscopy of HeLa cells incubated for 30 min with 5 (a) or 20 µM (b) of the indicated 
peptides. Figure S2 Confocal microscopy of HeLa cells incubated for 30 min with 5 (a) or 20 µM (b) of the indicated peptides.
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 Figure S2 Confocal microscopy of HeLa cells incubated for 30 min with 5 (a) or 20 µM (b) of the indicated 
peptides. 
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Figure S3 Size distributions per volume of HS-peptide clusters determined by DLS. The different peptide solutions 
(50 µM) were titrated into 100 µL of a 10 µM HS solution in a ZEN0040 disposable cuvette. Samples were 
incubated for 3 min at 37 °C, were mixed again and 3x12 measurements were performed.  
 
 
 
Figure S4 Uptake of peptides at 5 µM after heparinase treatment. (a-b) Flow cytometry histograms, (c) normalized 
median fluorescence. One single experiment is shown. 
 
Figure S3 Size distributions per volume of HS-peptide clusters determined by DLS. The different peptide 
solutions (50 µM) were titrated into 100 µL of a 10 µM HS solution in a ZEN0040 disposable cuvette. Samples 
were incubated for 3 min at 37 °C, were mixed again and 3x12 measurements were performed. 
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Figure S5 Proof for efficient removal of the glycocalyx. After the incubation with the enzyme cocktail, HeLa cells 
were stained as described before [1] (a, b). Briefly, cells were incubated with single chain antibody fragments 
(scFv’s) against epitopes of HS (HS4C3V-vsv), CS (I03H10V-vsv) and DS (LKN1V-vsv) for 45 min at RT. After 
washing with HBS, cells were incubated with the 2nd mouse-anti vsv (P5D4) antibody for 45 min at RT. Finally, 
cells were incubated with the 3rd antibody (goat-anti-mouse IgG Alexa Fluor 488) for 30 min at 4°C, detached by 
EDTA and measured by flow cytometry. (c) Staining of cell surface sialic acids was performed by metabolic 
labelling as described earlier [2]. Cells were incubated overnight in the presence or absence of 50 µM Ac4ManNAz. 
Cells were washed three times with HBS and incubated with 60 µM BCN-biotin (SynAffix, Nijmegen, the 
Netherlands) for 60 min at RT. After washing cells three times with HBS, and incubation with HBS containing 
Alexa Fluor 488-conjugated streptavidin (5 µg/mL) (Invitrogen, Eugene, USA) for 30 min at 4°C, followed by three 
final washing steps, cells were kept in pre-warmed culture medium and analyzed immediately by confocal 
microscopy. Detection of sialic acids by FACS was omitted because cell surface signal was lost already in non-
digested metabolically labeled cells after detachment with EDTA. (d) A loss of the signal during detachments was 
observed for hyaluronic acid. Here, cells were incubated with biotin conjugated hyaluronic acid binding protein 
(HABP) (Sigma Aldrich, St. Louis, USA) for 45 min at RT, followed by Streptavidin-conjugated Alexa Fluor 488 
incubation for 30 min at 4°C. Cells were kept in pre-warmed culture medium and analyzed by confocal microscopy. 
(e) Scatter plots showing the fraction of PI positive cells for the population of morphologically intact cells as gated 
Figure S5 Proof for eficient removal of the glycocalyx. After the incubation with the enzyme cocktail, HeLa 
cells were stained as described before [1] (a, b). Briely, cells were incubated with single chain antibody 
fragments (scFv’s) against epitopes of HS (HS4C3V-vsv), CS (I03H10V-vsv) and DS (LKN1V-vsv) for 45 min 
at RT. After washing with HBS, cells were incubated with the 2nd mouse-anti vsv (P5D4) antibody for 45 
min at RT. Finally, cells were incubated with the 3rd antibody (goat-anti-mouse IgG Alexa Fluor 488) for 30 
min at 4°C, detached by EDTA and measured by low cytometry. (c) Staining of cell surface sialic acids was 
performed by metabolic labelling as described earlier [2]. Cells were incubated overnight in the presence or 
absence of 50 μM Ac4ManNAz. Cells were washed three times with HBS and incubated with 60 μM BCN-
biotin (SynAfix, Nijmeg n, the Netherlands) for 60 min at RT. After was ing cells three times with HBS, nd 
incubation with HBS containing Alexa Fl or 488-conjugated streptavidi  (5 μ /mL) (Invitrogen, Eugene, USA) 
for 30 min at 4°C, followed by thre  inal washing steps, cells were kept in pre-warmed culture medium and 
analyzed immediately by confocal microscopy. Detection of sialic acids by FACS was omitted because cell 
surface signal was lost already in non-digested metabolically labeled cells after detachment with EDTA. (d) A 
loss of the signal during detachments was observed for hyaluronic acid. Here, cells were incubated with biotin 
conjugated hyaluronic acid binding protein (HABP) (Sigma Aldrich, St. Louis, USA) for 45 min at RT, followed 
by Streptavidin-conjugated Alexa Fluor 488 incubation for 30 min at 4°C. Cells were kept in pre-warmed 
culture medium and analyzed by confocal microscopy. (e) Scatter plots showing the fraction of PI positive cells 
for the population of morphologically intact cells as gated by forward versus sideward scatter (not shown). 
Propidium iodide (2.5 µg/mL) was added to the cells directly before the measurement.
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by forward versus sideward scatter (not shown). Propidium iodide (2.5 µg/mL) was added to the cells directly before 
the measurement. 
  
Figure S6 Flow cytometry histograms of peptides after 30 min incubation at 37 °C at 5 µM after full digestion of 
the glycocalyx. 
 
 
 
Figure S7 Flow cytometry histograms of Jurkat cells incubated with 1 (A) and 5 µM (B) of the indicated peptides 
for 30 min at 37°C.  
 
 
Figure S8 Confocal microscopy of Jurkat cells incubated for 30 min with 5 µM of the peptides at 37°C. 
Figure S6 Flow cytometry histograms of peptides after 30 min incubation at 37 °C at 5 µM after full digestion 
of the glycocalyx.
68 
 
by forward versus sideward scatter (not shown). Propidium iodide (2.5 µg/mL) was added to the cells directly before 
the measurement. 
  
Figure S6 Flow cytometry histograms of peptides after 30 min incubation at 37 °C at 5 µM after full digestion of 
the glycocalyx. 
 
 
 
Figure S7 Flow cytometry histograms of Jurkat cells incubated with 1 (A) and 5 µM (B) of the indicated peptides 
for 30 min at 37°C.  
 
 
Figure S8 Confocal microscopy of Jurkat cells incubated for 30 min with 5 µM of the peptides at 37°C. 
Figure S7 Flow cytometry histograms of Jurkat cells incubated with 1 (A) and 5 µM (B) of the indicated 
peptides for 30 min at 37°C. 
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i  Fl  cytometry histograms of Jurkat cells incubated with 1 (A) and 5 µM (B) of the indicate  pepti es 
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Figure S8 Confocal microscopy of Jurkat cells incubated for 30 min with 5 µM of the peptides at 37°C. Figure S8 Confocal microscopy of Jurkat cells incubated for 30 min with 5 µM of the peptides at 37°C.
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Figure S9 Flow cytometry histograms and medians of Ovcar-3 cells incubated for 30 min at 37°C with 5 µM (a, c) 
or 20 µM (b, d) and Caco-2 cells at 5 µM (e, g) and 20 µM (f, h). 
 
 
 
 
Figure S9 Flow cytometry histograms and medians of Ovcar-3 cells incubated for 30 min at 37°C with 5 µM 
(a, c) or 20 µM (b, d) and Caco-2 cells at 5 µM (e, g) and 20 µM (f, h).
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Figure S10 Correlations between stoichiometry (a-c) and binding constant (d-f) with the uptake efficiency at 5 µM 
in digested HeLa cells or in Jurkat cells at 1 or 5 µM. Each point represents the mean of at least two experiments. 
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ABSTRACT
For arginine-rich cell-penetrating peptides (CPPs), an association with heparan sulfate (HS) chains 
is considered the irst step in the stimulation of uptake for many cells. Much less is known about 
the role of HS chains in the cell-association and internalization of arginine-free amphipathic CPP 
such as Transportan-10 (TP10). Here, we report that various TP10 analogs differ in their capacity 
to accumulate on HS-rich plasma membranes in an HS-dependent manner. No accumulation was 
observed on HS-poor plasma membranes or when HS was removed by enzymatic cleavage. The 
TP10 analog that strongly clustered on the cell surface, also showed a pronounced capacity to 
form clusters with HS chains in solution. However, aggregation occurred in a thermodynamically 
different way compared to the interaction of arginine-rich CPP with HS. To monitor the impact 
of the peptide on the aggregation of the glycocalyx by time-lapse microscopy, sialic acids were 
visualized by metabolic labeling using copper-free click chemistry to attach luorophores to 
metabolically incorporated azido sugars. Strikingly, a highly enhanced HS-mediated accumulation 
on the plasma membrane of a particular TP10 analog did not correlate with a better uptake. 
These indings illustrate that the mode of interaction between cell-penetrating peptides and HS 
chains has important functional consequences regarding peptide internalization and that there is 
no direct coupling of interaction, accumulation and uptake.
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INTRODUCTION
Cell-penetrating peptides (CPPs) are a promising class of molecules that are being applied to 
shuttle membrane-impermeable cargo into cells. To date, most applications relate to biomedical 
research. Ultimately, the goal is to apply these molecules for therapeutic purposes. After almost 
twenty years of investigation, there is now a considerable understanding about the routes CPP 
may exploit to enter into cells [1, 2] and the kind of effects they have on the physiology of the 
cell [3]. There is a widespread agreement that the route of uptake depends on multiple factors, 
including the type and concentration of the CPP, the cell-type and the cargo, and that multiple 
import pathways may be exploited simultaneously [1, 4, 5]. The most prominent types of CPP 
that can be distinguished are the arginine-rich CPP and the cationic amphipathic CPP. The TAT-
peptide and nonaarginines are important representatives of the irst class [6, 7]. Transportan and 
its shorter analog TP10 are members of the second one [8, 9]. There is ample evidence that in 
spite of the physicochemical differences, transportans and the arginine-rich CPP are internalized 
by endocytosis, even though uptake routes may differ in details [10, 11].
In the analysis of molecular interactions leading to peptide uptake, studies in particular have 
addressed the electrostatic binding to lipids and glycosaminoglycans (GAGs), which are negatively 
charged sugars with a high abundance on the surface of most cell types [12-14].[5-8][5-8] One of 
the most prominent indings that has been obtained from GAG-binding studies is that arginine-
rich peptides have submicromolar afinities for heparan sulfate (HS) chains, whereas afinities 
for lipid membranes are much lower [13]. Indeed, abundant evidence exists for the notion that 
cationic CPPs have the ability to interact with GAGs in biological systems and that this interaction 
contributes to uptake [10, 15-21]{Formatting Citation}{Formatting Citation}{Formatting Citation}
{Formatting Citation}. 
According to a recent model, the initial interaction with arginine-rich CPP leads to GAG clustering 
and activation of intracellular signaling cascades, and both processes have been proposed to 
facilitate CPP uptake [20-22]. Speciically, syndecan-4, was shown to be closely involved in uptake 
[15]. This protein is a ubiquitously expressed member of the syndecan protein family, which next 
to glypicans is one of the two main families of membrane-bound HS-carrying proteins [23, 24]. 
But other membrane-associated proteoglycans may be involved as well [20]. The Rho GTPase 
Rac-1 has been suggested as a critical factor in peptide internalization [20]. Interestingly, highly 
similar mechanisms have been described for, amongst others, growth factors [25], nonviral 
delivery systems [26-28], viruses [29, 30], and bacteria [31]. These examples suggest that the 
exploitation of membrane-associated proteoglycans, and in particular syndecans, is a mechanism 
widely associated with cellular internalization. Additionally, HS chains have been reported to 
contribute to the uptake of guanidinium-rich CPP mimics [32, 33]. For S4
13
-PV peptides HS on 
the cell surface was required for particle formation [34]. For complexes between DNA and the 
more hydrophobic MPG-β, HS was required for the induction of lamellipodia formation and for a 
Rac-dependent cytoskeletal reorganization, associated with uptake [35].
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In the analysis of HS clustering, the introduction of luorescent reporter groups is a challenge. So far, 
studies have either employed luorescent fusion proteins of syndecans [15] or immunoluorescent 
labeling [36]. However, C-terminal fusions of syndecans abolish their PDZ motif and may 
therefore impair interactions of the cytoplasmic domain while immunoluorescent labeling of 
the extracellular domain or sugars may affect HS dynamics through cross-linking. Recently, 
metabolic labeling has been introduced as a powerful approach in chemical biology to introduce 
sugars for bioorthogonal labeling [37, 38]. However, in CPP research, this is a novelty. Cells are 
cultured in the presence of cell-permeable sugar esters carrying azido-functionalities. Inside the 
cells, the ester groups are cleaved off through the action of esterases and the sugars with the 
azido functionalities are incorporated into glycans analogous to the non azido-functionalized 
endogenous counterparts. After traficking to the cell surface, labels can be introduced through 
copper-free click chemistry [39].
Here, we show for transportan-10 (TP10) and a set of TP10 analogs that these CPPs also interact 
with heparan sulfates on the cell surface but that this interaction is thermodynamically and 
functionally different from the one described for arginine-rich CPP. Metabolic labeling of sialic 
acids was employed for the introduction of luorescent reporter groups in the glycocalyx and for 
monitoring the colocalization of peptide and sugar clustering on the cell surface. Signiicantly, 
the results indicate that HS chains have the capacity to sequester amphipathic CPP in a manner 
that is unproductive for uptake.
MATERIALS AND METHODS
Cell culture 
HeLa and Jurkat E6.1 cells were maintained in DMEM and RPMI 1640 (Gibco, Invitrogen, Eugene, 
U.S.A.), respectively, supplemented with 10 % fetal calf serum (FCS; PAN Biotech). All cells were 
incubated at 37°C in a 5 % CO
2
-containing, humidiied incubator. Cells were passaged every 2 
to 3 days.
Solid-phase peptide synthesis 
All peptides were synthesized on an automated Syro II multiple peptide synthesizer (MultiSynTech, 
Witten, Germany) with standard Fmoc protocols and HOBt/HBTU as coupling reagents. The 
unnatural amino acid CF
3
-Bpg was coupled manually for 2 h using diisopropylcarbodiimide (DIC) 
and HOBt. Peptides were N-terminally labeled with 5(6)-carboxyluorescein before cleavage 
off the resin and side chain deprotection. For luorescein labeling, a 5-fold molar excess 
of  5(6)-carboxyluorescein:DIC:HOBt (1:1:1) in dimethylformamide (DMF) was added to the 
peptide on the resin and was allowed to react for 12 h at room temperature. After washing 
with DMF, dichloromethane (DCM), methanol (MeOH) and diethyl ether, piperidine (20% v/v in 
DMF) was added for 30 min. Afterwards the resin was washed with DMF, DCM and MeOH, dried 
under reduced pressure and the peptide cleaved off the resin using a mixture of triluoroacetic 
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acid (TFA) (93.5%), triisopropylsilane (TIS, 4%) and H
2
O (2.5%). The iltrate was evaporated 
under a gentle stream of N
2
 and the crude peptide was precipitated using diethyl ether and 
lyophilized. The crude peptides were puriied by high-performance liquid chromatography 
(HPLC) on a preparative C18 column (22 × 250 mm) (Vydac, Hesperia, CA, USA) using water-
acetonitrile gradients supplemented with 5 mM HCl. The identity of all peptides was conirmed 
by mass spectrometry. The purity of the peptides was found to be over 95%. The concentration 
of luorescein-labeled peptides was determined by measuring A
492
 in Tris-HCl buffer (pH 8.8), 
assuming a molar extinction coeficient of 75,000 M-1 cm-1.
Bioorthogonal labeling of cells 
HeLa cells (40,000 cells/well) were seeded one day before the experiment in 8-well microscopy 
chambers (Nunc, Wiesbaden, Germany) and incubated in the absence or presence of Ac4ManNAz 
(50 μM) [38, 39] over night. For live-cell labeling, adherend cells were washed three times 
with HBS and incubated with BCN-biotin (60 μM, SynAfix, Nijmegen, The Netherlands) [40] 
or buffer (1 h, 20°C), washed three times with HBS and incubated with HBS containing Alexa 
Fluor 647-conjugated streptavidin (5μg/ml, Invitrogen). After incubation (30 min, 4°C), cells were 
washed three times and kept in pre-warmed culture-medium for 1 h at 37°C, 5% CO
2
 before 
treatment with CPPs and confocal microscopy studies. 
Imaging of peptide uptake by confocal microscopy 
HeLa cells were seeded one (40,000 cells/well), two (20,000 cells/well) or three (10,000 cells/
well) days before the experiment in 8-well microscopy chambers and grown to 75 % conluence. 
Cells were incubated with the indicated concentrations of peptides for 30 or 60 min at 37°C, as 
indicated per experiment. Cells were washed twice after incubation and living cells were analyzed 
immediately by confocal microscopy using a TCS SP5 confocal microscope (Leica Microsystems, 
Mannheim, Germany) equipped with an HCX PL APO 63 x N.A. 1.2 water immersion lens. Cells 
were maintained at 37°C on a temperature-controlled microscope stage. Annexin V-Alexa Fluor 
647 was used at a dilution of 1:50 (Invitrogen). For heparan sulfate removal HeLa cells were 
pre-incubated with 3 mIU of heparinase III (Ibex, Quebec, Canada) in DMEM containing 1 % 
FCS for 1 h at 37°C. For time-lapse confocal microscopy, cell culture medium was replaced by 
pre-warmed culture medium including 10 % FCS, containing TP10 or TP10 Gly2→L-CF
3
-Bpg in 
a inal concentration of 5 μM, followed by life cell confocal imaging at 37°C using excitation at 
488 nm and detection of luorescence over 500 - 550 nm (luorescein) and additional excitation 
at 633 nm and emission of detection over 650 - 750 nm (BCN-biotin / Streptavidin Alexa Fluor 
647 labeled sialic acids) over a timespan of 30 min.
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Flow cytometry 
HeLa cells were seeded in 24-well plates (Sarstedt, Numbrecht, Germany) at a density of 80,000 
cells/well one day prior to the experiment. Heparinase pre-treatments were performed as described 
above. Cells were incubated with 5 µM of the indicated peptide for 30 min or 1 h at 37°C, as 
indicated. When incubating the peptides at 4°C, cells were pre-incubated at 4°C for 10 min to 
ensure temperature adjustment. Subsequently, cells were washed, detached by trypsinization 
for 5 min or using a commercial cell-dissociation solution (Merck Millipore, Billerica, USA), spun 
down and re-suspended in 200 µl RPMI + 10 % fetal calf serum in the presence or absence of 0.4 
% (w/v) trypan blue. When cells were analyzed with trypan-blue solutions via low cytometry, the 
high concentration of 0.4 % (w/v) ensured that quenching was maintained. Propidium iodide was 
included at a concentration of 2.5 µg/ml, where indicated. Cellular luorescence was measured 
using a FACS-Calibur low cytometer using the 488 nm line of an argon ion laser for excitation 
(BD Biosciences, Erembodegem, Belgium) and the data was analyzed with the Summit software 
(Fort Collins, USA) or FCS Express Version 4 Research Edition (De Novo Software, Los Angeles, 
CA). Results were based on > 4000 cells gated on the basis of forward and sideward scatter. 
RESULTS
Membrane association of TP10 analogs in HS-expressing HeLa cells depends on the 
stereochemistry of the introduced 19F-NMR label 
The transportan analog TP10 (AYLLGKINLKALAALAKKIL-NH
2
) is a prototype amphipathic CPP 
that is cationic but free of arginine residues. For a solid-state 19F-NMR based study aimed at 
investigating the membrane-bound structure of TP10, a series of analogs with substitutions of 
individual residues by D- or L-enantiomers of triluoromethyl-bicyclopent-[1.1.1]-1-ylglycine (CF
3
-
Bpg) were synthesized (manuscript in preparation; Figure S1). The two TP10 analogs Gly2→L-
CF
3
-Bpg (A-L-CF3-Bpg-YLLGKINLKALAALAKKIL-NH
2
) and Leu4→L-CF
3
-Bpg (AGY-L-CF3-Bpg-
LGKINLKALAALAKKIL-NH
2
) showed a pronounced membrane staining in HS-expressing HeLa cells 
that was stronger than the one observed for the wild-type (wt) peptide. The observed membrane 
staining was similar to what we had observed previously for arginine-rich peptides that were 
largely or entirely composed of D-amino acids and that had shown a reduced uptake in comparison 
to their L-amino acid counterparts [18]. To assess whether amino acid chirality played a role in 
this binding pattern, we compared cell binding and cell uptake in HeLa cells of these two TP10 
analogs that had shown a pronounced membrane binding when an L-CF
3
-Bpg was introduced, 
with the TP10 analogs that had a D-CF
3
-Bpg substitution at the same position using confocal 
microscopy (Figure 1a). Remarkably, changing the stereochemistry of CF
3
-Bpg had a major impact 
on the membrane staining. Membrane-bound luorescence was markedly reduced or even absent 
for the counterparts that had a D-CF
3
-Bpg substitution. Testing the internalization eficiency by 
low cytometry after incubating the cells for 1 h with peptide and quenching of luorescence 
associated with the outside of the cell with trypan blue [41-43], we conirmed that most of 
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the visible luorescence for TP10 Gly2→L-CF
3
Bpg represented peptide bound to the extracellular 
lealet of the membrane (Figure 1c). The reduction of luorescence for TP10 Leu4→L-CF
3
-Bpg 
by trypan blue was signiicantly lower, despite a considerable membrane staining after 30 min. 
Thus, it can be concluded that TP10 Leu4→L-CF
3
-Bpg showed a higher internalization eficiency, 
whereas the internalization of all other tested peptides differed only mildly. Also, the strong 
membrane-staining TP10 Gly2→L-CF
3
Bpg analog showed the same internalization eficiency as 
the wild-type peptide. It should be noted that a proportion of extracellularly bound peptide may 
have been removed during the trypsinization step, which could lead to an underestimation of the 
amount of membrane-bound peptide. 
Next to the analysis of membrane binding and internalization in HeLa cells, we also investigated 
the behavior of these TP10 analogs in the suspension Jurkat E6.1 cell line. This cell line serves as 
a particularly interesting comparison, because it is known not to carry HS chains to any signiicant 
degree. Unlike HeLa cells it shows comparable uptake for D- and L-arginine-rich peptides [18]. 
In order to investigate to which extent HeLa and Jurkat cells also differ with respect to other 
glycosaminoglycans, we acquired an expression proile using a set of six single-chain antibody 
fragments with reactivity for epitopes present on chondroitin sulfates, dermatan sulfates and 
heparan sulfates (Figure S2). Most epitopes were present in large amounts on HeLa cells, and only 
marginally on Jurkat cells, thereby conirming their roles as model cell lines expressing high (HeLa) 
and low (Jurkat) amounts of HS. 
If the membrane binding observed in HeLa cells was mediated by HS chains, one would expect 
that the TP10 analogs Gly2→L-CF
3
-Bpg and Leu4→L-CF
3
-Bpg would be less enriched at the 
membrane in Jurkat cells. Indeed, when these cells were incubated for 30 min at 5 µM, no 
generalized membrane binding was evident by confocal microscopy for any of the TP10 analogs 
(Figure 1b). Instead, a trend towards a more intense cytoplasmic luorescence was observed and 
this cytoplasmic staining was more intense for those peptides that had shown higher membrane 
binding on HeLa cells. The absence of signiicant membrane binding of TP10 Gly2→L-CF
3
-Bpg 
was further conirmed by quantifying the internalization in the absence or presence of trypan 
blue, which resulted in much smaller differences for this particular peptide than on HeLa cells 
(Figure 1d). The differences are also evident from the low cytometry histograms, which showed 
a pronounced reduction of signal for TP10 Gly2→L-CF
3
-Bpg in HeLa cells when trypan blue was 
included (Figure S3b). No such shift was observed for TP10 wt (Figure S3a) in HeLa cells or in 
Jurkat cells for either of the two peptides (Figure S3c,d). 
The stronger cytoplasmic luorescence in Jurkat cells suggested that in comparison to HeLa cells, 
next to uptake by endocytosis cellular uptake could also occur by direct membrane translocation. 
To obtain further insight into the mechanism of uptake, cell association and uptake were also 
assessed at 4°C for TP10 and two of its analogs, a condition that is generally applied to test 
for an involvement of energy-dependent endocytosis in uptake. At 4°C, there was 90-95 % 
reduction of intracellular luorescence for all peptides consistent with endocytic uptake (Figure 
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1e). Remarkably, at 4°C TP10 Gly2→L-CF
3
-Bpg showed a much stronger membrane staining than 
the other two analogs as deduced from the capacity to quench this signal by trypan blue. 
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Figure 1: Cellular association and uptake of TP10 and TP10 analogs with D- or L-CF3-Bpg amino acid 
replacements in HeLa and Jurkat cells. a-b) HeLa (a) and Jurkat (b) cells were incubated with 5 µM of the 
respective peptides for 30 min at 37°C, washed and imaged immediately by confocal microscopy. The scale bar 
corresponds to 20 (a) and 10 µm (b). c-e) HeLa (c) and Jurkat (d, e) cells were incubated for 1 h at 37°C or 
additionally at 4°C (e) in 24-well plates with 5 µM (c, d) or 2.5 µM (e) of the indicated peptide. After washing the 
cells, cells were detached by trypsinization (only HeLa cells), washed by centrifugation (both cell lines) and 
resuspended in medium in the presence (light bars) or absence (dark bars) of trypan blue. The error bars represent 
Figure 1: Cellular association and uptake of TP10 and TP10 analogs with D- or L-CF
3
-Bpg amino acid 
replacements in HeLa and Jurkat cells. a-b) HeLa (a) and Jurkat (b) cells were incubated with 5 µM of the 
respective peptides for 30 min at 37°C, washed and imaged immediately by confocal microscopy. The scale 
bar corresponds to 20 (a) and 10 µm (b). c-e) HeLa (c) and Jurkat (d, e) cells were incubated for 1 h at 37°C or 
additionally at 4°C (e) in 24-well plates with 5 µM (c, d) or 2.5 µM (e) of the indicated peptide. After washing 
the cells, cells were detached by trypsinization (only HeLa cells), washed by centrifugation (both cell lines) 
and resuspended in medium in the presence (light bars) or absence (dark bars) of trypan blue. The error bars 
represent the range of two independent experiments for which luorescence was normalized relative to the 
signal obtained for TP10 without trypan blue. TP10 2GL/D = TP10 Gly2→L/D-CF
3
-Bpg; TP10 4LL/D = TP10 
Leu4→L/D-CF
3
-Bpg.
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Next, we set out to deine whether homogenous cytoplasmic luorescence represented intact 
peptide that had escaped the endosomes or luorescent fragments. For this purpose, cells were 
incubated with the broad-range cysteine protease inhibitor E64d. Previously, we had established 
that at concentrations at which the uptake of nona-arginine occurs via endocytosis, cytosolic 
luorescence could be abolished by a pre-incubation with E64d, which led us to reason that 
predominantly peptide fragments reach the cytosol, and not intact peptide [18, 44]. E64d did not 
affect the cytoplasmic staining. In combination with the reduction of uptake at 4°C this result 
supports the notion that the major part of TP10 and analogs access the cytosol by endosomal 
escape in an intact form (Figure S4). This inding is consistent with the fact that TP10 has a higher 
proteolytic stability against degradation by serum than nonaarginine [45].
Heparan sulfates and membrane binding
For D-amino acid-containing arginine-rich peptides, we had shown that the enzymatic removal 
of HS chains strongly reduced the membrane staining [18]. Furthermore, isothermal titration 
calorimetry (ITC) measurements to study the interaction of these peptides with heparan sulfates 
gave binding constants in the submicromolar range [18], suggesting that membrane staining 
was due to binding to heparan sulfates at the cell surface. Since TP10 lacks arginine residues and 
has a strong propensity to form an amphipathic α-helix [46, 47], we expected that TP10 would 
have a lower afinity for HS chains and perhaps a higher afinity for the lipid bilayer compared 
to arginine-rich peptides. Therefore, we wanted to directly assess the role of HS chains in the 
membrane-enrichment of the TP10 analog Gly2→L-CF
3
-Bpg. For this purpose, heparan sulfates 
were enzymatically digested off the surface of HeLa cells (Figure 2a). To assess in more detail 
whether heparinase III cleaved off the chains eficiently, we also analyzed the GAG proile after 
heparinase III treatment using three anti-HS antibodies, which showed indeed a reduction of over 
90 % for all three epitopes (Figure S2). 
To make sure that heparinase did not modify the overall structure of the plasma membrane or 
the capacity of lipophilic compounds to insert into the lipid bilayer, the plasma membrane stain 
CellMask was included as a control after the heparinase treatment. The distribution and intensity 
for CellMask were not changed after the treatment. In contrast, the heparinase treatment strongly 
reduced the intensity of the membrane staining of TP10 Gly2→L-CF
3
-Bpg (Figure 2a). We then 
continued to quantify the membrane accumulation and peptide internalization after the heparinase 
treatment, using a non-enzymatic dissociation solution to detach the cells from the 24-well-plate 
and trypan blue to quench any extracellular peptide. In agreement with the results from confocal 
microscopy, the heparinase treatment considerably reduced the membrane-associated fraction 
of TP10 Gly2→L-CF
3
-Bpg after 30 min incubation (Figure 2b), whereas membrane binding of 
the wild-type peptide was only mildly affected. Also after 30 min, the enhanced membrane-
accumulation of TP10 Gly2→L-CF
3
-Bpg did not translate into a greater internalization compared 
to TP10 wt, as deduced from the cell-associated luorescence in the presence of trypan blue 
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(Figure 2b). Heparinase treatment also did not affect the relative or absolute internalization 
eficiencies of TP10 wt and TP10 Gly2→L-CF
3
-Bpg after 30 min incubation. Notably, the relative 
degree of internalization of TP10 wt as compared to TP10 Gly2→L-CF
3
-Bpg was higher for a 
30 min incubation period than for a 60 min incubation, but it is unclear whether this indicates 
different kinetics or whether it relects saturation, export or degradation characteristics. This was 
not further addressed in this study. A further conirmation of the role of HS chains was obtained 
through co-incubating TP10 Gly2→L-CF
3
-Bpg with HeLa or Jurkat cells in the presence or absence 
of HS chains, which abolished membrane-binding in HeLa cells, whereas no major effect was 
observed in Jurkat cells (Fig 2c).
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Figure 2: Role of heparan sulfates in cell association. a) Effect of heparinase treatment on membrane staining of 
the TP10 analog Gly2→L-CF3-Bpg (Green: peptide; red: cell mask). The scale bar corresponds to 10 µm. b) 
Quantification of the effect of a heparinase treatment on the membrane staining of TP10 wt and its analog Gly2→L-
CF3-Bpg. HeLa cells were either treated with heparinase III (Hep III) or left untreated, and then incubated for 30 
min with 5 µM of the indicated peptide. Cells were detached using an enzyme-free cell-dissociation solution and 
cell-associated fluorescence was measured in the presence and absence of trypan blue by flow cytometry. c) Effect 
of competition with externally added HS chains on membrane binding of TP10 Gly2→L-CF3-Bpg. 2 µM of the 
peptide were incubated for 30 min at 37°C in the presence or absence of 5 µM HS. After the incubation, cells were 
washed twice and imaged immediately by confocal microscopy. The scale bar corresponds to 20 µm.  
 
 
Visualization of peptide and sugar clustering using metabolic labeling  
The most direct means to demonstrate that clustering of TP10 Gly2→L-CF3-Bpg is mediated by the 
presence of HS would be direct time-lapse visualization of peptide and sugar clustering on the cell 
surface. So far, such studies have mostly relied on the expression of fluorescent fusion proteins of 
syndecans. However, with the selection of a particular syndecan, this approach always carries a certain 
degree of arbitrariness and leads to overexpression of the selected glycosaminoglycan. In order to monitor 
the impact of the CPP on the subcellular distribution of the glycocalyx we therefore explored the use of 
metabolic sugar labeling, an approach that has not been used in drug delivery studies so far. Cells were 
cultured over night in the presence of peracetylated N-azidoacetyl-mannosamine (Ac4ManNAz) as a 
metabolic sugar precursor, resulting in the incorporation of azido-containing sialic acids in sialic acid 
glycoconjugates [38, 48]. Once these sugars have reached the cell surface, functional groups can be 
introduced by copper-free click chemistry (Figure S5). In this way, it was also possible to follow the 
effect of HS removal on GAG clustering. Fluorescence was introduced by coupling of a biotin moiety 
followed by incubation with Alexa Fluor 647-labeled streptavidin. For Hela cells, the labeling protocol 
resulted in a distinct staining of the entire plasma membrane (Figure 3, Figure S6, Figure S7). Since this 
protocol has not been used in the context of CPP delivery, we first assessed the impact of metabolic 
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staining of the TP10 analog Gly2→L-CF
3
-Bpg (Green: peptide; red: cell mask). The scale bar corresponds to 
10 µm. b) Quantiication of the effect of a heparinase treatment on the membrane staining of TP10 wt and 
its analog Gly2→L-CF
3
-Bpg. HeLa cells were either treated with heparinase III (Hep III) or left untreated, and 
then incubated for 30 min with 5 µM of the indicated peptide. C lls ere detached using an enzyme-free cell-
dissociation solution and cell-associated luorescence was measured in the presence and absence of trypan 
blue by low cytometry. c) Effect of competition with externally added HS chains on membrane binding of 
TP10 Gly2→L-CF
3
-Bpg. 2 µM of the peptide were incubated for 30 min at 37°C in the presence or absence 
of 5 µM HS. After the incubation, cells were washed twice an  imaged immediately by confocal microsc py. 
The scale bar corresponds to 20 µm. 
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Visualization of peptide and sugar clustering using metabolic labeling 
The most direct means to demonstrate that clustering of TP10 Gly2→L-CF
3
-Bpg is mediated by 
the presence of HS would be direct time-lapse visualization of peptide and sugar clustering on the 
cell surface. So far, such studies have mostly relied on the expression of luorescent fusion proteins 
of syndecans. However, with the selection of a particular syndecan, this approach always carries 
a certain degree of arbitrariness and leads to overexpression of the selected glycosaminoglycan. 
In order to monitor the impact of the CPP on the subcellular distribution of the glycocalyx we 
therefore explored the use of metabolic sugar labeling, an approach that has not been used 
in drug delivery studies so far. Cells were cultured over night in the presence of peracetylated 
N-azidoacetyl-mannosamine (Ac4ManNAz) as a metabolic sugar precursor, resulting in the 
incorporation of azido-containing sialic acids in sialic acid glycoconjugates [38, 48]. Once these 
sugars have reached the cell surface, functional groups can be introduced by copper-free click 
chemistry (Figure S5). In this way, it was also possible to follow the effect of HS removal on GAG 
clustering. Fluorescence was introduced by coupling of a biotin moiety followed by incubation 
with Alexa Fluor 647-labeled streptavidin. For Hela cells, the labeling protocol resulted in a distinct 
staining of the entire plasma membrane (Figure 3, Figure S6, Figure S7). Since this protocol has 
not been used in the context of CPP delivery, we irst assessed the impact of metabolic labeling 
on peptide uptake. Introduction of the azido-sugar alone had no impact on the uptake of TP10 
wt and showed a slight increase (8%) in binding of TP10 Gly2→L-CF
3
-Bpg to the cell surface. 
Labeling with streptavidin had also no impact on binding to the cell surface and uptake for TP10 
wt, and again showed just a slight increase (8%) in binding of TP10 2GL to the cell surface but 
no difference in uptake compared to the untreated control cells. Cells, incubated with R9 showed 
also an increase (38%) in binding to the cell surface, whereas the uptake was higher (15%/25%) 
for cells incubated with the azido sugar and additionally incubated with streptavidin, respectively 
(Figure S8). Overall these controls demonstrate that the oligovalency of streptavidin had no 
functional consequences, consistent with previous results on studies on tumor cell morphology 
and migration, in which metabolically labeled human melanoma cells developed the common 
mesenchymal phenotype [39].
Time-lapse imaging was performed for TP10 and TP10 Gly2→L-CF
3
-Bpg. Due to the presence 
of luorescently labeled peptide in the tissue culture medium the membrane accumulation of 
peptides was less pronounced than in the previous experiments, in which cells had been washed 
before imaging. For TP10 we only observed an enrichment of peptide in preexisting sugar clusters 
(Figure 3, Figure S6). For TP10 Gly2→L-CF
3
-Bpg clusters on the plasma membrane appeared over 
time that colocalized with an enrichment in labeled sugars (Figure 3, Figure S7). Most importantly, 
following heparinase treatment, the sialic acid labeling was left intact. However, the heparinase 
treatment virtually abolished the generation of TP10 Gly2→L-CF
3
-Bpg clusters on the plasma 
membrane.
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Figure 3. TP10 Gly2→L-CF
3
-Bpg but not TP10 wt induces clustering of HS chains. (a, b) HeLa cells were 
cultured over night in the presence of Ac4ManNAz (50 µM). Cells were either left untreated (a I-III, b I-III) or 
treated with heparinase III (a IV-VI, b IV-VI) for 1 h at 37°C, followed by labeling of incorporated azido sialic 
acid moieties with a bicyclo[6.1.0]nonyne (BCN)-biotin conjugate and secondary labeling with streptavidin-
Alexa Fluor 647. Subsequently, TP10 wt or TP10 2GL was administered in a inal concentration of 5µM, 
followed by time-lapse confocal microscopy over 30 min at 37°C. (a) Representative time-lapse confocal 
images of cells, showing no signs of cluster-formation of the administered TP10 in heparinase III un-treated 
(a I) and treated (a IV) cells and no apparent changes in the cell surface distribution of sialic acids (a II+V). (b) 
Time-lapse confocal images of cells, showing the formation of TP10 Gly2→L-CF
3
-Bpg clusters (I) accompanied 
by distinct cluster formation of cell surface sialic acid moieties (II), colocalized with Gly2→L-CF
3
-Bpg (III), 
highlighted by arrowheads. The distinct cluster formation of TP10 Gly2→L-CF
3
-Bpg as well as azido sialic 
acids is abandoned on cells, treated with heparinase III indicating the dependency of cluster formation on the 
presence of heparan sulfates (IV-VI). The false color look-up table ranges from black (low) to white (high). The 
scale bar corresponds to 20 µm.
Biochemical characterization of the interaction of TP10 analogs with HS
To obtain further insight into the nature of the interaction between HS chains and TP10 
analogs, we set out to measure the afinity of TP10 wt and the analog TP10 Gly2→L-CF
3
-Bpg 
for HS by isothermal titration calorimetry (ITC). However, using similar conditions that had 
given submicromolar afinities for D/L-R9 and D/L-penetratin [18], we could not obtain reliable 
dissociation constants. At 25°C, no binding enthalpy above background levels could be detected. 
Only at 37°C, the HS-TP10 interaction produced a signiicant change in enthalpy (data not shown). 
However, it was obvious that the occurrence of massive aggregation (see below) prevented the 
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determination of meaningful K
D 
values. 
In view of the ITC results, we resorted to dynamic light scattering (DLS), a method that would enable 
the detection and size determination of particles formed between HS and TP10 (analogs). Each 
TP10 analog, as well as TP10 wt and R9, all luorescein-labeled, were incubated at a concentration 
of 5 µM with 10 µM HS. The scattering intensity was measured before and directly after mixing 
the peptides with HS. Interestingly, the individual analogs varied greatly in the observed increases 
in scattering intensity in the presence of HS, which relected differences in the capacity of the 
TP10 analogs to form aggregates with HS. Prominently, the TP10 analog Gly2→L-CF
3
-Bpg, that 
showed the pronounced aggregation on the plasma membrane of HeLa cells, showed by far the 
highest increase in scattering intensity (Figure 4). It should be noted, however, that the scattering 
intensity is a function of both the size and the number of aggregates. Therefore, this parameter 
is not suitable to compare exact numbers of aggregates formed. Notably, the clusters that were 
formed between R9 and HS were considerably smaller than clusters between TP10 Gly2→L-CF
3
-
Bpg and HS (Figure S9). The aggregate sizes of the other TP10 analogs were generally closer to 
the size of those formed with TP10 Gly2→L-CF
3
-Bpg. However, aggregate sizes obtained for 
these other analogs were much more variable, making it dificult to present representative sizes 
(data not shown). The increased variability may be either due to the relatively low scattering signal 
or to a slower kinetics of aggregate formation. 
The interaction between the TP10 analogs and HS was further investigated by circular dichroism 
(CD). To eliminate an impact of kinetics on the observed results, all samples were measured after 
an initial incubation of 30 min at 37°C at varying HS/peptide ratios (Figure S10). Surprisingly, 
all TP10 analogs behaved in a very similar manner in the presence of HS chains. Strongly turbid 
solutions were obtained when TP10 or its analogs were mixed with HS up to the point of charge 
neutralization, which resulted in a severe depression of the CD signal due to differential light 
scattering and absorption lattening artifacts. Addition of more HS, however, led to clear solutions 
with a restored CD signal intensity. Noticeably, a large excess of HS led to a more pronounced 
α-helical structure in a comparable manner for all TP10 analogs including the wild type peptide, 
as is evident from the characteristic CD lineshape with a positive band at 192 nm, and two 
negative bands around 208 and 222 nm. Mixing HS with R9 did not result in turbid solutions 
at any HS-peptide ratio. These CD results conirm the observations obtained with dynamic light 
scattering above, namely that the clusters formed between HS and R9 are generally much smaller 
compared to clusters between HS and TP10 analogs. Also, no pronounced secondary structure of 
R9 could be discerned, which is in agreement with previous indings [49]. 
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Figure 4: Scattering intensity of peptide solutions as measured by dynamic light scattering. Peptide solutions 
were measured in the presence (+) or absence (-) of 10 µM HS chains. Error bars reflect the range of two 
independent experiments. TP10 2GL/D = TP10 Gly2→L/D-CF3-Bpg; TP10 4LL/D = TP10 Leu4→L/D-CF3-Bpg. 
 
Induction of phosphatidylserine exposure by TP10  
Very evidently for TP10 and its analogs, the interaction with HS chains does not contribute to peptide 
uptake. Our detailed biochemical analysis has shown that TP10 and the arginine rich peptides engage HS 
in fundamentally different manners. Finally, we were also interested to learn to which degree the two 
classes of peptides differed in their interaction with the lipid bilayer. Lipid bilayer remodeling has been 
repeatedly implicated in various CPP uptake mechanisms, and may in particular play an important role in 
direct peptide translocation – whereby the peptide directly accesses the cytosol from the extracellular 
environment [50, 51]. Here, we analyzed lipid bilayer organization by measuring to which degree the 
TP10 analogs and R9 induced phosphatidylserine (PS) exposure. Typically, PS is confined to the inner 
leaflet of the plasma membrane. Exposure of this phospholipid therefore indicates a disturbance of the 
lipid bilayer, which may be associated with peptide internalization. In this case a concentration of 25 µM 
was selected, since the PS-derived signal was expected to be too weak at 5 µM. For arginine-rich peptides 
at this concentration lipid remodeling through the induction of sphingomyelinase activation occurs. 
However, the integrity of the plasma membrane barrier function remains preserved [51]. R9 only induces 
punctuate exposure of PS, in combination with uptake through acid sphingomyelinase-dependent 
nucleation zones [51, 52] (Figure S11). When HeLa cells were incubated with TP10 at this concentration, 
already after 4 min a marked difference in PS exposure was observed, which coincided with massive 
internalization of peptides into the cytoplasm supporting the hypothesis that, although no specific 
membrane component could be identified in this experiment, the activity of TP10 is much more directed 
towards the lipid bilayer compared to R9 (Figure S11). When directly comparing TP10 and TP10 
Figure 4: Scattering intensity of peptide solutio s as measured by dynamic light scattering. Peptide 
solutions were measured in the presence (+) or absence (-) of 10 µM HS chains. Err r bars relect the range 
of two independent experiments. TP10 2GL/D = TP10 Gly2→L/D-CF
3
-Bpg; TP10 4LL/D = TP10 Leu4→L/D-
CF
3
-Bpg.
Induction of phosphatidylserine exposure b  TP10 
Very evidently for TP10 and ts analogs, the interaction with HS chains does not contribute to 
peptide uptake. Our detailed biochemical analysis has shown that TP10 and e arginine rich 
peptides engage HS i da entally different manners. Finally, we were also intere ted to learn 
to which degree the two classes of eptides differed i ir interaction with e lipid bilayer. Lipid 
bilayer remodeling has been repeatedly impl cated in various CPP uptak  mechani ms, and may 
in particular play an important role in direct peptide translocation – wh reby the peptide dir ctly 
accesses the cytosol from the xtracellular environment [50, 51]. Here, we analyzed lipid bilayer 
organization by measuring to which degree the TP10 anal gs and R9 induc d phosphatidyls rine 
(PS) exposure. Typica ly, PS is conined to the inn r lealet of the plasma membrane. Exposure of is 
phospholipid therefore indicates a disturbance of the lipid bilayer, which may be assoc ated with 
peptide internalization. In this case a concentration of 25 µM was selected, since the PS-deriv d 
signal was expected to be too weak at 5 µM. For arginine-rich peptides at this concentration lipid 
remodeling through the induction of sphingomyelinase activation occurs. How ver, the integrity 
of the plasma membra e barrier function remains preserved [11][51]. R9 only induces punctuate 
exposure of PS, in combination with uptake through acid sphingomyeli ase-dependent nucleation 
zones [51, 52] (Figure S11). When HeLa cells were incubated with T 10 at this concentration, 
already after 4 min a marked difference in PS exposure was observed, which coi cided with 
massive internalization of peptides into the cyt plasm supporting the ypothesis that, al ough 
no speciic membrane component could be identiied in this experiment, the activity of TP10 
is much more directed towards the lipid bilayer compared to R9 (Figure S11). When directly 
comparing TP10 and TP10 Gly2→L-CF
3
-Bpg, also at 25 µM and using identical settings, we found 
that TP10 Gly2→L-CF
3
-Bpg did not affect PS exposure at all. This result indicates that capture of 
the peptide in the glycocalyx prevented the peptide from disrupting bilayer organization (Figure 
5).
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Figure 5: Induction of PS exposure by TP10 and TP10 Gly2→L-CF3-Bpg. HeLa cells were co-incubated with 25 
µM of the indicated peptides and Annexin V-Alexa Fluor 647. Peptide internalization and PS exposure were 
followed from the first image acquired (t=0) up to 20 min by confocal microscopy. The scale bar corresponds to 20 
µm. Brightness and contrast were adjusted individually to optimize visualization. 
 
DISCUSSION 
Even though the field of CPP is moving ever closer to clinical applications, the molecular interactions 
playing a role in their cellular uptake are still under investigation. For arginine-rich peptides, there is 
considerable agreement that the interaction with HS chains on the plasma membrane is an important step 
in the initiation of internalization. For arginine-free amphipathic peptides such as TP10, however, much 
less is known about the role of HS in cellular uptake. Here, we show that TP10 analogs, in spite of a 
much lower affinity, form clusters with HS chains. Average cluster size is much larger than the one 
observed for nonaarginine. Most significantly, the enhanced aggregation of the TP10 analog Gly2→L-
CF3-Bpg did not translate into an enhanced internalization. This argues that the interaction of cells with 
this TP10 analog leads to an HS-dependent sequestration of the peptide on the plasma membrane in a 
Figure 5: Induction of PS exposure by TP10 and TP10 Gly2→L-CF
3
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with 25 µM of the indicated peptides and Annexin V-Alexa Fluor 647. Peptide internalization and PS exposure 
were followed from the irst image acquired (t=0) up to 20 in by confocal microsc py. The scale bar 
corresponds to 20 µm. Brightness an  contrast were adjust d individually to optimize visualization.
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interactions playing a role in their cellular uptake are still under investigation. For arginine-rich 
peptides, there is considerable agreement that the interaction with HS chains on the plasma 
embrane is an important step in the initiation of internalization. For arginine-free amphipathic 
peptid s such as TP10, however, much less is known bout he role of HS in cellular uptake. 
Here, we show that TP10 analogs, in spite of a much lower afinity, form clusters with HS chains. 
Average cluster size is much larger than the one observed for nonaarginine. Most signiicantly, 
the enhanced aggregation of the TP10 analog Gly2→L-CF
3
-Bpg did not translate into an 
enhanced internalization. This argues that the interaction of cells with this TP10 analog leads 
to an HS-dependent sequestration of the peptide on the plasma membrane in a manner that is 
unproductive with respect to peptide internalization. As a novelty in the study of CPP delivery we 
employed metabolic labeling to assess the impact of peptide binding on the distribution of the 
glycocalyx.
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When investigating the nature of the membrane accumulation of the TP10 analog Gly2→L-CF
3
-
Bpg, we found that it could be reduced either by a heparinase pre-treatment or by co-incubating 
the peptides with HS chains. In addition, in HS-poor Jurkat cells, no membrane staining was 
evident for the TP10 analogs at low concentrations, providing further support for the idea that 
the aggregation of TP10 analogs on the plasma membrane of HeLa cells is an HS-dependent 
process. Our demonstration that the amphipathic cationic TP10 peptides have the capacity to 
engage in interactions with HS on the cell surface is consistent with earlier results showing that 
cationic complexes containing amphipathic peptides, e.g. stearylated TP10, could be eficiently 
decomplexed in vitro by heparin [53]. Nevertheless, the observation that a heparinase treatment 
did not abolish the membrane staining completely indicates that other membrane components, 
e.g. chondroitin sulfate chains or sialic acid residues, may also be involved in the membrane 
accumulation of TP10 Gly2→L-CF
3
-Bpg. Alternatively, as suggested by the capacity of TP10 wt to 
disturb the lipid bilayer, the peptide may also interact more strongly with the plasma membrane 
in the absence of HS. Interestingly, peptide uptake in HeLa correlated positively with uptake in 
Jurkat cells for a set of TP10 analogs. This parallel behavior further conirms the notion that 
uptake eficiency is independent of the ability to accumulate on the plasma membrane in an 
HS-dependent manner. This observation is in contrast to earlier observations for D- and L-R9. 
Here, uptake in Hela cells was higher for L-R9 than for the D-counterpart while for Jurkat cells 
both peptides showed the same uptake eficiency [18]. The indings are, however, reminiscent of 
those found by Jiao et al., who for a set of peptides did not ind a correlation between membrane 
afinity and uptake eficiency [54]. One should be aware of the fact that our uptake studies were 
exclusively dependent on measurements of luorescence, which may be subject to changes in 
luorescence intensity at lower pH values and due to collision-quenching. However, extensive 
investigations into the possibility and extent of measurement artifacts that we performed in a 
previous study indicated that these effects are rather small, and that valid conclusions can be drawn 
from low cytometry studies [18], provided that the differences are suficiently clear, as is the case 
here. Also, luorescein shows little direct membrane interactions [55] compared for example to 
rhodamine luorophores (general experiences from our lab), and is therefore exquisitely suited for 
purposes such as the real-time imaging and subcellular distribution experiments performed in the 
context of this study. In itself, the membrane accumulation of TP10 analogs in an HS-dependent 
manner was surprising to us, since these peptides do not contain any arginines. No afinity could 
be determined for TP10 wt or TP10 Gly2→L-CF
3
-Bpg using isothermal titration calorimetry and 
it is well known that lysine-only peptides have rather low HS afinities. The reason for the lower 
afinity is the 2.5-fold lower enthalpic contribution of the binding of lysines to heparin compared 
to the binding of arginines [56][12][11]. The effect of exchanging lysine- and arginine-residues 
has been directly tested for a number of HS ligands, all showing much lower afinities for lysine-
containing HS ligands [56-58]. 
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The above observations, together with the lack of an effect of heparinase treatment on 
internalization, indicate that TP10 and its analogs do not engage with HS in a manner that 
leads to subsequent internalization, as has been described for arginine-rich CPPs as well as for a 
variety of unrelated proteoglycan ligands [25, 28-31]. Combined with our earlier indings on D- 
versus L-CPP, the indings thus lead us to propose that cell-penetrating peptides may interact with 
heparan sulfates in at least three functionally distinct manners that lead to different outcomes 
with respect to internalization. For arginine-rich peptides with a negative binding enthalpy, 
binding leads to uptake in a stereochemistry-dependent manner, which means that binding either 
induces uptake (L-analogs) or peptides remain sequestered by the glycocalyx (D-analogs). Third, 
for amphipathic CPP large clusters are formed on the plasma membrane that are unproductive 
for cell uptake (Figure 6). 
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Figure 6: Scheme for the proposed engagement of heparan sulfate chains in two distinct ways. a) Binding of 
peptides or other HS ligands leads to cluster formation, which then stimulates uptake through the activation of 
intracellular signaling cascades. b) Binding of peptides to HS leads to large peptide-HS clusters that are 
unproductive with regard to peptide uptake. 
 
Currently, the size of HS clusters has not been directly assessed on the plasma membrane. Padari et al. 
have recently directly assessed peptide-dependent differences of cluster size and shape on the plasma 
membrane for variants of the S413-PV peptide. Specifically, they found that reversing or scrambling the 
nuclear localization signal (NLS) in this peptide led to larger and more irregular structures on the plasma 
membrane, though the precise relationship of these findings to uptake efficiency was not addressed [34].   
Next to the assessment of cluster size, it would be highly interesting to directly assess the effects on the 
activation of downstream signaling cascades, e.g. Rac1 activation, that lead to peptide internalization. 
Also, it is not directly apparent how the large HS-containing CPP clusters observed here differ from HS 
clusters induced by the interaction of cells with cationic polyplexes for which syndecans promote uptake 
[59]. An interesting possibility that requires further research is that the sheer size of the CPP aggregates 
prevents their internalization. 
Recently, Amand et al. showed for penetratin and two variants containing either only lysine or only 
arginine residues that peptide uptake did not correlate with the affinity for the plasma membrane. Instead, 
the internalization efficiency correlated well with the ability to induce heparin clustering [58], even 
though overall there was little difference in the cell association between GAG-containing and GAG-
Figure 6: Scheme for th  propos d ngagement f hepara  sulfate chains in two di tinct ways. a) 
Binding of peptides or other HS ligands leads to cluster formation, which then stimulates uptake through the 
activation of intracellular signaling cascades. b) Binding of peptides to HS leads to large peptide-HS clusters 
that are unproductive with regard to peptide uptake.
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Currently, the size of HS clusters has not been directly assessed on the plasma membrane. Padari 
et al. have recently directly assessed peptide-dependent differences of cluster size and shape on 
the plasma membrane for variants of the S4
13
-PV peptide. Speciically, they found that reversing 
or scrambling the nuclear localization signal (NLS) in this peptide led to larger and more irregular 
structures on the plasma membrane, though the precise relationship of these indings to uptake 
eficiency was not addressed [34]. 
Next to the assessment of cluster size, it would be highly interesting to directly assess the effects 
on the activation of downstream signaling cascades, e.g. Rac1 activation, that lead to peptide 
internalization. Also, it is not directly apparent how the large HS-containing CPP clusters observed 
here differ from HS clusters induced by the interaction of cells with cationic polyplexes for which 
syndecans promote uptake [59]. An interesting possibility that requires further research is that the 
sheer size of the CPP aggregates prevents their internalization.
Recently, Amand et al. showed for penetratin and two variants containing either only lysine 
or only arginine residues that peptide uptake did not correlate with the afinity for the plasma 
membrane. Instead, the internalization eficiency correlated well with the ability to induce heparin 
clustering [58], even though overall there was little difference in the cell association between 
GAG-containing and GAG-deicient cells. In view of our results for arginine-rich and amphipathic 
CPP, these indings may also relate to the characteristics of penetratin. Besides GAGs, other 
“undeined factors” were also deemed of importance in determining the difference in uptake 
eficiency. Ziegler et al. showed that the coupling of WR9 to a PEG chain resulted in the loss of the 
ability to induce GAG clustering. Whereas this modiication resulted in only a moderately reduced 
afinity for HS chains, uptake was much lower, which they attributed to the inability of PEGylated 
WR9 to cluster HS chains. Interestingly, they found that uptake was much more reduced at 10 
µM than at 2 µM, which they interpreted by saying that clustering is mainly required for direct 
translocation at higher peptide concentrations [22].
Metabolic sugar labeling provided a powerful means to luorescently tag the glycocalyx and 
assess the colocalization of peptide aggregates with sugar clusters. In our case, we employed 
a sugar precursor that labeled sialic acids. While sialic acids are abundant posttranslational 
protein modiications next to cell surface glycosaminoglycan chains (e.g. HS), this strategy 
nevertheless provides powerful means to monitor the impact of CPP-membrane binding on sugar 
redistribution. The use of this approach to visualize the membrane proximal sialic acid moieties 
simultaneously with CPP binding dynamics to membrane distal located GAG chains prevents 
interference between potential recognition epitopes within the HS and the used CPPs. While 
in this way also glycan residues of proteins that did not carry HS were labeled, the absence of 
sialic acid clusters colocalizing with peptide aggregates following HS removal demonstrated that 
this approach enabled the monitoring of peptide induced glycosaminoglycan redistribution by 
time-lapse microscopy. Regarding the membrane behavior of TP10 in comparison to arginine-rich 
peptides, previous studies have indicated that TP10 already causes membrane disturbances and/
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or effects on cell proliferation at much lower concentrations compared to arginine-rich peptides 
such as TAT or penetratin in both adherent and suspension cell lines [60, 61]. Our study further 
supports the differences in the membrane behavior of arginine-rich CPP and TP10 through the 
comparison of R9 and TP10 with respect to their ability to induce PS exposure, a classical marker 
of membrane disturbance. Whereas at high concentrations R9 only caused local exposure of PS 
[51, 52][5], TP10 at high concentrations caused a rapid exposure of PS over the whole cell in a 
matter of minutes. This result clearly indicates that next to differences in HS engagement different 
interactions also occur at the plasma membrane for R9 and TP10. Interestingly, TP10 Gly2→L-CF
3
-
Bpg did not lead to any detectable PS exposure in HeLa cells at 25 µM, presumably because the 
peptide is effectively sequestered by the HS layer. Although not directly assessed, it is very likely 
that at this concentration TP10 wt is much more toxic due its capacity to directly interact with 
the plasma membrane.
In conclusion, our indings refute the general notion that GAG clustering always productively 
stimulates cellular uptake pathways. In contrast, TP10 analogs cluster with HS on the plasma 
membrane in a manner that is unproductive for uptake.
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SUPPLEMENTARY MATERIALS
Figure S1. Chemical structure of triluoromethyl-bicyclopent-[1.1.1]-1-yl-glycine (CF
3
-Bpg); (A) L-CF
3
-Bpg, (B) 
D-CF
3
-Bpg.
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Figure S2. GAG profiling of HeLa and Jurkat cells by flow cytometry. Expression of cell surface GAGs was 
measured after incubation with single chain antibody fragments directed against epitopes on heparan sulfates (HS)-, 
dermatan sulfates (DS)- and chondroitin sulfates (CS) chains. Efficient enzymatic degradation of HS chains with 
cells in suspension, leading to comparable expression levels to Jurkat cells, was performed by treatment of cells with 
3 mIU of heparinase III (dashed traces). Fluorescence represents median fluorescence intensities. (a) Flow 
cytometry histograms of one representative experiment; (b, c) Average intensities and standard deviations (SD) of 
(b) two and (c) three independent experiments showing (b) expression levels on Hela cells and (c) expression of HS 
epitopes after enzymatic removal normalized to expression levels of untreated cells. Hela cells were detached with 1 
mM EDTA-containing PBS resuspended in RPMI1640 culture medium containing 1% FCS with or without GAG-
degrading enzymes. Jurkat cells were washed with RPMI 1640 culture medium containing 1% FCS and then treated 
in the same way as HeLa cells.. Cells were washed afterwards three times with 1X HBS and incubated with anti-HS 
single chain antibodies, recognizing certain epitopes within the HS GAG chains, IdoA2S-GlcNS3S6S (HS4C3V-
vsv) [1], IdoA2S-GlcNS6S (A04B08V-vsv) [2] and GlcNS +/- 6S-GlcA/IdoA2S (EV3C3V-vsv) [3], anti-DS single 
chain antibodies, recognizing the epitopes 4/2,4-di-OS (LKN1V-vsv) [4] and IdoA-Gal-NAc4S (GD3A12V-vsv) [5] 
and the anti-CS single chain antibody, recognizing the epitope GlcA-GalNAc6S (I03H10V-vsv) [6] for 30 min at 
4°C. Cells were again washed three times with 1X HBS and incubated with the 2nd mouse-anti vsv (P5D4) for 30 
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times with 1X HBS and incubated with the 2nd mouse-anti vsv (P5D4) for 30 min at 4°C. After washing cells 
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min at 4°C, followed by washing steps and Flow cytometry measurements. 
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min at 4°C. After washing cells were finally incubated with a goat-anti-mouse IgG Alexa Fluor 488 conjugated 
antibody (Invitrogen) for 30 min at 4°C, followed by washing steps and Flow cytometry measurements.  
 
 
 Figure S3. Flow cytometry overlay images (c-d) and quantification (e) of the uptake of TP10 (a,c) and TP10 
Gly2→L-CF3-Bpg (b,d) in HeLa (a,b) and Jurkat cells (c,d). Cells were incubated for 1 h at 37°C in 24-well 
plates with 5 µM of the indicated peptide. After washing the cells by centrifugation and/or trypsinization (only 
HeLa cells), cells were resuspended in medium in the presence (blue curves) or absence (red curves) of trypan blue.  
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 Figure S4. Effect of the cysteine protease inhibitor E64d on the intracellular distribution of TP10 (analogs). 
Jurkat cells were (a) left untreated or (b) preincubated with 100 µM E64d in serum-free medium for 30 min at 37°C. 
This preincubation was followed by an incubation with 2.5 µM of the indicated peptides in RPMI + 10% FCS for 1 
h at 37°C without (a) or with (b) E64d. The scale bar corresponds to 20 µm.  
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 Figures S5. Bioorthogonal labeling procedure of cells. Incorporation of ManNAz, an azido derivate of ManNAc, 
into cells allows detection of cell surface sialic acids. Peracetylated N-azidoacethylmannosamine (Ac4ManNAz) can 
be taken up and comparably metabolized and used as other hexosamines. Exogenously added Ac4ManNAz diffuses 
into the cell and is deacetylated by intracellular esterases, and then enters into the salvage pathway, including 
phosphorylation of ManNAz to ManNAc-6-Phosphate by UDP-GlcNAc 2-epimerase/ManNAc-6- kinase (GNE) as 
the key enzyme in sialic acid biosynthesis, generation of phosphorylated Neu5Ac (Neu5Ac-9-phosphate) by N-
acetylneuraminic acid synthase (Neu5Ac-9-P synthetase/NANS) and dephosphorylation of Neu5Ac by N-
acetylneuraminic-acid Phosphatase (Neu5Ac-9-P Phosphatase/NANP) before entering the nucleus. Further 
modifications in the nucleus and the golgi apparatus take place, that involves CMP-Neu5Ac-Synthetase (CMAS) 
and SLC35A1 (solute carrier family 35/CMP-sialic acid transporter) and sialyltransferases (ST) before the azido-
sialic acids appear as part of glycan moities of glycoproteins at the cell surface. [7-9]. The detection of cell surface 
azido-sialic acids can be performed by using e.g. biotin-conjugated Bicyclo [6.1.0] nonyne (BCN) in a metal-free 
strain promoted alkyne-azide cycloaddition (SPAAC) reaction, giving stable 1,2,3-triazoles. Finally, a fluorophore-
conjugated streptavidin can be used to visualize bioorthogonal labeled sialic acids using e.g. confocal microscopy 
[10]. 
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 Figure S6. Time-lapse of the uptake of TP10 WT in HeLa cells. HeLa cells were incubated with 5 mM of the 
peptide with or without a pre-treatment with heparinase III. (I, IV) False color representations of the peptide, (II, V) 
the sialic acid stain and (III, VI) overlays of peptide and sialic acid with peptide depicted in green and sialic acid in 
red. The false color look-up table ranges from black (low) to white (high). The scale bar corresponds to 20 µm. 
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 Figure S7. Time-lapse of the uptake of TP10 Gly2→L/D-CF3-Bpg in HeLa cells. HeLa cells were incubated with 
5 µM of the peptide with or without a pre-treatment with heparinase III. (a, d) False color representations of the 
peptide, (b, e) the sialic acid stain and (c, f) overlays of peptide and sialic acid with peptide depicted in green and 
sialic acid in red. Sites of coclustering of peptide and the glycocalyx are depicted by arrows. The false color look-up 
table ranges from black (low) to white (high). The scale bar corresponds to 20 µm. 
Figure S7. Time-lapse of the uptake of TP10 Gly2→L/D-CF
3
-Bpg in HeLa cells. HeLa cells were incubated 
with 5 µM of the peptide with or without a pre-treatment with heparinase III. (a, d) False color representations 
of the peptide, (b, e) the sialic acid stain and (c, f) overlays of peptide and sialic acid with peptide depicted in 
green and sialic acid in red. Sites of coclustering of peptide and the glycocalyx are depicted by arrows. The 
false color look-up tabl  ranges from black (low) to white (high). The scale b  correspon s to 20 mm
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Figure S8: Impact of the bioorthogonal labeling on cell surface binding and uptake. HeLa cells were cultured 
over night in the presence or absence of Ac4ManNAz (50 µM), followed by labeling of incorporated azido sialic 
acid moieties with a bicyclo[6.1.0]nonyne (BCN)-biotin conjugate and secondary labeling with streptavidin-Cy5. 
For analysing the impact of incorporated azido sialic acid alone on binding to the cell surface and uptake oft he 
administered CPP, cells were incubated with Ac4ManNAz (50 µM), but labeling with BCN-biotin conjugate and 
secondary labeling with streptavidin-Cy5 were omitted.  Subsequentely, TP10, TP10 2GL or R9 were administered 
in a final concentration of 5µM, incubated for 1 hour at 37°C, 5% CO2 and measured in FACS. 
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 Figure S9. Size distribution of clusters formed by co-incubating R9 and TP10 Gly2→L-CF3-Bpg with HS 
chains. The size distribution by volume of clusters that originate from co-incubation of 5 µM TP10 Gly2→L-CF3-
Bpg (a) and 5 µM R9 (b) with 10 µM HS chains. Three successive measurements are shown for each peptide. Each 
measurement consisted of six runs of 10 s, performed at 37°C. Both peptides were fluorescein-labeled. DLS 
experiments were performed with a Zetasizer Nano S (Malvern Instruments Ltd, Malvern, UK). Equilibration time 
before measurements was 20 s. Initially, 100 µl of a 5 µM peptide solution was added into ZEN0040 disposable 
microcuvettes. Then, HS was added to the cuvettes to a concentration of 10 µM. Samples were then briefly mixed 
by pipetting up and down and measured directly afterwards.  
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Figure S10. Circular dichroism of R9 and TP10 and analogs in pure phosphate buffer (PB) and in 
the presence of HS chains. a-f) CD spectra in the presence of increasing amounts of HS. The peptides used 
are indicated in the graphs. g) The MRE at 210 nm vs HS/peptide ratio for TP10 wt and TP10 analogs. h) 
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The MRE at 199 nm vs HS/peptide ratio for R9. All peptides were luorescently labeled. MRE = mean residue 
ellipticity; CD = circular dichroism.TP10 2GL/D = TP10 Gly2→L/D-CF
3
-Bpg; TP10 4LL/D = TP10 Leu4→L/D-CF
3
-
Bpg. 20 µM solution of the peptide in 10 mM phosphate buffer was mixed in distinct steps with increasing 
concentrations of a HS (Sigma-Aldrich, St. Louis, USA, from bovine kidney) stock solution in 10 mM PB. 
The resulting peptide/HS ratios were in the range of ~ 4:1 down to ~1:25 (mol/mol, where the peptide/HS 
molar ratio refers to the disaccharide repeating unit of HS). After each addition the mixture was vigorously 
vortexed and incubated for 30 min at 37°C. Afterwards, spectra of the peptide/HS mixture were recorded at 
37°C using a J-815 spectropolarimeter (Jasco, Tokyo, Japan) over the range from 260 to 180 nm at 0.1 nm 
intervals, using a quartz glass cuvette of 1 mm optical path length (Suprasil, Hellma, Müllheim, Germany), a 
scan rate of 10 nm/min, 8 s response time and 1 nm bandwidth. Three scans were averaged and the baseline 
spectrum of the pure phosphate buffer or the corresponding pure HS solution in 10 mM phosphate buffer 
collected under identical experimental conditions was subtracted. Finally, the baseline-corrected spectra were 
processed with the adaptive smoothing method, which is part of the Jasco Spectra Analysis software. For 
calculating the mean residue ellipticity (MRE) spectra the concentration of the luorophore-labeled peptides 
was determined by measuring the absorption at 492 nm (maximum of the absorption band of the CF label) in 
10 mM phosphate buffer (pH 7.0), assuming a molar extinction coeficient of 75,000 M-1 cm-1.
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 Figure S11. Induction of PS exposure by R9 and TP10. HeLa cells were co-incubated with 25 µM of the 
indicated peptides and Annexin V-Alexa Fluor 647. Peptide internalization and PS exposure were followed from the 
first image acquired (t=0) up to 20 minutes by confocal microscopy. The scale bar corresponds to 20 µm. 
 
  
Figure S11. Induction of PS exposure by R9 and TP10. HeLa cells were co-incubated with 25 µM of the 
indicated peptid s and An exin V-Alexa Fluor 647. Peptide internalization and PS exp sure were followed 
from the rst image acquired (t=0) up to 20 minutes b  focal microscopy. The scale b r correspond  t  
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ABSTRACT
The internalization eficiencies as well as the uptake mechanism of cell-penetrating peptides (CPPs) 
depend, next to the type of CPP and the cargo, also on the cell type. Here, we demonstrate that 
the frequently used cell lines HeLa and HEK have fundamentally different uptake mechanisms and 
resolve the basis for these differences. Whereas in HeLa cells, for nonaarginine, a concentration-
dependent switch in uptake mechanism could be observed in which the peptide only entered 
into the cytosol by direct membrane penetration at high concentrations, in HEK cells, already 
at low concentrations, nonaarginine entered the cytoplasm. The hypothesis that the membrane 
potential is the driving force for peptide internalization was refuted using gramicidin A-induced 
depolarization and monitoring the membrane potential by whole cell patch clamp. Instead, the lipid 
composition, in particular, the absence of sphingomyelin, was identiied as the major determinant 
for the permissiveness of the membranes. Lipid analysis of the plasma membranes revealed that 
HEK cells have a low sphingomyelin content which coincides with a permissive membrane. In 
contrast, HeLa cells have a high sphingomyelin content relecting a resistant membrane and they 
can be rendered permissive by lowering the sphingomyelin content by sphigomyelinase-induced 
conversion into ceramide. This study gives new insights into the fundamental mechanisms of 
CPP internalization and thus may have a major impact on the development of cell-speciic CPPs.
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INTRODUCTION
Cell-penetrating peptides (CPPs) are frequently used as drug delivery vehicles because of their 
capacity to induce eficient cellular uptake of molecules that otherwise do not enter cells. Their 
applications range from delivery of small molecule drugs, to peptides, proteins [1], oligonucleotides 
and siRNA [2, 3], and nanoparticles [4, 5]. 
In order to enable a rational optimization of CPPs and understand cell type preferences, the 
entry mechanism of CPPs has been investigated intensively. For arginine-rich CPPs, three different 
internalization mechanisms have been described [6]: (passive) translocation, endocytosis and 
transduction. The mode of entry depends on the peptide concentration, the cell type and the 
conjugated cargo [7-10] but also on the structural characteristics of the peptide such as charge 
and stereochemistry of the amino acids [11]. For direct cytoplasmic entry at high concentrations, 
arginine-rich CPPs accumulate at certain membrane areas, so-called nucleation zones (NZ), which 
are colocalizing with ceramide platforms [12, 13]. Uptake via NZ, also called transduction, is 
restricted to arginine-rich CPP, such as nonaarginine [12] with the human lactoferrin-derived CPP 
[14] being a remarkable exception as this peptide only has four arginine residues. The membrane 
potential has been considered a driving force for the internalization of cationic CPPs. However, 
direct evidence of the membrane potential as a driving force for peptide uptake is still lacking 
since all measurements were conducted either with artiicial lipid vesicles or with cells incubated 
with potassium-rich media in order to diminish the membrane potential [15, 16].
Although the internalization of CPPs has been described to be cell line-dependent, the reasons 
for these differences are still unknown. Mueller et al. compared the internalization of several 
CPPs in four different cell lines after speciic treatments, for example after inhibition of proteases 
or endocytosis [9]. However, a functional characterization of cell lines with regard to membrane 
composition or expression of certain cell surface proteins is still lacking. A considerable amount 
of research has been conducted on the role of glycosaminoglycans (GAGs) in endocytosis since 
these are the irst (negatively) charged molecules the cationic CPPs encounter when approaching 
a cell [17, 18]. Several studies demonstrated a positive effect of GAGs on the internalization of 
CPPs [12, 19-21]. However, the role of GAGs depends on the type of CPP, and GAGs are probably 
not acting as autonomous receptors but rather as coreceptors as reviewed in Favretto et al. [18]. 
This hypothesis is further supported by the inding that in the absence of GAGs, CPPs still bind to 
the cells and are internalized [22]. 
In this study, we aimed to gain more insights into the cellular characteristics underlying the 
differential uptake mechanisms between cell lines with regard to the occurrence of direct 
translocation and transduction. When comparing the two frequently used cell lines HeLa and 
HEK, we observed major differences in the uptake mechanism of an arginine-rich CPP. Using 
for the irst time electrophysiological recordings in living cells during peptide internalization, we 
found that the membrane potential was not the decisive factor for internalization. Rather, detailed 
analyses of the plasma membranes identiied the lipid composition as the major determinant 
inluencing the uptake mechanism. 
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MATERIALS AND METHODS
Materials
All materials were obtained from Sigma-Aldrich, unless stated otherwise. The used 
sphingomyelinase (bSMase) is derived from Bacillus cereus and provided at a concentration of 
138 U/mL. Stock solutions of valinomycin (9 mM) and gramicidin A (1.06 mM) were prepared in 
DMSO and ethanol, respectively.
Cell culture
HeLa and HEK293T cells were obtained from the DSMZ (German Collection of Microorganisms 
and Cell Cultures, Braunschweig, Germany). HeLa cells were cultured in RPMI supplemented 
with 10 % fetal calf serum (FCS) (PAN Biotech, Aidenbach, Germany) whereas HEK cells were 
maintained in high glucose DMEM containing 10% FCS. Both cell lines were cultivated in 
an incubator at 37°C with 5% CO
2
. Cell culture media were purchased from Invitrogen (Life 
Technologies, Carlsbad, USA).
Peptides
Peptides were purchased from EMC microcollections (Tübingen, Germany). All peptides 
were N-terminally labelled with 5,6-carboxyluorescein and C-terminally amidated. Peptide 
concentrations were determined based on the absorbance of luorescein at 492 nm with 
a Novaspec II spectrophotometer (Pharmacia, New York, USA). Peptides were diluted in Tris-
HCl buffer (10 mM, pH 8.8) and an extinction coeficient of 75 000 M-1cm-1 was assumed for 
calculating peptide concentrations. 
Confocal laser scanning microscopy
Two days before the experiment 20,000 HeLa cells or 25,000 HEK cells were seeded in chambered 
coverslips (Nunc, Wiesbaden, Germany or Ibidi, Martinsried, Germany, respectively). Confocal 
microscopy was performed using a Leica SP5 microscope with an HCX PL APO 63× N.A. 1.2 water 
immersion lens (Leica, Mannheim, Germany). During image acquisition, cells were maintained at 
37°C. Fluorescein was excited using an argon ion laser at 488 nm and emission was collected 
between 500 and 550 nm. Cells were incubated with the indicated peptide concentrations and 
the speciic compounds, as indicated for each experiment. During imaging, cells were maintained 
in RPMI, unless stated otherwise.
Flow cytometry
80,000 HeLa cells or 100,000 HEK cells were seeded in 24-well plates one day before the 
experiment. After preincubating cells for 10 min with 1 µM gramicidin A or 10 µM valinomycin in 
RPMI or RPMI alone, cells were coincubated for 20 min with the indicated peptide concentrations. 
Cells were washed with RPMI twice, trypsinized, centrifuged and resuspended in RPMI + 10 % 
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FCS without phenol red. Fluorescence intensities were measured using a low cytometer (BD 
Biosciences, Erembodegem, Belgium). Approximately 10,000 intact cells were gated based on 
forward and sideward scatter. The Summit 4.3 software (Dako, Fort Collins, USA) was used for 
the analysis of gated cells. 
Patch-clamp combined with confocal laser scanning microscopy
For electrophysiological recordings, HEK293T cells or HeLa cells were cultured on 35 mm glass 
dishes and transferred to a recording chamber (Luigs & Neumann, Ratingen, Germany) on an 
upright ixed-stage scanning confocal microscope (TCS SP5 DM6000CFS, Leica Microsystems, 
Mannheim, Germany) equipped with an HCX APO L 20 × NA 1.0 water immersion objective (Leica 
Microsystems) as well as a cooled CCD-camera (DFC360FX, Leica Microsystems). Fluorescein was 
excited using the 488 nm line of an argon ion laser. Changes in cytosolic luorescence were 
monitored over time at 0.25–1 Hz frame rates. Patch pipettes (4–7 MΩ) were pulled from borosilicate 
glass capillaries (1.50 mm OD / 0.86 mm ID; Science Products) on a PC-10 micropipette puller 
(Narishige Instruments, Tokyo, Japan), ire-polished (MF-830 Microforge; Narishige Instruments) 
and illed with pipette solution containing 143 mM KCl, 2 mM KOH, 1 mM EGTA, 0.3 mM 
CaCl
2
 (free Ca2+ = 110 nM), 10 mM HEPES, 2 mM MgATP, 1 mM NaGTP; pH = 7.1 (adjusted 
with KOH); osmolarity = 290 mOsm. An agar bridge (150 mM KCl) connected the reference 
electrode and the bath solution. An EPC-10 ampliier controlled by Patchmaster 2.67 software 
(HEKA Elektronik, Lambrecht, Germany) was used for data acquisition. Both pipette (C
fast
) and cell 
membrane capacitance (C
slow
) were monitored and automatically compensated throughout the 
experiment. If not stated otherwise, signals were low-pass iltered (analog 3- and 4-pole Bessel 
ilters (–3 dB); adjusted to 1/
3
 - 1/
5
 of the sampling rate (5–10 kHz, depending on protocol). Electric 
noise was suppressed using a Hum Bug Noise Eliminator (Quest Scientiic, Vancouver, Canada). 
Between recordings, the holding potential (V
hold
) was –60 mV. All electrophysiological data were 
recorded in whole-cell coniguration at room temperature. Free Ca2+ and Mg2+ concentrations 
were calculated using WEBMAXC STANDARD (available at http://www.stanford.edu/~cpatton/
webmaxcS.htm). Cells were continuously superfused with extracellular solution containing: 145 
mM NaCl, 5 mM KCl, 1 mM CaCl
2
, 1 mM MgCl
2
, 10 mM HEPES; pH = 7.3 (adjusted with NaOH); 
osmolarity = 300 mOsm (adjusted with glucose). Stimuli were applied from air pressure-driven 
reservoirs via an 8-in-1 multi-barrel ‘perfusion pencil’ (Science Products, Hofheim, Germany) 
[23]. Individual numbers of cells / experiments (n) are denoted in igure legends. If not stated 
otherwise, results are presented as means ± SEM and statistical analyses were performed using 
paired or unpaired t-tests (as dictated by experimental design). Electrophysiological data were 
analyzed ofline using Patchmaster 2.67 (HEKA Elektronik), IGOR Pro 6.31 (WaveMetrics, Lake 
Oswego, OR) and Excel (Microsoft, Seattle, WA) software. 
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Plasma membrane isolation and lipid analysis
The protocol for extraction of lipids from the plasma membrane was adjusted from Yao et al. 
[24]. One million cells were seeded in petri dishes (145 mm) and grown for four days. Cells were 
washed twice with ice-cold HBS+ which is HBS containing protease inhibitor cocktail (Roche, Basel 
Switzerland) and 1 mM phenylmethylsulfonyl luoride (Sigma-Aldrich, St. Louis, USA) and scraped 
into HBS+. Cells from three petri dishes were pooled and homogenized with an Ultra Thorax (IKA 
T10 basic, IKA-Werke, Staufen, Germany) 3 times for 5 s with 1 min pause. A Bradford assay 
(Biorad, München, Germany) was performed to normalize for the protein content of the samples.
Cell lysates were centrifuged at 10,000 × g for 45 min at 4°C using an ultracentrifuge (Sorvall 
WX80, Thermo Scientiic, Waltham, USA). This ultracentrifuge was also used for all subsequent 
centrifugation steps at 4°C. Membrane pellets were resuspended in 5 % sucrose (in HBS+). 
Sample volumes corresponding to the same protein amounts were loaded onto a sucrose gradient 
(45% - 20% - 5%) and centrifuged overnight at 150,000 x g at 4°C in a swing-out rotor. The 
plasma membrane fraction, which was located on top of the 45% and inside the 20% layer, was 
diluted with HBS+ and centrifuged for 30 min at 200,000 x g. After resuspending the pellet in 
5% sucrose, it was loaded again onto a sucrose gradient and centrifuged for 1 h at 200,000 x 
g using a swing-out rotor. The plasma membrane fraction was collected at the interface of the 
45% and 20% layers. The pellet was diluted with milliQ, pelleted at 200,000g for 30 min and 
resuspended in 200 μL milliQ for lipid extraction. The lipid extraction (chloroform/methanol) and 
analysis (by matrix-assisted laser desorption and ionization time-of-light mass spectrometry) was 
performed according to Dinkla et al. [25]. 
RESULTS 
Differential uptake routes in HeLa and in HEK cells
HeLa and HEK cells are commonly used cell lines in in vitro uptake studies, due to their ease 
of handling and the large body of available data relating to these cells. Upon comparing these 
two cell lines with regard to the concentration-dependence of uptake of the arginine-rich CPP 
nonaarginine (R9), in HeLa cells, we observed endocytosis at low concentrations and uptake 
via nucleation zones resulting in a massive cytoplasmic luorescence at higher concentrations. 
This concentration-dependent switch has been reported earlier [12, 13] (Figure 1). In contrast, 
HEK cells already showed cytoplasmic luorescence at lower concentrations and less pronounced 
endocytic vesicles. This cytoplasmic luorescence increased with the peptide concentration and no 
concentration-dependent switch in import mechanism was observed. 
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 Figure 1: Concentration dependence of peptide uptake in HeLa compared to HEK cells. Cells were incubated 
with nonaarginine at the indicated concentrations in growth medium supplemented with FCS. Cells were washed 
and imaged by confocal microscopy. Scale bar denotes 40 μm. 
 
These different observations suggested that in HEK cells peptides continuously traverse the plasma 
membrane by translocation, while for HeLa cells, only above the concentration threshold of 10 µM, rapid 
direct uptake occurs. Induction of this import mechanism depends on the activation of sphingomyelinase. 
While the molecular details of this import mechanism and in particular sphingomyelinase activation are 
not yet clear, it is known that it leads to a remodeling of the plasma membrane through conversion of 
sphingomyelin to ceramide [13]. Importantly, also generation of ceramide by external addition of 
sphingomyelinase renders the membrane permeable to peptides, even at lower peptide concentrations. 
Since glycosaminoglycans (GAGs) and sialic acids were shown to be involved in the internalization of 
CPPs as reviewed by Favretto et al. [18], differences in the amount of glycosaminoglycans between cell 
lines may contribute to changes in uptake efficiencies of CPPs. Therefore, we compared the glycocalyx 
composition of HeLa and HEK cells (Supplementary Figure S1A). Overall, the detected amounts were 
similar for HeLa and HEK cells. For some epitopes, especially for chondroitin sulfate, HEK cells showed 
a lower expression. However, complete removal of the glycocalyx did not change the uptake mechanism 
of nonaarginine (Supplementary Figure S1B) indicating that the composition of the glycocalyx is not 
decisive for the uptake mechanism. 
Figure 1: Concentration dependence of peptide uptake in HeLa compared to HEK cells. Cells were 
incubated with nonaarginine at the indicated concentrations in growth medium supplemented with FCS. 
Cells were washed and imaged by confocal microscopy. Scale bar denotes 40 μm.
These different observations suggested that in HEK cells peptides continuously traverse the 
plasma membrane by translocation, while for HeLa cells, o ly above the concentratio  threshold 
of 10 µM, rapid direct uptake occurs. Induction of this import mechanism depends on the 
activation of sphingomyelinase. While the molecular details of this import mechanism and in 
particular sphingomyelinas activation are not ye  cl ar, it is known that it lea s t  a remodeling 
of the plasma membrane through conversion of sphingomyelin to ceramide [13]. Importantly, 
also generation of ceramide by external addition of sphingomyelinase renders the membrane 
permeable to peptides, even at lower peptide concentrations.
Since glycosaminoglycans (GAGs) and sialic acids were shown to be involved in the internalization 
CPPs as reviewed by Favretto et al. [18], ifferences in the am unt of glycosaminoglycans 
between cell lines may contribute to changes in uptake eficiencies of CPPs. Therefore, we 
compared the glycocalyx composition of HeLa and HEK cells (Supplementary Figure S1A). Overall, 
the detected amounts were similar for HeLa and HEK cells. For some epitopes, especially for 
chondroitin sulfate, HEK cells showed a lower expression. However, complete removal of the 
glycocalyx did not change the uptake mechanism of nonaarginine (Supplementary Figure S1B) 
indicating that the composition of the glycocalyx is not decisive for the uptake mechanism.
Considering the earlier implication of membrane potential in peptide uptake [16, 26] we decided 
to address whether differences in membrane potential existed for HEK and HeLa cells. 
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Different role of membrane potential in HeLa and HEK cells
First, we wanted to investigate whether changing the membrane potential affected 
the internalization eficiencies in HeLa and HEK cells. Since the membrane potential is 
considered the driving force for the internalization of CPPs, a further increase of the potential 
(hyperpolarization) was expected to promote internalization while diminishing the membrane 
potential (depolarization) would inhibit internalization. Two different compounds were selected 
in order to induce hyperpolarization or depolarization. Valinomycin is an ionophore selective for 
potassium ions which transports potassium ions into the extracellular space, thereby resulting in a 
hyperpolarization of the cell [27, 28]. In contrast, gramidicin A induces depolarization by forming 
a channel in the membrane which leads to the inlux of sodium [28, 29].
In order to test whether valinomycin and gramicidin A had indeed the expected effects on the 
membrane potential, we incubated cells with the compounds and recorded the membrane 
potential over time using whole-cell patch-clamp recordings (Supplementary Figure S2). The 
patch-clamp measurements had to be performed in Hepes-buffered solution in the absence 
of FCS which required the adjustment of the peptide concentration. However, the only effect 
of using regular growth medium without fetal calf serum was the lowering of the effective 
concentration of the CPP by about 50% (Supplementary Figure S3). The reason for this reduction 
is that the anionic serum proteins are sequestering the cationic CPPs resulting in a lower CPP 
concentration available for uptake into cells [8].
For HeLa cells in the absence of valinomycin or gramicidin A, a concentration-dependent switch in 
uptake mechanisms was observed (Figure 2) as it was already shown by confocal microscopy (Figure 
1). Depolarizing the membrane potential almost abolished the internalization of nonaarginine 
completely. Hyperpolarization had no signiicant effect on uptake. In contrast, in HEK cells, there 
was a gradual increase in luorescence intensities with increasing peptide concentrations and 
changing the membrane potential had only little effect on the internalization eficiencies (Figure 
2). Interestingly, gramidicin A showed a paradoxical increase in uptake eficiency. These results 
indicate that an “undisturbed” membrane potential is required for the eficient internalization 
into HeLa cells, whereas it is not for HEK cells.
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 Figure 2: Impact of changes of manipulation of membrane potential on uptake efficiencies of nonaarginine 
(R9). HeLa and HEK cells were preincubated with the indicated compounds or RPMI for 10 min which was 
followed by a 20 min coincubation with the indicated concentrations of R9. A) After the incubation, cells were 
washed, trypsinized and analyzed by flow cytometry. Averages of median fluorescence intensities of three 
independent experiments are shown. Error bars denote SEM. B) After the incubation, cells were washed and imaged 
by confocal microscopy. 10 µM R9 was used. Scale bar indicates 40 µm. 
 
Currently, only little is known about the molecular mechanism of nucleation zone-dependent uptake, 
except the involvement of acid sphingomyelinase [13]. In order to get more insight into the requirement 
of the membrane potential, we were particularly interested in correlating the membrane potential with 
uptake. Therefore, we combined confocal microscopy with patch-clamp recordings. For patch clamp 
experiments, we performed whole cell recordings which means that the membrane inside the patch pipette 
was ruptured and the potential across the whole plasma membrane was measured.  
To test whether the formation of NZ only depends on the formation of ceramide or whether the membrane 
potential is an essential requirement, we depolarized HeLa cells by an incubation with gramicidin A under 
continuous control of the membrane potential by patch clamp. In line with our previous observations 
(Figure 2), this inhibited the internalization of nonaarginine (Figure 3). Strikingly, when we replaced 
gramicidin A by bacterial sphingomyelinase (bSMase), we observed rapid cytoplasmic uptake whereas 
Figure 2: Impact of changes of manipulation of membrane potential on uptake eficiencies of 
nonaarginine (R9). HeLa and HEK cells were preincubated with the indicated compounds or RPMI for 10 
min which was followed by a 20 min coincubation with the indicated concentrations of R9. A) After the 
incubation, cells were washed, trypsinized and analyzed by low cytometry. Averages of median luorescence 
intensities of three independent experiments are shown. Error bars denote SEM. B) After the incubation, cells 
were washed and imaged by confocal microscopy. 10 µM R9 was used. Scale bar indicates 40 µm.
Currently, only little is known about the molecular mechanism of nucleation zone-dependent 
uptake, except the involvement of acid sphingomyelinase [13]. In order to get more insight into 
the requirement of the membran  potential, we were particularly interested in corr lating the 
membrane potential with uptake. Therefore, we combined confocal microscopy with patch-clamp 
recordings. F r patch clamp expe iments, we p rformed whole cell recordings which means that 
the membrane inside the patch pipette was ruptured and the potential across the whole plasma 
membrane was measured. 
To test whether the formation of NZ only depends on the formation of ceramide or whether the 
membrane potential is an essential requirement, we depolarized HeLa cells by an incubation with 
gramicidin A under continuous control of the membrane potential by patch clamp. In line with 
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our previous observations (Figure 2), this inhibited the internalization of nonaarginine (Figure 3). 
Strikingly, when we replaced gramicidin A by bacterial sphingomyelinase (bSMase), we observed 
rapid cytoplasmic uptake whereas the membrane potential remained constant in a depolarized 
state (Figure 3). These indings clearly contradict the original concept of membrane potential as a 
driving force. Apparently, changing the lipid composition was already suficient to permit entry of 
the peptide. Next, we wanted to investigate whether increasing permeability through conversion 
of sphingomyelin into ceramide is only applicable for arginine-rich peptides like nonaarginine or 
whether it is a general concept for CPPs. Therefore, we induced the formation of ceramide by 
the external addition of bacterial sphingomyelinase and added the amphipathic CPP penetratin 
which does not show internalization via NZ. However, ceramide formation did not alter the 
uptake mechanism of penetratin (Supplementary Figure S4).
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 Figure 3: Nucleation zone-dependent uptake is a function of membrane composition and not membrane 
potential. HeLa cells were incubated for 10 min with gramicidin A, followed by incubation with bSMAse for 10 
min. Then, nonaarginine was added. In the fluorescence micrographs the position of the pipette is outlined. In the 
lower panel a whole-cell potential recording for one cell during the time course of the experiment is shown.  
 
Lipid composition as a determinant for uptake mechanism 
Since the lipid composition of the plasma membrane and not the membrane potential was identified as a 
key determinant for the uptake mechanism in HeLa cells and direct membrane translocation was observed 
once sphingomyelin was converted into ceramide, we hypothesized that the direct membrane 
translocation of peptide in HEK cells may also be a consequence of a particular composition of the 
plasma membrane. To compare the lipid composition, plasma membranes of HeLa and HEK cells were 
isolated by sucrose density centrifugation and lipids were detected using mass spectrometry. Remarkably, 
while the plasma membrane of HeLa cells was rich in sphingomyelin, in the isolates of HEK cells hardly 
any sphingomyelin could be detected (Figure 4). When HeLa cells were treated with bSMAse, ceramide 
could be detected which is in agreement with our previous immunofluorescence staining that showed 
colocalization of NZ with ceramide [13]. 
Figure 3: Nucleation zone-dependent uptake is a function of membrane composition and not 
membrane potential. HeLa cells were incubated for 10 min with gramicidin A, followed by incubation with 
bSMAse for 10 min. Then, nonaarginine was added. In the luorescence micrographs the position of the 
pipette is outlined. In the lower panel a whole-cell potential recording for one cell during the time course of 
the experiment is shown. 
Lipi  co positi n as a determinant for uptake mechanism
Since the lipid composition of the plasma membrane and not the membrane potential was 
identiied as a key determinant for the uptake mech nism in HeLa cells and direct membrane 
translocation was observed once sphingomyelin was converted into ceramide, we hypothesized 
that the direct membrane translocation of peptide in HEK cells may also be a consequence of 
a particular composition of the plasma membrane. T  co pare the lipid compos tion, plasma 
membranes of HeLa and HEK cells were isolated by sucrose density centrifugation and lipids were 
detected using mass spectrometry. Remarkably, while the plasma membrane of HeLa cells was 
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rich in sphingomyelin, in the isolates of HEK cells hardly any sphingomyelin could be detected 
(Figure 4). When HeLa cells were treated with bSMAse, ceramide could be detected which is in 
agreement with our previous immunoluorescence staining that showed colocalization of NZ with 
ceramide [13].
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 Figure 4: Positive ion MALDI-TOF mass spectra of membrane lipid extracts from HeLa and HEK cells. 
Samples were diluted 1:1 (v/v) with the matrix (0.5 M 2,5-dihydroxybenzoic acid in methanol). All peaks are 
labelled based on their m/z ratios and matrix cluster ions are marked by asterisks. A) HEK cells, B) HeLa cells, C) 
HeLa cells treated for 20 min with 1200 mU/mL bSMase at 37°C. Cer, ceramide; PC, phosphatidylcholine; SM, 
sphingomyelin. 
 
DISCUSSION 
In this study we show that HEK and HeLa cells differ in the uptake mechanism of nonaarginine. In HEK 
cells, a concentration-independent direct translocation across the plasma membrane and into the cytosol is 
observed, while in HeLa cells, direct cytoplasmic entry requires the conversion of sphingomyelin into 
ceramide. This conversion may either occur through activation of endogenous acid sphingomyelinase at 
high peptide concentrations or through addition of exogenous sphingomyelinase.  
Our lipidomics analyses show that, in contrast to HeLa cells, the plasma membrane of HEK cells contains 
only little sphingomyelin. Thus, sphingomyelin is a key determinant regulating the permissiveness of the 
membrane towards peptide transport. Importantly, as a consequence of the scarcity of sphingomyelin in 
HEK cells, only small amounts of ceramide can be formed. Therefore, rather the absence of 
sphingomyelin than the presence of ceramide should be linked to direct membrane permeation of the 
peptides. In line with these observations, it had been shown that the DNA methyltransferase inhibitor 
decitabine increases the sensitivity of drug-resistant cancer cells to chemotherapeutics by decreasing the 
sphingomyelin content in the plasma membrane [30]. Cancer cells with high drug sensitivity were poor in 
sphingomyelin.  
Importantly, our experiments refute the role of the membrane potential in peptide uptake. Once the 
plasma membrane is permissive for peptide translocation to occur, the concentration gradient is sufficient 
to drive import into the cytoplasm. As an alternative to gramicidin A, in some studies, the membrane 
potential was changed by incubating cells with a potassium-rich buffer which resulted in inhibition of 
peptide uptake [8, 26, 31]. Rothbard et al. showed that the induction of hyperpolarization by valinomycin 
increased the uptake of octaarginine in Jurkat cells, whereas a depolarization by gramicidin A decreased 
the uptake [26]. At this point, we do not have an explanation for the discrepancies of the valinomycin 
experiments. 
Large unilamellar vesicles were often used to study the importance of the membrane potential. They were 
filled and incubated with buffers mimicking the intracellular and extracellular environment of a cell 
thereby manipulating the membrane potential [15, 16]. Despite of its simplicity, when testing the 
requirement of the membrane potential for CPP internalization, most of these studies only used very 
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Samples were diluted 1:1 (v/v) with the matrix (0.5 M 2,5-dihydroxybenzoic acid in methanol). All peaks are 
labelled based on their m/z ratios and matrix cluster ions are marked by asterisks. A) HEK cells, B) HeLa cells, 
C) HeLa cells treated for 20 min with 1200 mU/mL bSMase at 37°C. Cer, ceramide; PC, phosphatidylcholine; 
SM, sphingomyelin.
DISCUSSION
In this study we show that HEK and HeLa cells differ in the uptake mechanism of nonaarginine. 
In HEK cells, a concentration-independe t direct tran locati n acro s the plasma membrane 
and into the cytosol is observed, while in HeLa cells, direct cytoplasmic entry requires the 
conversion of sphingomyelin int  ceramide. This conversion may either occur through activation 
of endogenous acid sphingomyelinase at high peptide concentrations or through addition of 
exogenous sphingomyelinase. 
Our lipidomics analyses show that, in contrast to HeLa cells, the plasma membrane of HEK cells 
contains only little sphingomyelin. Thus, sphingomyelin is a key determinant regulating the 
permissiveness of the membrane towards peptide transport. Importantly, as a consequence of the 
scarcity of sphingomyelin in HEK cells, only small amounts of ceramide can be formed. Therefore, 
rather the absence of sphingomyelin than the presence of ceramide s ould be linked to direct 
membrane permeation of the peptides. In line with these observations, it had been shown that 
the DNA methyltransferase inhibitor decitabi e incre ses the s nsitivity of drug-resista t cancer 
cells to chemotherapeutics by decreasing the sphingomyelin content in the plasma membrane 
[30]. C cer ells with high drug sensitivity were poor in sphingomy in. 
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Importantly, our experiments refute the role of the membrane potential in peptide uptake. Once 
the plasma membrane is permissive for peptide translocation to occur, the concentration gradient 
is suficient to drive import into the cytoplasm. As an alternative to gramicidin A, in some studies, 
the membrane potential was changed by incubating cells with a potassium-rich buffer which 
resulted in inhibition of peptide uptake [8, 26, 31]. Rothbard et al. showed that the induction of 
hyperpolarization by valinomycin increased the uptake of octaarginine in Jurkat cells, whereas 
a depolarization by gramicidin A decreased the uptake [26]. At this point, we do not have an 
explanation for the discrepancies of the valinomycin experiments.
Large unilamellar vesicles were often used to study the importance of the membrane potential. 
They were illed and incubated with buffers mimicking the intracellular and extracellular 
environment of a cell thereby manipulating the membrane potential [15, 16]. Despite of its 
simplicity, when testing the requirement of the membrane potential for CPP internalization, most 
of these studies only used very simple vesicles consisting of derivatives of phosphatidylcholine and 
–glycerol. Terrone et al. also included cholesterol, sphingomyelin and a glycolipid into the vesicles 
giving a better representation of the plasma membrane and tested internalization eficiencies for 
penetratin and oligoarginines [16]. In general, there was only a very poor uptake in the absence 
of a membrane potential with the exception that oligoarginines and –lysines were internalized 
into cholesterol-rich vesicles. The induction of a membrane potential by valinomycin resulted in 
increased internalization eficiencies regardless of the type of peptide and lipid composition of 
the vesicles. This is in contrast to our indings where the absence of sphingomyelin rendered 
the membrane more permissive. One explanation for these differences might be the differences 
in the incubation times: 20 minutes in our versus 12 hours in the other study. The role of 
sphingomyelin in the leakiness of vesicles with regard to peptide was also investigated [32, 
33]. It was shown that the conversion of sphingomyelin into ceramide by bSMAse resulted in a 
stronger internalization of arginine-rich CPPs into giant plasma membrane vesicles (GPMVs) [34]. 
Changing the sphingomyelin content in very simple liposomes yielded much more permissive 
membranes which is in agreement with our results [33]. 
Importantly, removal of the glycocalyx did not change the uptake mechanism. Bechara et al. 
performed a study in which they tried to separate the effects of GAGs and sphingomyelin by 
comparing wildtype cells and GAG-deicient cells which were treated with sphingomyelinase [34]. 
They showed that the increase in internalization after sphingomyelinase treatment was stronger 
for the wildtype cells compared to the GAG-deicient cells. However, they just measured the total 
amounts of peptides which were internalized without determining the uptake mechanism which 
is involved which is in our opinion the most important factor. Therefore, for the GAG-deicient 
cells direct uptake may already occur at lower peptide concentrations while for GAG-expressing 
cells this requires conversion of sphingomyelin.
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In this study, we performed for the irst time whole-cell patch-clamp recordings simultaneously 
with time-lapse confocal microscopy to monitor uptake kinetics and address the interdependence 
of membrane potential and peptide uptake. Instead of addressing the capacity of the CPP to 
induce membrane channels by protocols adequate for single-channel recordings [35, 36], we were 
interested in the impact of the peptide on the whole-cell membrane potential. When considering 
the translocation of peptides through permissive membranes, the question arises why gramicidin 
A-induced depolarization inhibits nucleation zone-dependent import. One may conceive that the 
membrane potential enhances the accumulation of the peptide at the plasma membrane which 
contributes to the triggering of nucleation zone-dependent import. Alternatively, the membrane 
potential may be involved in the activation of endogenous ASMase. 
The absence of further depolarization upon peptide entry provides further evidence that 
nucleation zone formation and translocation do not compromise membrane integrity. This is in 
line with the exclusion of propidium iodide [12] and contradicts the hypothesis of pore formation 
[37, 38]. One interesting concept in lipid research is the spontaneous formation of pores or lipid 
ion channels [39]. The propensity of ions to traverse such pores follows the chaotropic series, 
which would readily provide an explanation why nucleation zone-dependent entry is restricted 
to arginine-rich CPPs.
To conclude, one may consider the nucleation zone-dependent direct cytoplasmic entry of HeLa 
cells at high peptide concentrations only as a special case of direct membrane permeation, 
where the peptide activates cellular processes that remodel the plasma membrane in a way that 
direct entry can occur. Therefore, in the case of HEK cells, the plasma membrane is intrinsically 
permissive, while in HeLa cells, this permissiveness is a result of molecular processes induced by 
the peptide. Importantly, this direct entry is observed for a luorescein-labelled peptide. It had 
been argued before, that a luorophore interferes with direct membrane permeation [40]. Here 
we show that this clearly is not the case.
Overall, our data helps resolving the longstanding dispute with respect to import mechanism, in 
particular direct membrane permeation versus endocytosis 
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 Figure S1: Composition of the glycocalyx in HeLa and HEK cells and effect of digestion on uptake 
mechanism of R9. A) One day before the experiment 80,000 HeLa cells or 100,000 HEK cells were seeded in 24-
well plates (Greiner Bioone, Kremsmünster, Austria). For metabolic labeling of sialic acid, 50 μM N-
azidoacetylmannosamine in RPMI + 10 % FCS [1, 2] was directly added to the cells during seeding. At the day of 
the experiment, cells were detached using 2 mM EDTA and incubated for 90 min with 60 μM BCN-biotin 
(SynAffix, Nijmegen, the Netherlands), washed twice with PBS by centrifugation and incubated for 30 min at 4°C 
with Alexa Fluor 488-conjugated streptavidin (10 μg/mL) (Invitrogen, Carlsbad, USA). Glycosaminoglycans were 
stained using scFvs according to Verdurmen et al. [3] with the modification that PBS was used instead of HBS and 
that the staining was performed with EDTA-detached cells. The following scFvs were used for heparan sulfate (HS): 
HS4C3 (HS1) [4], EV3C3 (HS2) [5], AO4B08 (HS3) [6, 7]. LKN1V was used for detection of dermatan sulfate 
(DS) [8] and I03H10V for chondroitin sulfate (CS) [9]. Fluorescence intensities were measured by flow cytometry. 
For details see materials and methods. Median fluorescence intensities were corrected for unspecific signals of the 
fluorescently labeled antibodies. The average of two experiments is shown (n=0), error bars denote SEM. B) HeLa 
and HEK cells were seeded for confocal microscopy as described in materials and methods. The glycocalyx (HS, 
CS, DS, sialic acid, hyaluronic acid) of cells was digested or left untreated as described by Wallbrecher et al. [10], 
followed by a 20 min incubation with 5 µM R9 in RPMI + 10 % FCS. Cells were washed and analyzed by confocal 
microscopy. Scale bar denotes 40 µm. 
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 Figure S2: Effects of valinomycin and gramicidin A and bSMAse on the membrane potential. HeLa (A) or 
HEK cells (B) were incubated with the indicated concentrations of the respective compounds and the membrane 
potential was recorded. C) Changes of membrane potential upon administration of the compounds were calculated 
and the average of several cells is shown. Error bars indicate SEM. Numbers indicate number of cells which were 
patched for each condition.  
Figure S2: Effects of valinomycin and gramici in A and bSM se on the membrane potential. HeLa 
(A) or HEK cells (B) were incubated with the indicated concentrations of the respective compounds and 
the membrane potential was recorded. C) Changes of membrane potential upon administration of the 
compounds were calculated and the average of several cells is shown. Error bars indicate SEM. Numbers 
indicate number of cells which were patched for each condition. 
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 Figure S3: Concentration dependence of uptake in HeLa compared to HEK cells in the absence of serum. 
Cells were incubated with nonaarginine at the indicated concentrations in growth medium without FCS for 20 min 
after which cells were washed and used for confocal microscopy immediately. Scale bars denotes 40 μm. 
 Figure S4: Effect of bSMAse treatment on the uptake mechanism of R9 and penetratin. HeLa cells were 
preincubated with 1200 mU/mL bSMAse in RPMI + 10 % FCS for 10 min at 37 °C. Then, nonaarginine or 
penetratin were added to a final concentration of 5 µM. Cells were washed and imaged with confocal microscopy. 
Scale bars denote 40 μm. 
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ABSTRACT
Cell-penetrating peptides (CPPs) possess the capacity to induce cell entry of themselves and 
attached molecular cargo, either by endocytosis or by direct translocation. Conformational 
constraints have been described as one means to increase the activity of CPPs, especially for 
direct crossing of the plasma membrane. Here, we explored the structure-activity-relationship 
of bicyclic peptides for cell entry. These peptides may be considered minimal analogues of 
naturally occurring oligocyclic peptide toxins and are a promising scaffold for the design of 
bioactive molecules. Increasing numbers of arginine residues that are primarily contributing to 
cell-penetrating activity were introduced either into the cycles, or as stretches outside the cycles, 
at both ends or at one end only. In addition, we probed for the impact of negatively charged 
residues on activity for both patterns of arginine substitution. Uptake was investigated in HeLa 
cells by low cytometry and confocal microscopy. Overall, uptake eficiency showed a positive 
correlation with the number of arginine residues. The subcellular distribution was indicative of 
endocytic uptake. One linear stretch of arginines coupled outside the bicycle was as effective in 
promoting uptake as substituting the same number of arginines inside the bicycles. However, 
the internally substituted analogues were more sensitive to the presence of negatively charged 
residues. For a given bicyclic peptide, uptake was more effective than for the linear counterpart. 
Introduction of histidine and tryptophans further increased uptake eficiency to comparable levels 
as that of nonaarginine despite the larger size of the bicyclic backbone. The results demonstrate 
that both arginine clustering and spatial constraints are uptake-promoting structural principles, 
an observation that gives freedom in the introduction of cell-penetrating capacity to structurally 
constrained scaffolds.
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INTRODUCTION
Eficient cellular import is still a major hurdle in drug development. Many small molecules as well 
as biomacromolecules such as siRNA enter cells only poorly, thus requiring chemical modiications 
or carriers to induce cellular uptake. Over the past 20 years, there has been increasing interest in 
cell-penetrating peptides (CPPs) as carriers. These cationic or amphipathic peptides of about 8 to 
30 amino acids in length can be coupled to drugs covalently or noncovalently [1].
A high density of positive charge is a characteristic of the large majority of CPPs [2]. While for the 
amphipathic CPPs lysine residues frequently act as carriers of positive charge, the arginine-rich 
CPPs, as the name already suggests, possess a high density of arginine side chains. Prominent 
examples for the latter are the Tat peptide derived from the HIV transactivating protein [3] and 
the oligoarginines [4, 5]. The particular role of arginines has been ascribed to the capacity of 
the guanidinium group to engage in bidentate hydrogen bond interactions for example with 
negatively charged sugars on the plasma membrane [6]. 
For most CPPs and CPP-cargo complexes uptake occurs via endocytosis. This uptake mechanism 
requires endosomal escape in order to achieve delivery to the cytosol. However, next to endocytosis, 
CPPs can also enter via different mechanisms of direct membrane permeation. At low peptide 
concentrations, there is evidence for direct translocation across the plasma membrane [7], while 
at high concentrations arginine-rich CPPs induce an activation of acid sphingomyelinase followed 
by rapid cytoplasmic entry via ceramide-rich membrane platforms, also coined nucleation zones 
[8]. This latter uptake mechanism has also been referred to as transduction [9]. 
It has been proposed that interactions of CPPs with negatively charged heparan sulfate (HS) 
proteoglycans of the glycocalyx play a key role in triggering uptake [10-14]. However, overall the 
role of HS is not clear as cells that are poor in HS expression such as Jurkat cells also show eficient 
uptake of CPPs [15, 16]. 
Structural variants of the linear peptide backbone have always played an important role in CPP 
research, both in investigating the mechanisms of peptide uptake as well as in the development 
of vectors with speciic uptake characteristics and activity. For analogues of arginine-rich CPPs 
the role of structural lexibility has been scrutinized. Wender et al. showed that besides the 
number of arginine residues a longer and lexible spacer between the guanidino group and 
the peptide backbone improved uptake, indicating that structural lexibility of peptides is yet 
another important factor for internalization [17]. In contrast, it was also shown that cyclization 
of oligoarginines increased uptake by transduction [18]. This observation was ascribed to the 
increased conformational rigidity of the cyclic molecule and a longer spacing between the 
guanidino groups. For a CPP derived from the human milk protein lactoferrin, uptake also 
depends on the presence of a disulide bond formed by terminal residues [10]. However, in 
this case this observation can be attributed to the generation of a higher local arginine density 
[14]. Notably, also the entry mechanism of several oligocyclic peptide toxins that exert their 
activity inside the cell bears similarities with the one of CPPs. Examples are maurocalcine [19] 
and crotamine [20]. For maurocalcine, current evidence supports endocytosis subsequent to HS 
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binding as the mechanism of uptake, even though the molecular target resides on the cytosolic 
face of the membrane of the endoplasmic reticulum [21].
Overall, constraining an oligopeptide into a polycycle represents a highly interesting principle 
for the generation of conformationally constrained, compact molecules which are less prone 
to enzymatic degradation. However, the formation of a deined array of multiple disulide 
bonds, which are most frequently used for cyclization, can be synthetically challenging. Using 
tris (bromomethyl)benzenes, bicyclic molecules can be synthesized from peptides bearing three 
cysteine residues using straightforward chemistry [22]. Here, we employed this “CLIPS”-chemistry 
(Chemical LInkage of Peptides to Scaffolds) to investigate the structure-activity relationship of 
arginine-substituted bicyclic peptides with respect to uptake eficiency and mechanism. Arginine 
residues were either placed in the cyclic parts of the molecule or attached to the N- or C-terminal 
ends outside the bicycle. Uptake eficiency and subcellular distribution were investigated by 
low cytometry and confocal microscopy. Furthermore, the impact of cyclization on uptake was 
assessed for a subset of bicycles and the interaction with HS studied using isothermal titration 
calorimetry. Finally, we investigated whether the incorporation of histidine and tryptophan 
residues next to arginines had an impact on endosomal escape. The design principles elucidated 
here will guide the implementation of cell-penetrating capacity into such types of constrained 
bioactive molecules. 
RESULTS 
Design of the bicyclic peptides 
All bicyclic peptides were based on a core structure of three cysteine residues into which two 
six amino-acid loop segments of glycine and serine residues were introduced (Figure 1). The 
N-terminus was extended with an alanine and an aminohexanoic acid spacer to attach the 
carboxyluorescein moiety needed to follow cellular uptake by low cytometry and confocal 
microscopy. A glycine residue was added at the C- terminal end (Table 1). 
Increasing numbers of arginine residues, to a maximum of eight, were introduced either into the 
cycles in replacement for serine residues (IA group) or attached outside the cycles to either one 
(C-terminus) or both ends of the bicyclic peptide (EA group) (Table 1). In order to explore whether 
a speciic structural arrangement of arginines in the cycles also had an inluence on activity, 
several analogues with the same number of arginines but at different positions were synthesized. 
Since the ultimate goal would be to achieve cell penetration for a bioactive molecule, we also 
introduced arginines into a bicycle that had been identiied as an inhibitor of the human plasma 
kallikrein protease [23] by phage display library screening. Since this peptide (kCA2) contained 
negatively charged aspartate and glutamate residues we wanted to learn to what extent the 
presence of negatively charged residues was compatible with uptake. To address the impact of 
cyclization on uptake, we also synthesized several linear analogues. A inal group was composed 
of analogues in which histidine and tryptophan residues were introduced next to arginines to 
investigate whether their presence had an impact on uptake and endosomal release. 
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Table 1. Sequences of the bicyclic peptides used in this study. 
Name group Peptide sequence Total 
charge
IA0 Internal arginine FITC-Ahx-ACSGSGSGCGSGSGSCGa 0
IA2 FITC-Ahx-ACSGRGSGCGSGRGSCGa,b +2
IA4a FITC-Ahx-ACRGSGRGCGRGSGRCGa +4
IA4b FITC-Ahx-ACSGRGRGCGRGRGSCGa +4
IA6a FITC-Ahx-ACRGRGRGCGRGRGRCGa +6
IA6b FITC-Ahx-ACGRGRGRCRGRGRGCGa +6
IA6c FITC-Ahx-ACRGRGRGCRGRGRGCGa +6
IA6d FITC-Ahx-ACGRGRGRCGRGRGRCGa +6
IA8a FITC-Ahx-ACRGRRRGCGRRRGRCGa +8
IA8b FITC-Ahx-ACRRSRRGCGRRSRRCGa +8
kCA2 Kallikrein inhibitor with internal 
arginines
FITC-Ahx-ACSDRFRNCPADEALCGa -1
kCA3 FITC-Ahx-ACRDRFRNCPADEALCGa 0
kCA4 FITC-Ahx-ACRDRFRNCPADERLCGa +1
kCA5 FITC-Ahx-ACRDRFRRCPADERLCGa +2
kCA6 FITC-Ahx-ACRDRFRRCPADRRLCGa +4
CA2 Control internal arginine FITC-Ahx-ACSGRGRGCGSGSGSCGa +2
CA3 FITC-Ahx-ACRGRGRGCGSGSGSCGa +3
CA4 FITC-Ahx-ACRGRGRGCGSGSRSCGa +4
CA5 FITC-Ahx-ACRGRGRRCGSGSRSCGa +5
CA6 FITC-Ahx-ACRGRGRRCGSGRRSCGa +6
EA2x1 External arginines FITC-Ahx-ARCSGSGSGCGSGSGSCGRa +2
EA2x2 FITC-Ahx-ARRCSGSGSGCGSGSGSCGRRa +4
EA2x3 FITC-Ahx-ARRRCSGSGSGCGSGSGSCGRRRa +6
EA2x4 FITC-Ahx-ARRRRCSGSGSGCGSGSGSCGRRRRa +8
EA1x8 FITC-Ahx-ACSGSGSGCGSGSGSCGRRRRRRRRa +8
kEA2x1 Kallikrein inhibitor with external 
arginines
FITC-Ahx-ARCSDRFRNCPADEALCGRa +1
kEA2x2 FITC-Ahx-ARRCSDRFRNCPADEALCGRRa +3
kEA2x3 FITC-Ahx-ARRRCSDRFRNCPADEALCGRRRa +5
kEA2x4 FITC-Ahx-ARRRRCSDRFRNCPADEALCGRRRRa +7
kEA1x8 FITC-Ahx-ACSDRFRNCPADEALCGRRRRRRRRa +7
IA8b L Linear variants FITC-Ahx-ACRRSRRGCGRRSRRCGd +8
CA6 L FITC-Ahx-ACRGRGRRCGSGRRSCGd +6
EA1x8 L FITC-Ahx-ACSGSGSGCGSGSGSCGRRRRRRRRd +8
kEA1x8L FITC-Ahx-ACSDRFRNCPADEALCGRRRRRRRRd +7
EA8_4H Histidine/tryptophan peptides FITC-Ahx-ACSHSGHGCGHGSHSCGRRRRRRRRa +8
EA8_2H2W FITC-Ahx-ACSHSGWGCGHGSWSCGRRRRRRRRa +8
IA5_2H1W FITC-Ahx-ACHGRRWGCGRHRGRCGa +5
aAll cysteines form disulide bridges with the T3- scaffold.
bArginine is highlighted in bold, negative charges are underlined. The N-termini are labeled with FITC and the 
C-termini are amidated.
ckCA2 is identical to the high-afinity kallikrein inhibitor reported by Heinis and Winter [23]
dAll cysteines were capped with iodoacetamide.
142  |  Chapter 6
124 
 
 Figure 1. General structure of the bicyclic CPPs used in this study. 
 
Cellular uptake of bicyclic peptides  
First, uptake of peptides with internal arginines (IA) was tested by flow cytometry, at both 5 and 20 μM. 
These concentrations were selected because for arginine-rich peptides at 5 μM uptake typically occurs via 
endocytosis, while at 20 μM rapid cytoplasmic import is observed [24]. Also, cells showed this rapid 
uptake for cyclic deca-arginine at 15 μM using serum-free conditions [18].  
At 5 µM, the uptake efficiency of the tested bicyclic peptides showed a positive correlation with the 
number of arginines (Figure 2A-C). For the analogue with two and four arginines (IA2 and IA4a-b), 
uptake was less than 10% of that of nonaarginine. Interestingly, for the set of analogues with six arginine 
residues (IA6a-d), only IA6b, in which the arginine residues were positioned at every other position, was 
taken up significantly better than the peptides with fewer arginine residues (Supplementary Table 1). The 
uptake efficiency further increased by introducing two more arginine residues, with the peptide having the 
regularly distributed arginine pairs (IA8b) showing the highest uptake. However, even for this most 
efficient bicycle, uptake was only about 45% of the import of nonaarginine, which was used as a 
reference. 
At 20 μM the uptake differences were similar to those at 5 µM (Supplementary Figure 2). There were no 
differences between the peptides with six and eight arginines, though. In addition, the most efficient 
peptides displayed only 20% of the uptake of nonaarginine. The flow cytometry histograms showed no 
indications of rapid cytoplasmic import which either constitutes itself as a strong rightward shift of the 
histogram or by the presence of a second population.  
Figure 1. General structure of the bicyclic CPPs used in this study.
Cellular uptake of bicyclic peptides 
First, uptak  of peptides with internal arginines (IA) was tested by low cytometry, at both 5 and 
20 μM. These concentrations were selected because for arginine-rich peptides at 5 μM uptake 
typically occurs via endocytosis, while at 20 μM rapid cytoplasmic import is observed [24]. Also, 
cells showed this rapid uptake for cyclic deca-arginine t 15 μM using serum-f ee conditions [18].
At 5 µM, the uptake eficiency of the tested bicyclic peptides showed a positive correlation with 
the number of arginines (Figure 2A-C). For the analogue with two and four arginines (IA2 and 
IA4a-b), uptake was less than 10% of that of nonaarginine. Interestingly, for the set of analogues 
with six arginine residues (IA6a-d), only IA6b, in which the arginine residues were positioned at 
every oth r position, was taken up signiicantly better than the peptides with fewer arginine 
residues (Supplementary Table 1). The uptake eficiency further increased by introducing two 
more arginine residues, with the peptide having the regularly distributed arginine pairs (IA8b) 
showing the highest uptake. H wever, even for this most eficient bicycl , upt ke was only about 
45% of the import of nonaarginine, which was used as a reference.
At 20 μM the uptake differences were similar to those at 5 µM (Supplementary Figure 2). There 
were no differences between the peptides with six and eight arginines, though. In addition, the 
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most eficient peptides displayed only 20% of the uptake of nonaarginine. The low cytometry 
histograms showed no indications of rapid cytoplasmic import which either constitutes itself as a 
strong rightward shift of the histogram or by the presence of a second population. 
Confocal laser scanning microscopy demonstrated that luorescence was present in punctate 
structures at 5 µM indicating that the bicycles are taken up by endocytosis (Figure 2D, 
Supplementary Figure 1). For microscopy, we focused on the concentration of 5 µM, because 
low cytometry had not shown any evidence of a concentration-dependent change in uptake 
mechanism. 
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Confocal laser scanning microscopy demonstrated that fluorescence was present in punctate structures at 
5 µM indicating that the bicycles are taken up by endocytosis (Figure 2D, Supplementary Figure 1). For 
microscopy, we focused on the concentration of 5 µM, because flow cytometry had not shown any 
evidence of a concentration-dependent change in uptake mechanism.  
 
 Figure 2. Structure-activity relationships of the bicyclic peptides with arginine substitutions within the cycles 
(IA group). (A, B) Flow cytometry histograms of bicycles and nonaarginine at 5 µM for HeLa cells after 1 h 
incubation with peptides. (C) Average median of at least 3 flow cytometry measurements and the standard error. All 
values were corrected for the background of cells incubated without peptides. (D) Intracellular distribution of the 
indicated peptides at 5 µM determined by confocal microscopy. The same settings were used for image acquisition 
of both peptides. Scale bar represents 20 µm. 
 
Figure 2. Structure-activity relationships of the bicyclic peptides with arginine substitutions within 
the cycles (IA group). (A, B) Flow cytometry histograms of bicycles and nonaarginine at 5 μM for HeLa 
cells after 1 h incubation with peptides. (C) Average median of at least 3 low cytometry measurements and 
the standard error. All values were correct d for the background o  e ls ncubated without peptides. (D) 
Intracellular distribution of the indicated peptides at 5 µM deter ined by confocal microscopy. The same 
settings were used for image acquisition of both peptides. Scale bar represents 20 µm.
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Next, we assessed the impact of negatively charged amino acids on the import eficiency by 
introducing arginine substitutions into the kallikrein inhibitor peptide [23] (CA group). The 
positioning of arginines deviated from that of the irst set in order to avoid substitution of residues 
speciic for the inhibitor. Arginines were placed into a bicycle either without the negatively 
charged residues present in the kallikrein inhibitor (CA group) or into the kallikrein inhibitor 
AC
T3
SDRFRNC
T3
PADEALC
T3
G that contains three negatively charged residues (kCA group). kCA2 
(AC
T3
SDRFRNC
T3
PADEALC
T3
G) is identical to the bicycle having the highest afinity for the kallikrein 
protease [23]. For the CA group, uptake was lower than for the IA group, but this needs to be 
attributed primarily to the fact that these bicycles carried a lower number of positive charges 
(Supplementary Figure 3). For arginine-substituted variants of the kallikrein-derived peptides 
(kCA), uptake was even lower than for the respective control peptides (CA), demonstrating that 
the presence of negatively charged residues in close proximity to arginine residues compromised 
uptake (Supplementary Figure 3). 
After having explored the impact of arginine substitutions within the bicycles, we were interested 
in the activity of bicycles for which arginines were attached externally (EA group). In this way, 
the design of these molecules followed the more classical approach where a cell-penetrating 
moiety is attached to a cargo molecule. At the same time, the arginine residues are not subject to 
conformational constraints any more. Oligoarginines were attached to both ends of the bicycle at 
the same time, or only to the C-terminus. The kallikrein inhibitor was also included to assess the 
impact of the presence of negative charge in this structural arrangement (kEA group).
Again, uptake eficiency correlated positively with the number of arginines (Figure 3). When a stretch 
of eight arginines was added at the C-terminus (EA8), the uptake was twice as high compared 
to two stretches of four arginines at both termini (EA2x4) (for statistics see Supplementary Table 
2). Here, the negative charge of the kallikrein inhibitor had no effect on uptake, which stands 
in sharp contrast to what was observed for the internally substituted bicycles; uptake for the 
analogue extended by an octaarginine (kEA8) and having the kallikrein inhibitor motif was in 
the same range as uptake for the bicycle that carried eight external arginine substitutions (EA8). 
Confocal microscopy experiments revealed mainly endosomal staining (Supplementary Figure 4). 
Cytoplasmic staining was also visible for peptides EA1x8 and kEA1x8 (Figure 3D).
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 Figure 3. Structure-activity relationship of the bicyclic peptides with external oligoarginine elongations (EA 
group). (A, B) Flow cytometry histograms of bicycles and nonaarginine at 5 µM for HeLa cells after 1 h incubation 
with peptides. (C) Average median of at least two flow cytometry measurements and the standard error. (D) 
Subcellular distributions of the bicyclic peptide EA1x8 and kEA1x8 at 5 µM measured by confocal microscopy. The 
same settings were used for image acquisition of both peptides. Scale bar represents 20 µm. 
 
Comparison of bicyclic with linear variants  
Characterization of the bicycles indicated that an external octaarginine stretch promoted uptake as 
effectively as the same number of arginines within the conformationally constrained bicycle. To evaluate 
whether cyclization contributed to activity of these bicycles or whether activity was a function of the 
Figure 3. Structure-activity relationship of the bicyclic peptides with external oligoarginine 
elongations (EA group). (A, B) Flow cytometry histograms of bicycles and nonaarginine at 5 μM for HeLa 
cells after 1 h incubation with peptides. (C) Average median of at least two low cytometry me s rements 
and the standard error. (D) Subc llular dist ibutions of the b cyclic peptid  EA1x8 and kEA1x8 at 5 µM 
measured by confocal microscopy. The same settings were used for image acquisition of both peptides. Scale 
bar represents 20 µm.
Comparison of bicyclic with linear v riants 
Characterization of the bicycles indicated that an external octaarginine stretch promoted uptake 
as effectively as the same number of arginines within the conformationally constrained bicycle. 
To evaluate whether cyclization contributed to activity of these bicycles or whether activity was a 
function of the arrangement of arginines in the primary peptide structure, bicyclic variants were 
tested next to their linear counterparts (Table 1). 
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Figure 4. Uptake of selected bicyclic peptides and their corresponding linear variants after different 
incubation times. HeLa cells were incubated for 1 h (A-D) or 18 h (E-H) with 5 µM of the peptides at 37°C. 
(A-B, E-F) Representative low cytometry histograms. (C, G) Average median of ive (C) or two (G) low 
cytometry measurements and the standard error. All values were corrected for the background luorescence 
(cells incubated without peptides) and medians of each experiment were normalized to nonaarginine (* 
indicates p<0.05, ** p<0.001, *** p<0.0001). (D, H) Confocal microscopy images of the intracellular 
distribution of selected peptides. Different settings were used for image acquisition of peptides after 1 h (D) 
and 18 h incubation (H). Scale bar represents 20 µm.
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Two bicycles with internal substitutions (IA8b, CA6) and two C-terminally extended bicycles with/
without the kallikrein sequence ((k)EA1x8) were included. We restricted our analysis to 5 μM 
peptide concentrations, as before no concentration dependence was observed in the uptake 
experiments. In all cases, uptake of the bicyclic variants was more effective than uptake of the 
linear ones (Figure 4) (for statistics see Supplementary Table 3). Except for differences in uptake 
eficiency, confocal microscopy did not reveal remarkable differences in subcellular localization of 
the peptides. 
Next to assessing uptake eficiency after short-term incubation (1 h), we were also interested in 
determining whether cyclization conferred an advantage over longer incubation times of 18 h. 
In 10% fetal calf serum, nonaarginine is degraded with a half-life of about 1 h [25]. Cyclization 
should protect the peptides against proteolytic breakdown, thereby increasing the cell-associated 
luorescence in comparison to the linear counterparts. Furthermore, we were also interested 
to learn whether luorescence was still punctate or whether a more pronounced release into 
the cytosol would occur. In this analysis, we also included one bicycle with six internal arginine 
substitutions (CA6) to determine whether the potential stabilization to proteolysis over longer 
incubation times would compensate for less eficient uptake over short incubation times.
For most peptides, the cell-associated luorescence was lower after 18 h compared to 1 h, which 
is indicative of proteolytic breakdown followed by release of luorescein [26] (Figure 4). However, 
for all except one peptide (CA6), this drop in luorescence was lower for the cyclic variant than for 
the linear counterpart (Figure 5) (for statistics see Supplementary Table 4). This result demonstrates 
that the spatial constraint also conferred an advantage for long-term activity which is probably 
due to proteolytic stability [26]. Overall, the remaining cell-associated luorescence was higher for 
the peptides with lower charge (CA6). This may be explained either by the fact that these peptides 
entered cells more slowly and were therefore longer protected against proteolytic degradation or 
by a preferential cleavage next to arginine residues. However, after 18 h the punctate subcellular 
distribution of luorescence was even more pronounced than after 1 h, indicating that only those 
peptides that had been sequestered in endolysomal structures were retained, while cytoplasmic 
luorescence was released.
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Figure 4. Uptake of selected bicyclic peptides and their corresponding linear variants after different 
incubation times. HeLa cells were incubated for 1 h (A-D) or 18 h (E-H) with 5 µM of the peptides at 37°C. (A-B, 
E-F) Representative flow cytometry histograms. (C, G) Average median of five (C) or tw  (G) flow cytometry 
measurements and the standard error. All values were corrected for the background fluorescence (cells incubated 
without peptides) and medians of each experiment were normalized to nonaarginine (* indicates p<0.05, ** 
p<0.001, *** p<0.0001). (D, H) Confocal microscopy images of the intracellular distribution of selected peptides. 
Different settings were used for image acquisition of peptides after 1 h (D) and 18 h incubation (H). Scale bar 
represents 20 µm. 
 
Two bicycles with internal substitutions (IA8b, CA6) and two C-terminally extended bicycles 
with/without the kallikrein sequence ((k)EA1x8) were included. We restricted our analysis to 5 μM 
peptide concentrations, as before no concentrati n dependence was obser d in the uptake experiments. 
In all cases, uptake of the bicyclic variants was more effective than uptake of the linear ones (Figure 4) 
(for statistics see Supplementary Table 3). Except for differences in uptake efficiency, confocal 
microscopy did not reveal remarkable differences in subcellular localization of the peptides.  
Next to assessing uptake efficiency after short-term incubation (1 h), we were also interested in 
determining whether cyclization conferred an advantage over longer incubation times of 18 h. In 10% 
fetal calf serum, nonaarginine is degraded with a half-life of about 1 h [25]. Cyclization should protect the 
peptides against prote lytic breakdo n, thereby increasing the cell-associated fluorescence in comparison 
to the linear counterparts. Furthermore, we were also interested to learn whether fluorescence was still 
punctate or whether a more pronounced release into the cytosol would occur. In this analysis, we also 
included one bicycle with six internal arginine substitutions (CA6) to determine whether the potential 
stabilization to proteolysis over longer incubation times would compensate for less efficient uptake over 
short incubation times. 
For most peptides, the cell-associated fluorescence was lower after 18 h compared to 1 h, which is 
indicative of proteolytic breakdown followed by release of fluorescein [26] (Figure 4). However, for all 
except one peptide (CA6), this drop in fluorescence was lower for the cyclic variant than for the linear 
counterpart (Figure 5) (for statistics see Supplementary Table 4). This result demonstrates that the spatial 
constraint also conferred an advantage for long-term activity which is probably due to proteolytic stability 
[26]. Overall, the remaining cell-associated fluorescence was higher for the peptides with lower charge 
(CA6). This may be explained either by the fact t at these peptides entered cells mor  slowly and were 
therefore longer protected against proteolytic degradation or by a preferential cleavage next to arginine 
residues. However, after 18 h the punctate subcellular distribution of fluorescence was even more 
pronounced than after 1 h, indicating that only those peptides that had been sequestered in endolysomal 
structures were retained, while cytoplasmic fluorescence was released. 
 
 Figure 5. Cellular retention of fluorescence. The fluorescence intensity of the 18 h incubation was divided by that 
of the 1 h incubation (from the same experiment), represented by a percentage. The percentages of two experiments 
were averaged and plotted. Error bars show standard errors. 
Figure 5. Cellular retention of luorescence. The luorescence intensity of the 18 h incubation was divided 
by that of the 1 h incubation (from the sam  experiment), represented by a percentage. The percentages of 
two experiments were averaged and plotted. Error bars show standard errors.
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Stability of different classes of bicyclic peptides 
The external elongation with arginines proved to be as eficient in promoting uptake as the 
substitution with the same number of arginines within the bicycles. However, oligoarginines are 
known to serve as substrates for the furin protease [27, 28]. To obtain a direct experimental 
validation for the differences in proteolytic stability, the degradation of two bicyclic peptides was 
followed in serum over time (Figure 6). In human serum the externally elongated peptide kEA1x8 
was less stable than IA6b. The half-life of kEA1x8 was approximately 30 min and the half life of 
IA6b was more than 1 h. The control incubation of the peptides in PBS showed no breakdown of 
the peptide or loss of luorescence.
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Stability of different classes of bicyclic peptides  
The external elongation with arginines proved to be as efficient in promoting uptake as the substitution 
with the same number of arginines within the bicycles. However, oligoarginines are known to serve as 
substrates for the furin protease [27, 28]. To obtain a direct experimental validation for the differences in 
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 Figure 6. Proteolytic stability of IA6b and kEA1x8. The fraction of intact peptide was measured over time when 
incubated in 50% human serum (diluted with PBS) and in PBS. The SEM of three experiments was calculated for 
each condition and varied between 0.1% and 1%. 
 
Interaction of bicyclic and linear peptides with heparan sulfate (HS)  
Previously, we had investigated the thermodynamics of the interaction of linear nonaarginine with HS 
using isothermal titration calorimetry [15]. Even though the role of HS in the induction of peptide uptake 
is still under debate [16], these negatively charged oligosaccharides interact with arginine-rich CPPs at 
the cell surface [12]. In particular, we were interested to learn whether cyclization affected the entropic 
changes related to peptide binding. Next to EA2x4 (with both C- and N-terminal tetra-arginines), the 
internally substituted IA8b bicyclic peptide (with eight arginines) was selected.  
The bicyclic IA8b had a dissociation constant of 0.18 μM which is very similar to the one determined for 
nonaarginine previously [15] (Table 2). Interestingly, the dissociation constant of the peptide with the two 
external tetraarginines (EA2x4) for HS was more than twice as high as that for nonaarginine which is 
fully consistent with the lower uptake efficiency for EA2x4 as compared to IA8b. For both peptides, the 
enthalpy of the reaction and the entropy loss were on the same order of magnitude as for nonaarginine 
(Table 2, Supplementary Figure 6). 
  
Figure 6. Proteolytic stability of IA6b and kEA1x8. The fraction of intact peptide was measured over 
time when incubated in 50% human serum (diluted with PBS) and in PBS. The SEM of three experiments was 
calculated for each condition and varied between 0.1% and 1%.
Interaction of bicyclic and linear peptides with heparan sulfate (HS) 
Previously, we had investigated the thermodynamics of the interaction of linear nonaarginine 
with HS using isothermal ti ration calorimetry [15]. Even though the rol  of HS in the induction 
of peptide uptake is still under debate [16], these negatively charged oligosaccharides interact 
with arginine-rich CPPs at the cell surface [12]. In particular, we were interested to learn whether 
cyclization affected the entr pic changes related to peptide bindi g. Next to EA2x4 (wi h both 
C- and N-terminal tetra-arginines), the internally substituted IA8b bicyclic peptide (with eight 
arginines) was selected. 
The bicyclic IA8b had a dissociation consta t of 0.18 μM which is very similar to the one 
determined for nonaarginine previously [15] (Table 2). Interestingly, the dissociation constant of 
the peptide with the two external tetraarginines (EA2x4) for HS was more than twice as high 
as that for nonaarginine which is fully consistent with the lower uptake eficiency for EA2x4 as 
compared to IA8b. For both peptides, the enthalpy of the reaction and the entropy loss were on 
the same order of magnitude as for nonaarginine (Table 2, Supplementary Figure 6).
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Table 2. Properties of binding of bicyclic peptides to HS.
      enthalpy entropy    
  N Sites/HS K
D
 (µM) ΔH Kcal/mol ΔS cal/(mol*deg) ΔH /molpep ΔH /Arg
EA2x4 (n=3) 12 ± 51 0.45 ± 0.05  -64 ± 3  -180 ± 2  -6.6 ± 3  -0.82 ± 0.42
IA8b (n=2) 14 ± 2 0.18 ± 0.09  -73 ± 4  -214 ± 14  -5.3 ± 1  -0.66 ± 0.13
1Values were obtained by measuring: enthalpy, stoichiometry and afinity. Other properties were determined 
by using Gibbs free energy law. ΔG =-RTlnK
d 
= -ΔH–TΔS. Free energy (ΔG) and entropy (ΔS) were calculated 
with temperature (T) and gas constant (R).
Bicyclic peptides with histidine and tryptophan substitutions
After having shown that the bicylic peptides were retained in the endosomes, we were aiming 
to promote the endosomal escape of these peptides by introducing histidine and/or tryptophan 
residues into the bicyclic peptides. Histidine and tryptophan were already shown to have a 
positive effect on endosomal escape. For histidine this has been assigned to the “proton sponge” 
effect of the imidazole ring leading to the rupture of the endosomes and/or with the capacity 
of the imidazole to interact with the endosomal membrane [29-32]. Moreover, tryptophan can 
destabilize the endosomal membranes by interacting and inserting into the lipid bilayer [33, 34] 
and thereby promote endosomal rupture. We designed three bicyclic peptides (Table 1) based 
on IA5 and EA1x8, one containing four histidine residues (EA8_4H) and two bicycles containing 
both two histidine residues and either one (IA8_2H1W) or two tryptophan residues (EA8_2H2W). 
The peptides showed the same uptake eficiency as nonaarginine, being much higher than the 
uptake eficiencies of the corresponding peptides with only the external or internal arginine 
substitutions (Figure 7). However, the intracellular localization was comparable to that of other 
peptides (Figures 3D, 7C). Nevertheless, the data indicates that introduction of histidine and/or 
tryptophan had a clear added value on uptake eficiency. 
DISCUSSION
Here, we explored the structure-activity relationship of cellular uptake for conformationally 
constrained bicyclic CLIPS-peptides [22]. In particular, we addressed the introduction of cell-
penetrating capacity by substitutions inside the bicycles and by external elongations with 
arginines. All linear tricysteine peptides were synthesized using Fmoc-based solid-phase synthesis 
followed by the very eficient tandem ligation-cyclization reaction with tris(bromomethyl) benzene 
under high dilution conditions (100-500 µM) using the CLIPS- chemistry. The eficiency of these 
reactions is generally very high (>70%) but is slightly sequence-dependent. For the bicyclic 
peptides reported in this paper the overall isolated yields (after preparative HPLC puriication) 
ranged between 30% and 40%. 
150  |  Chapter 6
133 
  
Figure 7. Uptake of bicyclic peptides, modiied with histidine and tryptophan, and R9 in HeLa cells. 
HeLa cells were incubated for 1 h at 37°C with 5 µM of the indicated peptides. (A) Flow cytometry histograms. 
(B) Average median of four low cytometry measurements and the standard error. (C) Subcellular distribution 
of luorescence was visualized by confocal microscopy. The same settings were used for image acquisition of 
all peptides. The scale bar denotes 20 µm.
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Through introduction of arginines, we were able to make the inhibitor for human kallikrein 
protease cell permeable. Overall, there was a positive correlation of import with the number of 
arginine residues. At least four arginine residues were required to achieve a signiicant import, 
both for internal arginine substitutions and for external elongation. Uptake of the bicycles was 
more eficient than that of their linear counterparts, which is consistent with previous data 
from experiments with arginine-rich peptides. It was shown that conformationally constraining 
oligoarginines through cyclization promoted uptake [18]. Furthermore, we had shown for a 
lactoferrin-derived CPP that cyclization through formation of a disulide bridge enhanced the 
interaction with heparan sulfates through a local increase of arginine density [10, 14]. Since the 
internally substituted bicycles had arginines introduced into a scaffold consisting of serines and 
glycines, the lactoferrin-derived peptide may be the more valid comparison.
The fact that the bicycles with the external arginines showed a more eficient uptake than their 
linear counterparts can be explained by the higher compactness in conjunction with a higher 
proteolytic stability afforded by cyclization. In addition, one consecutive stretch of arginine residues 
(EA1x8) was more active in inducing uptake than two external elongations, with each half the 
number of arginines (EA2x4) which demonstrates that local charge density is a decisive factor in 
inducing uptake. It is important to note that despite the fact that the CLIPS-peptides are relatively 
large cargos, through the incorporation of arginine residues, we achieved an uptake eficiency 
that was up to 45% that of nonaarginine. The introduction of histidine and tryptophan residues 
into the arginine-rich bicycles further increased the uptake eficiencies to levels of nonaarginine. 
This is quite remarkable given the fact that the bicyclic scaffold, compared to nonaarginine, may 
be considered a large scaffold which may decrease the uptake eficiency [35]. These structural 
insights will be highly relevant for rendering bioactive, conformationally constrained peptides cell 
penetrating, especially when the pharmacophore contains histidine residues. 
Interestingly, there were no indications of nucleation zone dependent import, also not at higher 
concentrations. Even though for some peptides luorescence was also present in the cytosol, the 
major part of luorescence was conined to punctate structures, strongly indicative of endocytic 
uptake. Therefore, there were also no indications that cyclization increased translocation eficiency, 
relating to a direct membrane permeation without activation of acid sphingomyelinase [36]. In 
contrast, nonaarginine [24] and its cyclic counterpart [18] showed highly eficient nucleation 
zone-dependent import. For the internally substituted peptides, this may be attributed to the 
fact that the induction of this import pathway, which provides direct access into the cytoplasm 
critically depends on local arginine density. For the terminally substituted peptide this is consistent 
with the observation that this import route is compromised by cargo exceeding the size of a small 
peptide [8, 9].
Our results also illustrate the added value of a comparison of long over short incubation times 
for a deeper understanding of the impact of cyclization on import and intracellular sequestration. 
Nowadays, cells are typically incubated with CPPs for 30 min to 1 h only. This choice is primarily 
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motivated by the fact that for longer incubation times the peptides distribute over intracellular 
compartments and as a consequence information on import routes is lost [24]. Also, elimination 
of peptide through proteolytic degradation may superimpose import [26]. However, as cyclization 
improved the proteolytic stability, testing of longer incubation times is particularly useful in 
determining the impact of this modiication on long-term import capacity and intracellular 
retention. In fact, with one exception (CA6), bicyclic peptides showed a stronger intracellular 
retention over longer incubation times than their linear counterparts. 
For two peptides we conirmed that the external elongation was more sensitive to proteolytic 
degradation than the internal substitution. However, although the externally substituted peptide 
was proteolytically less stable (kEA1x8) than the internally substituted one (IA6b), kEA1x8 was 
taken up more eficiently than IA6b. Overall the data indicate that a consecutive stretch of 
arginine residues has the strongest uptake promoting effect. However, the peptide with the 
internal substitution will better retain long-term activity due to a higher proteolytic stability.
Also, for one bicycle (CA6) that showed rather little uptake after 1 h, cell-associated luorescence 
was about as high as that of the other peptides after the longer incubation time. This result also 
indicates that instead of selecting CPPs based on maximum activity during short-term incubation, 
for in vivo applications it would be desirable to select CPPs based on activity during long-term 
incubation, which may identify CPPs with fewer arginines and therefore reduced sequestration 
into the liver and kidney [37, 38].
For several CPPs, the requirement of HS for eficient cellular import has been reported [39, 40]. 
Here, we showed that the afinities of two bicyclic peptides with the same number of arginines 
for HS varied by a factor of 2.5: the bicyclic peptide with eight internal arginines had a 2.5x 
higher afinity compared to the one with two external tetra-arginine stretches. This difference 
in HS afinity is in line with the more eficient uptake of the higher afinity peptide supporting 
the importance of HS for uptake of these bicyclic peptides. However, for both bicycles the 
thermodynamic parameters were in the same range as for nonaarginine, which demonstrates 
that cyclization did not afford an advantage in the entropy changes for HS-binding.
In conclusion, we successfully demonstrated the synthesis and cyclization of cell-penetrating 
bicyclic CLIPS-peptides by the introduction of arginine residues. The CLIPS architecture afforded 
peptides with long-term proteolytic stability that promoted uptake eficiency. In the future, 
the obtained insights will guide the introduction of cell-penetrating capacity into bioactive, 
conformationally constrained peptides.
EXPERIMENTAL PROCEDURES
Cell culture 
HeLa cells originally obtained from the American Type Culture Collection (Rockville, USA) were 
cultured in RPMI 1640 supplemented with 10 % Fetal Calf Serum (FCS) (all from Gibco, Invitrogen, 
Eugene, USA). Cells were grown in an incubator at 37 °C with a humidiied atmosphere and 5% 
CO
2 
for 2 or 3 days before passaging. 
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Peptide synthesis 
All linear tricysteine peptides with an N-terminal carboxyluorescein group were synthesized 
using standard Fmoc-based solid-phase peptide synthesis on a Rink-amide resin. The bicyclic 
peptides were then formed via a tandem ligation-cyclization reaction with equimolar amounts 
of tris(bromomethyl) benzene (1.05 equiv) in a mixture of ACN/H
2
O 1:3 under high dilution 
conditions (typically at 100-500 µM) using ammonium bicarbonate as a base (pH~8.0). The 
eficiency of these reactions is generally very high (>70%) but varies slightly for different sequences. 
The overall isolated yields for the reported bicycles (after preperative HPLC puriication) ranged 
between 30% and 40%.
For the synthesis of the linear variants of the bicycle peptides, we alkylated the linear tricysteine 
peptides with a slight excess (~2 equiv) of iodoacetamide under the same reaction conditions 
as used for the cyclization reaction. The conversions were complete within 1 h and workup and 
puriication of the peptides followed the same route as described for the bicyclic peptides. The 
concentrations of luorescein-labeled peptides were determined by measuring the absorbance 
of luorescein at 492 nm, assuming a molar extinction coeficient in 100 mM Tris-HCl pH 8.8 of 
75 000 cm-1M-1 on a Novaspec II visible spectrophotometer (Pharmacia/Pizer, New York, USA).
Flow cytometry 
HeLa cells were seeded in a 24-well plate (Greiner Bio-One, Kremsmuenster, Austria) at a density 
of 80 000 cells per well 1 day, 40 000 cells per well 2 days before the experiment. Peptides were 
diluted to 5 or 20 µM depending on the experiment in phenol red-free RPMI containing 10% FCS. 
After washing the cells with Hepes-buffered saline (HBS; 10 mM HEPES, 135 mM NaCl, 5 mM KCl, 
5 mM MgCl
2
, 1.8 mM CaCl
2
), 400 µL of the peptide solution was added per well. The peptides 
were incubated for 1 or 18 h at 37 °C followed by washing twice with HBS. For detachment and 
removal of surface-bound peptide, 300 µL trypsin (Pan Biotech, Aidenbach, Germany) was added 
and the cells were incubated for 5 min at 37 °C and washed by centrifugation (5 min, 1000 rpm). 
After resuspension in phenol red-free medium, internalized peptide was quantiied with a FACS-
Calibur Flow Cytometer (BD Biosciences, Erembodegem, Belgium) and gated for living cells based 
on forward versus sideward scatter. For each peptide condition at least 10 000 gated cells were 
measured and analyzed with the Summit software (Fort Collins, USA).
Confocal microscopy 
40 000 HeLa cells per well were seeded in 8-well nunc chambers one day, or 20 000 cells per 
well 2 days in advance of the experiment (Thermo Fisher Scientiic, Rochester, USA). The peptides 
were diluted in phenol red-free RPMI + 10% FCS to 5 or 20 µM. After washing the cells with 
HBS, 200 µL of the solution containing the peptide was added per well. The cells were incubated 
for 1 or 18 h at 37 °C, washed twice with HBS and inally 200 µL phenol red-free RPMI + 10% 
FCS were added per well. The cellular distribution of luorescence was recorded using a TCS SP5 
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confocal microscope (Leica Microsystems, Mannheim, Germany) equipped with an HCX PL APO 
63 x 1.2 N. A. water immersion lens at 37 °C. For excitation of luorescein an argon ion laser was 
used (488 nm) and emission was collected between 500 and 550 nm.
Isothermal Titration Calorimetry (ITC) 
ITC experiments were performed with an ITC
200
 Microcal instrument (Microcal LLC, Wolverton 
Mill, UK). Peptide and HS (average molecular weight 13.6 kDa, Celsus Lab, Cincinnati USA) 
solutions were diluted in HBS to 30 µM and 90 µM, respectively. The sample cell was illed with 
the peptide solution and 38 times 1 µL of the HS solution was injected into the sample cell at 25 
ºC. Data were analyzed using the ITC
200
 microcal software.
Stability Studies
Analysis of proteolytic stabilities of the bicyclic peptides was performed by mixing 1.0 mg/mL 
solutions of the peptide in PBS, containing 100 mg/mL of umbelliferone (Sigma, Aldrich) as an 
internal standard, with equal volumes (1:1) of commercial human serum (Sigma, Aldrich) and 
incubating the samples at 37 ºC. At certain time intervals (1, 2, 4, 8, 16, 32 h), a 50 µL sample 
was taken from the solution, mixed with 100 µL of a 10% solution of triluoroacetic acid (TFA) 
in water (to precipitate serum proteins), centrifuged for 4 min at 13 000 rpm, and subsequently 
analyzed by UPLC/MS (Acquity, Waters) to quantify the amount of remaining peptide by peak 
integration. Peak areas were quantiied using the internal standard umbelliferone and normalized 
to values determined at t=0 s. 
Statistics 
To compare the uptake eficiency between experiments, the median luorescent intensities of the 
tested peptides were normalized to nonaarginine (100%). Statistical analyses were performed 
with Graphpad Prism. In order to compare the signiicance of differences between peptides 
of one group, one-way analyses of variance (Anova) (p<0.05) were performed, followed by a 
Bonferroni correction involving all pairs of comparison. The signiicance of differences between 
the bicyclic and the linear variants was tested using unpaired t-tests. Since in each experiment 
all uptake eficiencies were normalized to the uptake of nonaarginine, for some igures, median 
values for peptides tested in different experiments were averaged and combined in one igure.
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Supplementary Figure 1. Confocal microscopy of the remaining IA group peptides. HeLa cells were incubated 
with the peptides for 1 hour at 37 °C, washed and analyzed by confocal microscopy. IA6c, IA6d and IA8a were 
tested in a separate experiment with different settings than the other peptides.  
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50.19 
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EA2x1 vs kEA2x1 -0.4 0.0246
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No ns -60.84 to 
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EA2x1 vs kEA2x2 -4.95 0.3052 No ns -65.39 to 
55.49 
Supplementary Figure 1. Confocal microscopy of the remaining IA group peptides. HeLa cells were 
incubated with the peptides for 1 hour at 37 °C, washed and analyzed by confocal microscopy. IA6c, IA6d 
and IA8a were tested in a separate experiment with different settings than the other peptides. 
Supplementary Table 1. Statistical analysis of IA group.
One-way analysis of variance          
Bonferroni’s Multiple 
Comparison Test
Mean Diff. t Signiicant? 
P < 0.05?
Summary 95% CI of diff
IA0 vs IA2 -0.7667 0.1712 No ns -17.20 to 15.66
IA0 vs IA4a -3.8 0.8484 No ns -20.23 to 12.63
IA0 vs IA4b -9.633 2.151 No ns -26.06 to 6.798
IA0 vs IA6a -14.73 3.29 No ns -31.16 to 1.698
IA0 vs IA6b -19.21 5.076 Yes *** -33.10 to -5.328
IA0 vs IA6c -10.43 2.329 No ns -26.86 to 5.998
IA0 vs IA6d -14.93 3.334 No ns -31.36 to 1.498
IA0 vs IA8a -31.13 6.951 Yes *** -47.56 to -14.70
IA0 vs IA8b -44.1 11.87 Yes *** -57.72 to -30.48
IA0 vs R9 -99.8 22.28 Yes *** -116.2 to -83.37
IA2 vs IA4a -3.033 0.6773 No ns -19.46 to 13.40
IA2 vs IA4b -8.867 1.98 No ns -25.30 to 7.564
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IA2 vs IA6a -13.97 3.118 No ns -30.40 to 2.464
IA2 vs IA6b -18.45 4.873 Yes ** -32.33 to -4.561
IA2 vs IA6c -9.667 2.158 No ns -26.10 to 6.764
IA2 vs IA6d -14.17 3.163 No ns -30.60 to 2.264
IA2 vs IA8a -30.37 6.78 Yes *** -46.80 to -13.94
IA2 vs IA8b -43.33 11.67 Yes *** -56.96 to -29.71
IA2 vs R9 -99.03 22.11 Yes *** -115.5 to -82.60
IA4a vs IA4b -5.833 1.302 No ns -22.26 to 10.60
IA4a vs IA6a -10.93 2.441 No ns -27.36 to 5.498
IA4a vs IA6b -15.41 4.072 Yes * -29.30 to -1.528
IA4a vs IA6c -6.633 1.481 No ns -23.06 to 9.798
IA4a vs IA6d -11.13 2.486 No ns -27.56 to 5.298
IA4a vs IA8a -27.33 6.103 Yes *** -43.76 to -10.90
IA4a vs IA8b -40.3 10.85 Yes *** -53.92 to -26.68
IA4a vs R9 -96 21.43 Yes *** -112.4 to -79.57
IA4b vs IA6a -5.1 1.139 No ns -21.53 to 11.33
IA4b vs IA6b -9.581 2.531 No ns -23.47 to 4.306
IA4b vs IA6c -0.8 0.1786 No ns -17.23 to 15.63
IA4b vs IA6d -5.3 1.183 No ns -21.73 to 11.13
IA4b vs IA8a -21.5 4.8 Yes ** -37.93 to -5.069
IA4b vs IA8b -34.47 9.281 Yes *** -48.09 to -20.84
IA4b vs R9 -90.17 20.13 Yes *** -106.6 to -73.74
IA6a vs IA6b -4.481 1.184 No ns -18.37 to 9.406
IA6a vs IA6c 4.3 0.9601 No ns -12.13 to 20.73
IA6a vs IA6d -0.2 0.0447 No ns -16.63 to 16.23
IA6a vs IA8a -16.4 3.662 No ns -32.83 to 0.03100
IA6a vs IA8b -29.37 7.908 Yes *** -42.99 to -15.74
IA6a vs R9 -85.07 18.99 Yes *** -101.5 to -68.64
IA6b vs IA6c 8.781 2.32 No ns -5.106 to 22.67
IA6b vs IA6d 4.281 1.131 No ns -9.606 to 18.17
IA6b vs IA8a -11.92 3.149 No ns -25.81 to 1.968
IA6b vs IA8b -24.89 8.766 Yes *** -35.30 to -14.47
IA6b vs R9 -80.59 21.29 Yes *** -94.47 to -66.70
IA6c vs IA6d -4.5 1.005 No ns -20.93 to 11.93
IA6c vs IA8a -20.7 4.622 Yes ** -37.13 to -4.269
IA6c vs IA8b -33.67 9.066 Yes *** -47.29 to -20.04
IA6c vs R9 -89.37 19.95 Yes *** -105.8 to -72.94
IA6d vs IA8a -16.2 3.617 No ns -32.63 to 0.2310
IA6d vs IA8b -29.17 7.854 Yes *** -42.79 to -15.54
IA6d vs R9 -84.87 18.95 Yes *** -101.3 to -68.44
IA8a vs IA8b -12.97 3.492 No ns -26.59 to 0.6572
IA8a vs R9 -68.67 15.33 Yes *** -85.10 to -52.24
IA8b vs R9 -55.7 15 Yes *** -69.32 to -42.08
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Supplementary Table 2. Statistical analysis of EA group.
Table Analyzed EA_5uM-normalized        
One-way analysis of variance          
Bonferroni’s Multiple 
Comparison Test
Mean Diff. t Signiicant? 
P < 0.05?
Summary 95% CI of diff
EA2x1 vs EA2x2 -1.4 0.08631 No ns -61.84 to 59.04
EA2x1 vs EA2x3 -4.35 0.2682 No ns -64.79 to 56.09
EA2x1 vs EA2x4 -10.25 0.6319 No ns -70.69 to 50.19
EA2x1 vs EA1x8 -37.98 2.92 No ns -86.44 to 10.48
EA2x1 vs kEA2x1 -0.4 0.02466 No ns -60.84 to 60.04
EA2x1 vs kEA2x2 -4.95 0.3052 No ns -65.39 to 55.49
EA2x1 vs kEA2x3 -5.95 0.3668 No ns -66.39 to 54.49
EA2x1 vs kEA2x4 -13.3 0.82 No ns -73.74 to 47.14
EA2x1 vs kEA1x8 -43.99 3.528 No ns -90.45 to 2.473
EA2x1 vs R9 -99.05 7.051 Yes *** -151.4 to -46.71
EA2x2 vs EA2x3 -2.95 0.1819 No ns -63.39 to 57.49
EA2x2 vs EA2x4 -8.85 0.5456 No ns -69.29 to 51.59
EA2x2 vs EA1x8 -36.58 2.813 No ns -85.04 to 11.88
EA2x2 vs kEA2x1 1 0.06165 No ns -59.44 to 61.44
EA2x2 vs kEA2x2 -3.55 0.2189 No ns -63.99 to 56.89
EA2x2 vs kEA2x3 -4.55 0.2805 No ns -64.99 to 55.89
EA2x2 vs kEA2x4 -11.9 0.7337 No ns -72.34 to 48.54
EA2x2 vs kEA1x8 -42.59 3.416 No ns -89.05 to 3.873
EA2x2 vs R9 -97.65 6.952 Yes *** -150.0 to -45.31
EA2x3 vs EA2x4 -5.9 0.3637 No ns -66.34 to 54.54
EA2x3 vs EA1x8 -33.63 2.586 No ns -82.09 to 14.83
EA2x3 vs kEA2x1 3.95 0.2435 No ns -56.49 to 64.39
EA2x3 vs kEA2x2 -0.6 0.03699 No ns -61.04 to 59.84
EA2x3 vs kEA2x3 -1.6 0.09864 No ns -62.04 to 58.84
EA2x3 vs kEA2x4 -8.95 0.5518 No ns -69.39 to 51.49
EA2x3 vs kEA1x8 -39.64 3.179 No ns -86.10 to 6.823
EA2x3 vs R9 -94.7 6.742 Yes *** -147.0 to -42.36
EA2x4 vs EA1x8 -27.73 2.132 No ns -76.19 to 20.73
EA2x4 vs kEA2x1 9.85 0.6073 No ns -50.59 to 70.29
EA2x4 vs kEA2x2 5.3 0.3268 No ns -55.14 to 65.74
EA2x4 vs kEA2x3 4.3 0.2651 No ns -56.14 to 64.74
EA2x4 vs kEA2x4 -3.05 0.188 No ns -63.49 to 57.39
EA2x4 vs kEA1x8 -33.74 2.706 No ns -80.20 to 12.72
EA2x4 vs R9 -88.8 6.322 Yes *** -141.1 to -36.46
EA1x8 vs kEA2x1 37.58 2.89 No ns -10.88 to 86.04
EA1x8 vs kEA2x2 33.03 2.54 No ns -15.43 to 81.49
EA1x8 vs kEA2x3 32.03 2.463 No ns -16.43 to 80.49
EA1x8 vs kEA2x4 24.68 1.898 No ns -23.78 to 73.14
EA1x8 vs kEA1x8 -6.008 0.7661 No ns -35.23 to 23.21
EA1x8 vs R9 -61.07 6.007 Yes *** -98.95 to -23.19
kEA2x1 vs kEA2x2 -4.55 0.2805 No ns -64.99 to 55.89
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kEA2x1 vs kEA2x3 -5.55 0.3422 No ns -65.99 to 54.89
kEA2x1 vs kEA2x4 -12.9 0.7953 No ns -73.34 to 47.54
kEA2x1 vs kEA1x8 -43.59 3.496 No ns -90.05 to 2.873
kEA2x1 vs R9 -98.65 7.023 Yes *** -151.0 to -46.31
kEA2x2 vs kEA2x3 -1 0.06165 No ns -61.44 to 59.44
kEA2x2 vs kEA2x4 -8.35 0.5148 No ns -68.79 to 52.09
kEA2x2 vs kEA1x8 -39.04 3.131 No ns -85.50 to 7.423
kEA2x2 vs R9 -94.1 6.699 Yes *** -146.4 to -41.76
kEA2x3 vs kEA2x4 -7.35 0.4531 No ns -67.79 to 53.09
kEA2x3 vs kEA1x8 -38.04 3.051 No ns -84.50 to 8.423
kEA2x3 vs R9 -93.1 6.628 Yes *** -145.4 to -40.76
kEA2x4 vs kEA1x8 -30.69 2.461 No ns -77.15 to 15.77
kEA2x4 vs R9 -85.75 6.105 Yes *** -138.1 to -33.41
kEA1x8 vs R9 -55.06 5.814 Yes *** -90.35 to -19.78
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Supplemental Figure 2. (A, B, E, F) Flow cytometry histograms of bicylic peptides and nonaarginine at 20 µM for 
HeLa cells after 1 h incubation with peptides. (C, G) Average median of two flow cytometry measurements and the 
standard error. 
Supple ental Figure 2. (A, B, E, F) Flow cytometry histograms of bicylic peptides and nonaarginine at 
20 μM for HeLa cells after 1 h incubation with peptides. (C, G) Average median of two low cytometry 
measu ements and the standard error.
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Supplemental Figure 3. Structure - activity relationships of the (k)CA bicyclic peptide set. (A, B, E, F) Flow 
cytometry histograms of bicycles and nonaarginine at (A, B) 5 µM and (E, F) 20 µM for HeLa cells after 1 h 
incubation with peptides. (C) Average median of at least two flow cytometry measurements and the standard error. 
(G) Median is showing a single experiment. All values were corrected for background of cells incubated without 
peptides. (D) Confocal microscopy of the bicyclic peptides CA4 and CA6. Scale bar represents 20 µm. 
Supple ental Figure 3. Structure - activity relationships of the (k)CA bicyclic peptide set. (A, B, E, F) Flow 
cytometry histograms of bicycles and nonaarginine at (A, B) 5 μM and (E, F) 20 μM for HeLa cells after 1 h 
incubation with peptides. (C) Average median of at least two low cytometry measurements and the standard 
error. (G) Median is showing a single experiment. All values were corrected for background of cells incubated 
without peptides. (D) Confocal microscopy of the bicyclic peptides CA4 and CA6. Scale bar represents 20 µm.
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Supplementary Figure 4. Confocal microscopy of the remaining EA group peptides. HeLa cells were incubated 
with 5 µM of the peptides for 1 hour at 37 °C washed and analyzed by confocal microscopy. The scale bar 
corresponds to 20 µm. The EA and kEA images were are obtained in different experiments. 
Supplementary Table 3. Statistical analysis of bicyclic peptides compared to linear peptides after 1h incubation. 
Table Analyzed 
1h_5uM 
    
Column A IA8b CA6 EA1x8 kEA1x8 
Supplementary Figure 4. Confocal microscopy of the remaining EA group peptides. HeLa cells were 
incubated with 5 µM of the peptides for 1 hour at 37 °C washed and analyzed by confocal microscopy. The 
scale bar corresponds to 20 µm. The EA and kEA images were are obtained in different experi ents.
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Supplementary Table 3. Statistical analysis of bicyclic peptides compared to linear peptides after 1h 
incubation.
Table Analyzed
1h_5uM
Column A IA8b CA6 EA1x8 kEA1x8
vs vs vs vs vs
Column B IA8b L CA6 L EA1x8 L kEA1x8 L
Unpaired t test        
P value 0.0001 0.0049 0.2603 0.0656
P value summary *** ** ns ns
Are means signif. different? 
(P < 0.05)
Yes Yes No No
One- or two-tailed P value? Two-tailed Two-tailed Two-tailed Two-tailed
t, df t=5.817 df=11 t=3.594 df=10 t=1.193 df=10 t=1.997 df=14
Supplementary Table 4. Statistical analysis of bicyclic peptides compared to linear peptides after 18 h 
incubation.
Table Analyzed
18h_5uM
Column A IA8b CA6 EA1x8 kEA1x8
vs vs vs vs vs
Column B IA8b L CA6 L EA1x8 L kEA1x8 L
Unpaired t test        
P value 0.0014 0.0106 0.0005 0.0496
P value summary ** * *** *
Are means signif. different? 
(P < 0.05)
Yes Yes Yes Yes
One- or two-tailed P value? Two-tailed Two-tailed Two-tailed Two-tailed
t, df t=7.911 df=4 t=3.657 df=6 t=6.846 df=6 t=2.453 df=6
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Supplemental Figure 5. Confocal microscopy with 5 µM of the selected bicyclic and linear peptides after 1 h (A) 
and 18 h incubation (B) in HeLa cells. Different settings were used for image acquisition of peptides after 1 hour (A) 
and 18 hour incubation (B). 
 
Supplemental Figure 5. Confocal microscopy with 5 µM of the selected bicyclic and linear peptides after 1 h 
(A) and 18 h incubation (B) in HeLa cells. Different settings were used for image acquisition of peptides after 
1 hour (A) and 18 hour incubation (B).
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Supplemental Figure 6. Interaction between bicyclic or linear peptides and HS determined by ITC. The amount of 
heat released upon binding of HS per injection over time for the indicated peptides. In the top plot the change of heat 
over time is recorded, with on the y-axes the µcal/sec and on the x-axes Molar ratio and time (min). Each injection is 
represented by one peak. In the bottom plots the integrated heat per injection is indicated by a point value, where the 
y-axes is kcal/mole of the injectant and the x-axes is molar ratio. Representative recordings for EA2x4 (A) and IA8b 
(B). 
 
 
  
Supplemental Figure 6. Interaction between bicyclic or linear peptides and HS determined by ITC. The 
amount of heat released upon binding of HS per injection over time for the indicated peptides. In the top plot 
the change of heat over time is recorded, with on the y-axes the µcal/sec and on the x-axes Molar ratio and 
time (min). Each injection is represented by one peak. In the bottom plots the integrated heat per injection 
is indicated by a point value, where the y-axes is kcal/mole of the injectant and the x-axes is molar ratio. 
Representative recordings for EA2x4 (A) and IA8b (B).
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ABSTRACT
A small library of oligoarginine peptides equipped with terminal cysteines was studied with 
respect to their cell-penetrating properties. The peptides themselves were inactive but gained the 
ability to enter cells upon extension of their sequence through disulide bridge formation. 
Cell-penetrating peptides (CPPs) are peptides that can induce the cellular uptake of (bio)molecules 
that otherwise only poorly enter cells [1, 2]. Because of this, they are being regarded as promising 
tools for drug delivery [3]. However, there are still major challenges that hamper the pharmaceutical 
use of CPPs [4]. Despite being extensively studied, the exact mechanism of cellular uptake is yet to 
be elucidated and varies among different classes of CPPs [5]. Nevertheless, it is generally agreed 
that after connecting a large cargo to a CPP, these complexes are almost exclusively taken up by 
endocytosis [6]. Therefore, circumventing endocytotic entrapment of the CPP payload will make 
CPPs more suitable for pharmaceutical use [7]. But perhaps most importantly, the clinical use of 
CPPs is limited because of the lack of cell-type speciicity of most CPPs and because temporal 
control over their uptake is still unavailable [4]. Recently, we and others have reported delivery 
systems in which an inactivated CPP can be activated by an external trigger, such as UV-light, 
a change in pH or enzymatic cleavage [8-10]. However these triggers may be phototoxic or 
require tumor-induced pH shifts or speciic enzymatic activity. Here we present a redox-sensitive 
activatable system based on disulide bridge formation. This physiologically benign coupling 
chemistry between two cysteines allows the combination of two truncated and inactivated CPPs 
into a functional system and has the potential to become a useful complementary strategy for the 
modular activation of cellular uptake.
One of the most promising classes of CPPs are the oligoarginines [11]. Interestingly, these CPPs only 
show cellular uptake ability if a minimum amount of six arginines are present in a single sequence 
[12, 13]. This inspired us to investigate if by conjugation of two smaller inactive oligoarginine 
fragments an active conjugate could be obtained. Here we show this to be a feasible strategy. 
Activation of CPPs by disulfide bridge formation of truncated precursors  |  169
7
153 
 
 
Figure 1: Schematic structures of truncated peptides (R3, R4, R5), activating peptides (*R3, *R4, *R5), 
extended peptides (R3–R5, R4–R4, R4–R5, R5–R3, R5–R4, R5–R5), non-reducible peptide (R4–t–R4), R8 and 
the peptides containing the hydrophobic spacer (R4-Aoc-R5, R5-Aoc-R4). 
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A truncated and thus inert CPP was synthesised that could be selectively linked to a complementary 
short oligoarginine to obtain an active CPP. The irst peptide, the ‘‘truncated peptide’’ (R4) (Figure 
1, truncated peptide R4), consisted of four arginine residues and had a C-terminal cysteine 
residue to provide a handle for linkage to the second (activating) peptide. This activating peptide 
(*R4) consisted of a tetra-arginine stretch and a cysteine residue at the N-terminus (Figure 1, 
activating peptide *R4). Its thiol was functionalised with 3-nitro-2-pyridinesulfenyl (Npys), which 
both protects the thiol and activates it for rapid disulide bridge formation at neutral pH [14]. 
Using this protecting group, homodimerization of the peptides was circumvented.
To allow luorescence-based techniques for evaluation of uptake eficiency, the truncated peptide 
was N-terminally labelled with luorescein isothiocyanate (FITC) using an ε-aminohexanoic acid 
spacer (Ahx). By mixing the truncated and activating peptide at pH 7.5, a disulide-linked peptide 
was obtained, consisting of 8 arginines and an N-terminal FITC-label (Figure 1 – extended peptide 
R4–R4). 
Cellular uptake into HeLa cells of both the truncated peptide (R4) and the extended peptide 
(R4–R4) was visualised using confocal luorescence microscopy. Cells were incubated with 5 µM 
peptide in serum-containing medium for 30 minutes at 37 °C. This experiment showed that the 
truncated peptide was indeed not able to enter cells, whereas, much to our satisfaction, the 
extended peptide clearly showed cellular uptake. Encouraged by these results, a small library 
of peptides (Figure 1) was synthesized to further investigate this induced activity. The additional 
truncated and activating peptides that were obtained consisted of three or ive arginines. By 
combining these peptides, ive extended peptides were obtained, composed of 8 or 9 arginine 
residues in total (Figure 1).
Even though disulide bridges are stable in the extracellular environment, they are prone to 
reduction in intracellular compartments [15]. To investigate the inluence of the reducibility of the 
linkage, a triazole-linked variant (R4–t–R4) of the disulide-linked R4–R4 peptide was synthesized 
(Figure 1). This peptide was obtained after a copper catalyzed click reaction [16] between a 
tetra-arginine peptide functionalised with azido-homoalanine at its N-terminus and another 
tetra-arginine sequence containing propargylglycine at its C-terminus. Furthermore, linear octa- 
(R8) and nona-arginine (R9) were used as positive controls to compare the uptake behavior of 
the disulide-linked peptides to native linear oligoarginines. These control peptides were also 
N-terminally labeled with FITC. 
This small peptide library allowed us to study the relation between uptake behaviour and subtle 
structural differences, e.g. by varying the position of the disulide bridge. The uptake eficiency 
of the peptides at a concentration of 5 µM in HeLa cells was quantiied using low cytometry 
and visualised using confocal luorescence microscopy (Figure 2A). Prior to the experiments it 
was demonstrated using Ellman’s test [17] that the disulide bridge of the extended peptides 
was intact, and a free thiol was present in the case of the truncated peptides. For reference, R8, 
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R9 and the triazole-linked peptide (R4–t–R4) were also studied. The main observation of these 
experiments was that the truncated peptides were indeed inactive, whereas the extended peptides 
showed a clear uptake. The peptides did not show any toxic effects (Supplementary Figure S1). 
Interestingly, the extended peptides consisting of eight arginine residues were all internalised 
with eficiencies comparable to that of control peptide R8. Furthermore, the reducibility of the 
disulide bridge did not inluence the uptake properties, as the extended peptide R4–R4 was 
taken up to the same extent as its triazole-linked analogue R4–t–R4. However, for the peptides 
containing nine arginine residues, a striking difference in uptake was found between extended 
peptide R4–R5 and extended peptide R5–R4. While R4–R5 was taken up nearly as eficiently as 
R9, R5–R4 was taken up even less than R4–R4. The position of the disulide bridge is the only 
distinction between the two peptides, suggesting that this signiicantly inluences the uptake 
eficiency of these extended peptides. To explain this difference, three additional peptides were 
synthesised: the R5–R5 peptide and analogues to R4–R5 and R5–R4, for which the two arginine 
parts were linked together via an aminooctanoic acid spacer (Aoc) instead of a disulide bridge; 
FITC–Ahx–RRRR–Aoc– RRRRR–NH2 (R4–Aoc–R5, Figure 1) and FITC–Ahx–RRRRR– Aoc–RRRR–
NH2 (R5–Aoc–R4, Figure 1). Using aminooctanoic acid as a spacer, the atomic distance between 
the two peptide parts remains the same, however lexibility and hydrophobicity are introduced. 
Uptake of these additional peptides was tested using low cytometry under the same conditions 
as in the previous experiment.
Interestingly, for R5–R5 the same diminished uptake was observed as for R5–R4. Furthermore, the 
aminooctanoic acid linked peptides showed a similar difference in uptake eficiency as between 
R4–R5 and R5–R4, albeit less pronounced (Figure 3).
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Arginine-rich peptides are substrates as well as inhibitors of furin proteases and either role depends on the 
length of the peptide [18]. As our experiments were performed in the presence of serum, differences in 
uptake efficiency may be related to differences in sensitivity to proteolytic breakdown. Fluorescence 
correlation spectroscopy (FCS) was carried out to study the stability of the peptides in serum over time. 
This showed that the extended peptides were equally or more stable in serum than control peptide R9 
(Supplementary Figure S2). 
To study the uptake behaviour of the extended peptides more carefully, cellular localisation studies using 
confocal fluorescence microscopy were carried out (Figure 2). Again, HeLa cells were treated with 5 µM 
of peptides for 30 min at 37 °C. We observed no fluorescence for the truncated peptides, indicating that 
they were indeed not taken up. The positive controls, R8 and R9, showed clear punctuate spots indicating 
endocytosis. Similar patterns were observed for the corresponding extended peptides R4–R4, R3–R5, R4–
R5 and R5–R3. Again, the uptake of R5–R4 and R5–R5 was diminished. These results corroborate the 
flow cytometry experiment.  
Because it was previously described that the mechanism in which arginine-rich CPPs can enter cells is 
strongly concentration dependent [19], both flow cytometry and confocal fluorescence studies were 
repeated at a higher concentration of 20 µM (Figure 2B). The flow cytometry experiment showed an 
interesting difference in internalization efficiency among the peptides containing eight arginines. The 
extended peptide R4–R4 showed to be taken up equally well as the positive control R8, however, the 
uptake of peptides R3–R5 and R5–R3, as well as that of the triazole-linked analogue R4–t–R4, was 
slightly diminished. In the same experiment, the uptake of the extended peptides, R4–R5 and R5–R4, was 
compared to the positive control R9. Now, both extended peptides were taken up much less efficiently 
than R9. This is a remarkable observation compared to the results obtained at 5 µM, where R4–R5 was 
taken up in the same amount as R9. Interestingly, uptake of R5–R5 was increased compared to R4–R5 
and R5–R4, but this peptide was still taken up less efficiently than R4–R4. These results suggest that at a 
high concentration (20 µM) other CPP sequence characteristics influence the uptake than those that 
govern this process at a lower concentration (5 µM). Confocal fluorescence studies allowed us to 
investigate this observation in more detail. This experiment showed that at high concentration several 
Figure 2: Uptake studies of truncated and extended peptides at 5 (A) and 20 µM (B) in serum-containing 
medium. Cell were incubated for 30 minutes and washed. Bar diagrams show low cytometry results. 
Confocal luorescence images of the indicated peptides are shown. 
Arginine-rich peptides are substrates as well as inhibitors of furin proteases and either role 
depends on the length of the peptide [18]. As our xperiments were performed in the pres nce 
of serum, differences in uptake eficiency may be related to differences in sensitivity to proteolytic 
breakdown. Fluorescence correlation spectroscopy (FCS) was carried out to study the stability of 
the peptides in serum o er time. This showed that the extended peptides were equally or more 
stable in serum than control peptide R9 (Supplementary Figure S2).
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To study the uptake behaviour of the extended peptides more carefully, cellular localisation 
studies using confocal luorescence microscopy were carried out (Figure 2). Again, HeLa cells 
were treated with 5 µM of peptides for 30 min at 37 °C. We observed no luorescence for the 
truncated peptides, indicating that they were indeed not taken up. The positive controls, R8 and 
R9, showed clear punctuate spots indicating endocytosis. Similar patterns were observed for the 
corresponding extended peptides R4–R4, R3–R5, R4–R5 and R5–R3. Again, the uptake of R5–R4 
and R5–R5 was diminished. These results corroborate the low cytometry experiment. 
Because it was previously described that the mechanism in which arginine-rich CPPs can enter 
cells is strongly concentration dependent [19], both low cytometry and confocal luorescence 
studies were repeated at a higher concentration of 20 µM (Figure 2B). The low cytometry 
experiment showed an interesting difference in internalization eficiency among the peptides 
containing eight arginines. The extended peptide R4–R4 showed to be taken up equally well 
as the positive control R8, however, the uptake of peptides R3–R5 and R5–R3, as well as that 
of the triazole-linked analogue R4–t–R4, was slightly diminished. In the same experiment, the 
uptake of the extended peptides, R4–R5 and R5–R4, was compared to the positive control R9. 
Now, both extended peptides were taken up much less eficiently than R9. This is a remarkable 
observation compared to the results obtained at 5 µM, where R4–R5 was taken up in the same 
amount as R9. Interestingly, uptake of R5–R5 was increased compared to R4–R5 and R5–R4, but 
this peptide was still taken up less eficiently than R4–R4. These results suggest that at a high 
concentration (20 µM) other CPP sequence characteristics inluence the uptake than those that 
govern this process at a lower concentration (5 µM). Confocal luorescence studies allowed us 
to investigate this observation in more detail. This experiment showed that at high concentration 
several different uptake mechanisms can play a role, depending on the position of the disulide 
bridge, the amount of arginines present in the peptide sequence and the hydrophobicity of 
the peptide. For the positive control R8, three distinctive localisations of luorescence can be 
observed: punctate spots that originate from endocytosis, diffuse signals in the cytosol indicating 
either endosomal escape or direct translocation, but also bright luorescent cells. The latter 
might have been caused by uptake through nucleation zones [20]. Similar results were obtained 
for R4–R4, while its triazole-linked analogue R4–t–R4 mainly showed cytosolic staining but no 
uptake via nucleation zones. Interestingly, for peptides R3–R5 and R5–R3 only punctuate spots 
were observed. For R9, uptake via nucleation zones seemed to be the main mechanism of entry. 
Remarkably, for peptides R4–R5 and R5–R4 only punctate signals were observed; however, 
for R5–R5 all three luorescence patterns (described above) were observed. For R5–R5 we also 
observed some aggregation of the peptide on the cell membrane, which might have caused a 
slight overestimation of the luorescence signal in the low cytometry experiment.
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R4 and R5–R5) yields more active CPPs. Furthermore, it was observed that the extended peptide R4–R3 
could not induce uptake, suggesting that a minimum of 8 arginine residues is needed for extended 
peptides to become active CPPs (Figure 3). A final indication that the spatial arrangement of 
oligoarginines appears to be crucial for inducing specific pathways was obtained from the uptake 
experiment of the aminooctanoic acid linked peptides R4–Aoc–R5 and R5–Aoc–R4 (Figure 3). In 
contrast to the disulfide bridge extended peptides R4–R5 and R5–R4, R4–Aoc–R5 and R5–Aoc–R4 are 
taken up by several mechanisms, with great similarity to R9. This indicates that next to structural 
arrangement of the arginine residues, the hydrophobicity and flexibility of the peptide also play a role in 
uptake. 
In brief, we have shown the possibility of activating a set of truncated oligoarginines into cell-penetrating 
peptides by extending their sequence through disulfide linkage to complementary oligoarginines. The 
uptake efficiency of the resulting extended peptides heavily depended on the arrangement of arginine 
residues. This system offers a new, physiologically relevant strategy to control the moment of uptake of 
CPPs. 
  
Figure 3: Uptake studies of peptides containing the Aoc spacer compared to the other extended peptides 
and R4-R3 at 5 (A) and 20 µM (B) in serum-containing medium. Cells were incubated for 30 minutes and 
washed. Bar diagrams show low cytometry results. Confocal luorescence images of the indicated peptides. 
Previous reports describe that uptake via nucleation zones is concentration-dependent but is 
also highly inluenced by the peptide sequence [20, 21]. This uptake process is considered to be 
much faster than endocytosis, causing a large difference in uptake eficacy among the extended 
peptides, depending on whether or not uptake via nucleation zones is achieved. Our results 
suggest that the position of the disulide bridge, and hence the structural arrangement of the 
arginine residues thus strongly inluences the mechanism of uptake. This corroborates earlier 
work by Wender t al., in which oligoarginines were interrupted by various lexible spacers, 
inducing changes in uptake eficacy and mechanisms [22]. Our indings furthermore indicate that 
a symmetric distribution of th  guani inium groups in the peptide (R4–R4 and R5– ) yields mo  
active CPPs. Furthermore, it was observed that the extended peptide R4–R3 could not induce 
uptake, suggesting that a minimum of 8 arginine residues is needed for extended peptides to 
become active CPPs (Figure 3). A inal indication that the spatial arrangement of oligoarginines 
appears to be crucial for inducing speciic pathways was obtained from the uptake experiment 
of the aminooctanoic acid linked peptides R4–Aoc–R5 and R5–A c–R4 (Figure 3). In contrast 
to the disulide bridge extended peptides R4–R5 and R5–R4, R4–Aoc–R5 and R5–Aoc–R4 are 
taken up by several mechanisms, with great similarity to R9. This indicates that next to structural 
arrangement of the arginine residues, the hydrophobicity and lexibility of the peptide also play 
a role in uptake.
In brief, we have shown the possibility of activating a set of truncated oligoarginines into cell-
penetrating peptides by extending their sequence through disulide linkage to complementary 
oligoarginines. The uptake eficiency of the resulting extended peptides heavily depended on the 
arrangement of arginine residues. This system offers a new, physiologically relevant strategy to 
control the moment of uptake of CPPs.
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EXPERIMENTAL SECTION
Reagents
NovaPEG Rink amide resins and polystyrene Rink amide resins were purchased from Novabiochem 
and Fmoc-L-amino acids from Bachem (Bubendorf, Switzerland) or Novabiochem (EMD Chemicals, 
Gibbstown, USA). Boc-Cys(Npys) was obtained from Bachem (Bubendorf, Switzerland). Fmoc-
L-γ-azidohomoalanine was purchased from Chiralix (Nijmegen, The Netherlands). Fmoc-ε-
aminohexanoic acid was purchased from Novabiochem and Fmoc-8- aminooctanoic acid from 
Sigma Aldrich. Dulbecco’s modiied Eagle medium, fetal bovine serum, and RPMI were obtained 
from Invitrogen, Eugene, U.S.A.). The cell counting kit (CCK-8) was obtained from Dojindo 
Molecular Technologies (Rockville, U.S.A.). Carboxyluorescein-labelled nona-arginine was 
purchased from EMC microcollections (Tübingen, Germany). All other chemicals were purchased 
from Baker, Fluka or Sigma Aldrich and used as received.
Peptide synthesis
General peptide synthesis
Peptides were synthesised on NovaPEG Rink amide or polystyrene Rink amide resins using a 
Labortec640 peptide synthesizer (Labortec, Bubendorf, Switzerland), employing a standard 
Fmoc solid-phase peptide synthesis (SPPS) protocol. In brief, the resin was swollen in DMF for 
30 minutes prior to use. The Fmoc protecting groups were removed by washing the resin with 
piperidine in DMF (20%, v/v) and then shaking it 3 times for 6 minutes with another portion of 
piperidine in DMF. The desired sequence of amino acids was coupled to the resin using Fmoc-L-
amino acids (3.0 equiv), diisopropylcarbodiimide (DIPCDI, 3.3 equiv) and N-hydroxy benzotriazole 
(HOBt, 3.6 equiv). Peptide couplings were monitored using the Kaiser test. After the inal Fmoc 
removal the resin was washed with DMF, DCM, i-PrOH, DCM, i-PrOH and air-dried for at least 2 h.
Synthesis of luorescein-labeled peptides
The following peptides were synthesised using standard SPPS as described above: 
R3 (FITCAhxArgArgArgCys- NH
2
), R4 ((FITC-AhxArgArgArgArgCys-NH
2
), R5 
((FITCAhxArgArgArgArgArgCys- NH
2
),R8 ((FITC-AhxArgArgArgArgArgArgArgArg-
NH
2
), R4-Aoc-R5 (FITC-AhxArgArgArgArgAocArgArgArgArgArg-NH
2
) and R5-Aoc-R4 
(FITCAhxArgArgArgAocArgArgArgArgArgArg- NH
2
) For these peptides, the last coupling step 
was performed using luorescein isothiocyanate (FITC, 2 equiv.) and N,N-diisopropylethylamine 
(DIEA, (3 equiv.) in DMF/DCM (1:1 v/v). The reaction was monitored by using the Kaiser test [23]. 
The peptides were cleaved from the resin by suspension in a mixture of triluoroacetic acid/water/
triisopropyl-silane/thioanisole (90:5:2.5:2.5 v/v/v/v) for 6 h. The free peptides were precipitated in 
Et
2
O, redissolved in water and lyophilised yielding the crude peptides. The crude peptides were 
puriied by reversed phase HPLC and subsequently lyophilised yielding a yellow powder. Purity 
was evaluated by analytical reversed-phase HPLC and identity conirmed by mass spectrometry.
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Synthesis of activating peptides
The following peptides were synthesised using standard SPPS as described above:
*CR3 (C(Npys)ArgArgArg-NH
2
); *CR4 (C(Npys)ArgArgArg-NH2) ) and *CR5 (C(Npys)ArgArgArg-
NH
2
). The last coupling was performed using 3 equiv. Boc-Cys(Npys), 3.3 equiv DIPCDI and 3.6 
equiv HOBt in DMF. The peptides were cleaved from the resin by suspension in a mixture of 
triluoroacetic acid/water/triisopropyl-silane(92.5:5:2.5 v/v/v) for 6 h. The free peptides were 
precipitated in Et
2
O, redissolved in water and lyophilised yielding the crude peptides. The crude 
peptides were puriied by reversed phase HPLC yielding a yellow powder after lyophilisation. Purity 
was evaluated by analytical reversed phase HPLC and identity conirmed by mass spectrometry.
Preparation of extended peptides
Disulide linkage between the activating and truncated peptides was achieved by dissolving the 
truncated peptide in a 0.1 M degassed sodium phosphate buffer (pH 7.4) and subsequently 
mixing it with 1.1 equiv. activating peptide. During this reaction, the inal peptide concentration 
was 1 to 5 mM. The reaction was monitored by reversed-phase HPLC. At the end of the reaction, 
the resulting peptides were puriied by reversed-phase HPLC on a C18 column, using a linear 
gradient of acetonitrile in an aqueous solution containing 0.1% (v/v) TFA. After lyophilisation, the 
peptides were obtained as yellow powders. All peptides were obtained with a purity > 95%, as 
assessed by analytical reversed phase HPLC. Peptides were analyzed by mass spectrometry on a 
Thermo Finnigan LCQ-Advantage MAX ESI-ion trap.
Synthesis of triazole-linked peptide R4-t-R4
R4-Ppg and Azh-R4 were synthesised using standard SPPS as described above. Structures are 
shown in Supplementary Figure 3. The copper-mediated click-reaction between the two peptides 
was performed by dissolving 0.99 μmol of both peptides together with 24 μmol CuSO
3
·5H
2
O in 
water (1 mL). Lutidine (49.4 μmol) was suspended in the reaction mixture and stirred under Ar 
over night. Sodium ascorbate (20.0 μmol) was added and the reaction was stirred for another 
night. The crude peptide was puriied by reversed-phase HPLC on a C18 column, using a linear 
gradient of acetonitrile in an aqueous solution containing 0.1% (v/v) TFA. After lyophilisation, 
the peptide was obtained as a yellow powder with a purity of > 95% as assessed by analytical 
reversed phase HPLC.
Cell culture
HeLa cells were maintained in sterile conditions in DMEM or RPMI (Gibco, Invitrogen, Eugene, 
U.S.A.) supplemented with 10 % heat-inactivated fetal calf serum (FCS; PAN Biotech). All cells 
were incubated at 37 ºC in a humidiied atmosphere of 5 % CO
2
. Cells were passaged every 2 
to 3 days.
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Flow cytometry
HeLa cells were seeded in 24-well plates (Sarstedt, Numbrecht, Germany) one (80,000 cells/well) 
or two (40,000 cells/well) days prior to the experiment. On the day of the experiment, cells were 
incubated with the peptide solutions (5 μM or 20 μM) for 30 min at 37°C in RPMI + 10% FCS. 
After washing the cells with HBS buffer pH 7.4 (10 mM HEPES, 135 mM NaCl, 5 mM KCl, 5 
mM MgCl
2
, 1.8 mM CaCl
2
), cells were detached by trypsinisation for 5 minutes, spun down and 
resuspended in 200 μL RPMI + 10% FCS. The luorescence was measured using a FACSCalibur 
low cytometer (BD Biosciences, Erembodegem, Belgium) and subsequently data was analyzed 
with the Summit software (Fort Collins, USA). Results were based on 10,000 gated cells.
Confocal laser scanning microscopy
HeLa cells were seeded in chambered coverslips (Nunc, Wiesbaden, Germany) at a density of 
40,000 cells (one day) or 20,000 cells per well (two days prior) to the experiment. Cells were 
incubated with the indicated peptide concentrations for 30 min at 37 ºC. Cells were washed twice 
after incubation with RPMI + 10 % FCS and living cells were analysed immediately by confocal 
microscopy using a TCS SP5 confocal microscope (Leica Microsystems, Mannheim, Germany) 
equipped with an HCX PL APO 63 x N.A. 1.2 water immersion lens. Cells were maintained at 37 
ºC on a temperature-controlled microscope stage. Fluorescein was excited by an argon laser at 
488 nm and emission was collected between 500 and 550 nm. 
This work was inancially supported by the Dutch Science Foundation (NWO) and by the Ministry 
of Education, Culture and Science (Gravity program 024.001.035). Petra Bovee-Geurts is 
acknowledged for help with the luorescence correlation spectroscopy measurements.
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 Figure S1: Cell viability of the peptides. Cell viability was evaluated using Cell Counting Kit-8 (CCK-
8, Dojindo Molecular Technologies, U.S.A). HeLa cells were seeded in 96-well plates to obtain 40,000 
cells/well the day of the experiment. On the day of the experiment, cells were incubated with 100 µL 
peptide solution in DMEM for 30 minutes at 37°C. Cells were washed 3 times with DMEM + 10% FCS 
and maintained in this solution after the last washing step. After 4 hours of incubation, the supernatant 
was removed and a solution of CCK-8 (10 % in DMEM + 10% FCS) was added. After 3 hours of 
incubation at 37 °C, the absorbance was measured at 450 nm using a microplate reader (Wallac Victor 
1420 multilabel counter, Perkin Elmer). The experiments were performed in triplicates and repeated twice 
independently. A value of 100% survival was obtained by measuring cells that were not incubated with 
peptides and viability of cells treated with the peptides was calculated from this. Mean values +/- SEM 
are given. 
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PBS. Samples were thawed on ice and diluted 200 times with Tris buffer pH 8.8. 20 µL of this diluted 
solution was taken for FCS measurement. Measurements (per samples 5 measurements of 20 s) were 
performed on a TCS SP5 confocal microscope (Leica Microsystems) equipped with a dual channel FCS 
unit using an Argon laser for the excitation of fluorescein at 488 nm. Data was analyzed with a 2 
component fit using the ISS VISTA. 
 
 
 
Figure S3: Structures of R4-Ppg and Azh-R4. 
  
  
Figure S2: Stability of the peptides was measured by Fluorescence correlation spectroscopy. Peptide 
samples (5 μM) were prepared in HBS supplemented with 10% FCS and heated to 37ºC using a heat block. 
Aliquots (5 μL) were collected at the indicated time points, diluted 20 times with protease inhibitor cocktail 
and were directly frozen (Roche, Mannheim, Germany). After 8h proteinase K (2 mg/mL) (Roche, Mannheim, 
Germany) was added to the remaining peptide solution and incubated for 5 h at 37ºC. After this incubation, 
the sample was treated as the previous samples. For FCS measurements, 384 well plates were coated with 
0.1% BSA (Roche, Mannheim, Germany) for 30 min and washed twice with PBS. Samples were thawed on ice 
and diluted 200 times with Tris buffer pH 8.8. 20 μL of this diluted solution was taken for FCS measurement. 
Measurements (per samples 5 measurements of 20 s) were performed on a TCS SP5 confocal microscope 
(Leica Microsystems) equipped with a dual channel FCS unit using an Argon laser for the excitation of 
luorescein at 488 nm. Data was analyzed with a 2 component it using the ISS VISTA.
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SUMMARY AND FUTURE DIRECTIONS
During the last decades, detailed insights were obtained into the molecular mechanisms of 
diseases which resulted in a paradigm change in drug development towards a target-oriented 
drug discovery approach. Drug development aims at designing molecules in such a way that they 
only address the desired target, thereby eliciting the desired therapeutic response and avoiding 
off-target effects. The drawback of this approach is that designed drugs with activity against a 
certain target frequently do not possess drug-like characteristics. In particular, the physicochemical 
properties of the candidate drug may not be suitable for clinical applications. One possibility to 
overcome this hurdle is the combination with drug delivery vectors, for example nanoparticles. 
Nanoparticles can be modiied so that they overcome the limitations of the barriers the drug has 
to cross. In addition, nanoparticles can protect the drug from degradation and the polymers, 
which constitute the matrix of the nanoparticles, can be selected in such a way that they enable 
the encapsulation of various drugs and to achieve controlled release of the encapsulated drug. 
Drug delivery vehicles can be functionalized with targeting molecules to increase the local drug 
dose at the site of interest and if the target resides inside cells, also penetration enhancers can 
be used to increase the internalization. In this way, it is aimed to increase the therapeutic effects 
and reduce the side effects.
This thesis is about cell-penetrating peptides (CPPs) which act as penetration enhancers to 
overcome the plasma membrane and deliver drugs directed against intracellular targets. Since 
the irst step in the internalization of CPPs and CPP-conjugated drugs is the encounter with the 
plasma membrane, understanding of interactions with components of the plasma membrane 
and the role of these for uptake has been one active area in CPP research.
Research in this thesis aimed at obtaining a better understanding of the structural requirements 
of CPPs on the one hand and the composition of the plasma membrane on the other hand which 
favor eficient internalization of the CPPs. These new insights will contribute to the development 
of new drug delivery vehicles. Chapter 1 provides a general introduction to CPPs and their 
application in drug development.
The role of glycosaminoglycans in the delivery of cell-penetrating peptides
Cell-penetrating peptides and most other drug delivery vectors are cationic. When cells are exposed 
to these delivery vectors, the irst component these peptides encounter is the glycocalyx, a thick 
layer of sugar molecules with the anionic glycosaminoglycans (GAGs) being one of the major 
components. Therefore, it is not surprising that CPPs interact with the GAGs. However, a critical 
literature review revealed that the subsequent effect on uptake depends on the characteristics of 
the CPP (chapter 2). We compared the involvement of GAGs between CPPs with that of other 
drug delivery vectors and viruses. It became clear that GAGs by themselves are probably not 
acting autonomously in internalization. Rather, GAGs may be acting as coreceptors and/or GAG 
clusters may recruit yet unknown receptors.
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In chapters 3 and 4 we designed several variants of the human lactoferrin-derived CPP hLF 
and the transportan analog TP10 and characterized these variants with regard to GAG binding 
and clustering, and subsequent internalization. We had shown before that the arginine-rich 
hLF peptide requires a disulide bridge for eficient internalization [1]. In chapter 3 we show 
that by introducing arginine residues into the linear peptide, which lacks the disulide bridge, 
the uptake could be restored to levels of the wildtype peptide. However, a circular variant with 
additional arginine residues was internalized even better than the linear variant. When measuring 
the thermodynamic parameters of the GAG-hLF interaction by isothermal titration calorimetry, 
we identiied a clear correlation between the stoichiometry of binding and the uptake eficiency: 
the fewer peptide molecules were bound to one GAG molecule, the more eficient was the 
internalization. Next to the number of arginine residues also the circular conformation of 
the peptide affected the stoichiometry. This result may be interpreted in a way that peptides 
with a low-stoichiometry may have a better cross-linking ability for the GAGs than the high-
stoichiometry peptides. However, if cross-linking of GAGs by CPPs promotes uptake, then this 
cross-linking is not equivalent with clustering, as it was identiied in chapter 4. Dynamic light 
scattering revealed enormous differences in the size of clusters formed by different amphipathic 
TP10 analogs and one type of GAG. This formation of large clusters, which was conirmed on 
live cells using metabolic labeling of sialic acids, did not result in an increased uptake. It was 
hypothesized that the clusters were too large to be internalized. 
The effect of the lipid composition on the uptake mechanism
Next to endocytosis and nucleation zone-dependent uptake, there is also the possibility for direct 
permeation into cells at low micromolar concentrations. Interestingly, when comparing HEK and 
HeLa cells, evidence for direct penetration was only obtained for HEK but not for HeLa cells. In 
chapter 5 we analyzed which differences between these two cell lines are determinants for this 
direct permeation. The most obvious explanation for the difference in uptake mechanism between 
HEK and HeLa cells had been the composition of the glycocalyx. A thick glycocalyx could, for 
example, compromise direct interactions of the peptides with the plasma membrane. However, 
there were no major differences in the glycocalyx composition detected and enzymatic removal 
of the glycocalyx did not change the uptake mechanism. In addition, the membrane potential 
was long regarded as a driving force for CPP uptake. We could show, however, that for these two 
cell lines not the membrane potential but the lipid composition of the plasma membrane is the 
decisive factor for direct permeation. When lipids were extracted from the plasma membranes 
of these two cell lines and analyzed by mass spectrometry, clear differences in sphingomyelin 
levels were detected. Whereas sphingomyelin was present in HeLa cells, it was almost completely 
absent in HEK cells indicating that sphingomyelin compromises direct permeation. As further 
support for this model, in HeLa cells, direct permeation requires the conversion of sphingomyelin 
into ceramide [2]. Based on these results, we establish a concept of resistant and permissive 
membranes for import of arginine-rich cell-penetrating peptides.
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Structural requirements of CPPs
The cyclization of peptides was described to improve uptake eficiency which was attributed to 
an increased conformational coninement of the arginine residues [3] and an improved resistance 
against proteolytic degradation. In chapter 6 we explored structural principles to render bicyclic 
peptides cell-penetrating. These bicyclic peptides have a molecular weight of 2-3 kDa and can 
be regarded as a general conformationally constrained scaffold for bioactive molecules. Next to 
a general structure containing only glycine and serine residues, we also included an inhibitor for 
the human plasma protease kallikrein as a model. In general, uptake eficiencies depended on the 
number of arginine residues. The addition of a stretch of eight arginines outside the cycles was 
as eficient as the introduction of arginines inside the cycles. However, variants with the internal 
substitutions were less prone to proteolytic degradation. In general, bicylic peptides were shown 
to be more stable than their linear counterparts demonstrating a clear advantage of the bicyclic 
peptides. Next to arginines, the introduction of histidine and tryptophan residues also promoted 
uptake. 
Chapter 7 describes a strategy to render short oligoarginines, which are too short to be internalized 
by cells, cell-permeable. This strategy involved disulide bridge formation between two short 
oligoarginine chains. We could show that the uptake eficiency and mechanism depended on 
the positioning of the disulide bridge within the peptide. Whereas rapid cytoplasmic uptake 
via nucleation zones was only observed for peptides with a symmetric arrangement of arginine 
residues and a minimum of four arginine residues in each peptide chain, for endocytosis only very 
speciic arrangements of arginine residues were unfavorable for uptake. In particular, the uptake 
eficiency of two peptides which contained ive arginine residues N-terminal of the disulide 
bridge and four or ive arginine residues C-terminal of the disulide bridge was compromised. 
When the disulide bridge was replaced by a hydrophobic polycarbon linker, we observed a 
positive effect on nucleation zones and only a small or no effect on endocytosis indicating that 
the hydrophobicity and lexibility of the linker between the two oligoarginines also had an effect 
on the internalization eficiency.
Future directions
Cell-penetrating peptides have been subject to extensive fundamental and applied research 
for more than 20 years. These peptides were shown to have a broad spectrum of applications 
ranging from delivery of peptides to oligonucleotides and to nanoparticles. Nowadays, an 
increasing number of CPP-conjugates are entering clinical trials (see Table 2 in chapter 1). Despite 
the considerable structural variety of CPPs, it is quite remarkable that all conjugates which are 
currently in clinical trials are conjugated to Tat or a Tat variant which may be attributed to the 
fact that for this peptide the irst proof-of-concept of in vivo delivery was obtained [4]. It will be 
important to explore further CPPs for in vivo applications to identify possibly even more suitable 
candidates.
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For introduction of cell permeability two strategies can be followed: either a CPP can be covalently 
conjugated or complexed to a therapeutic molecule; or an active molecule, for example a peptide 
inhibitor, could be rendered cell-permeable by the incorporation of a cell-penetrating activity. 
Given the fact that arginine residues and in particular the guanidinium groups are promoting the 
internalization into cells, this knowledge can be used to make an existing (therapeutic) peptide 
cell-permeable, as we have shown for a bicyclic scaffold (chapter 6). Another example are the 
supercharged proteins in which amino acids at the protein surface are mutated into lysine or 
arginine residues yielding net charges ranging from -30 to +48 [5]. The delivery eficiency of a 
protein conjugated to a positively charged GFP protein was improved enormously compared to a 
protein conjugated to a CPP [6].
In this thesis, detailed structure-activity relationships are provided for the interaction between 
cell-penetrating peptides and components of the glycocalyx which differ for amphipathic and 
arginine-rich peptides. Since the composition of the glycocalyx differs between cell types, these 
indings might be exploited for targeting certain CPPs to speciic tissues or cell types. CPPs were 
shown to clearly differ in their tissue distribution [7]. Further insights into the uptake mechanism 
should lead to an enhancement of cell- or tissue-tropism of CPPs. 
In addition, also the insights into the role of the lipid composition for direct penetration could 
be exploited for cell-speciic targeting. It had been shown that resistant cancer cells could be 
sensitized for a chemotherapeutic drug, which was due to increased internalization of the 
chemotherapeutic drug, by decreasing the sphingomyelin levels [8]. In addition, glioma cells were 
shown to contain only low levels of sphingomyelin [9]. Therefore, a higher internalization of 
the CPP into glioma cells is expected compared to other cells. This characteristic could then be 
exploited by conjugating a CPP to a chemotherapeutic drug, thereby promoting the eficient 
internalization into glioma cells. A detailed lipid analysis of cancer cells and healthy cells, for 
example by imaging mass spectrometry [10], would provide important information on whether 
increased sphingomyelin levels are a general characteristic of resistant cancer cells. If this was 
true, then decreasing sphingomyelin levels in combination with CPP-mediated drug delivery 
might be applied as a general new concept to promote elimination of resistant cancer cells.
A question that still remains to be answered is whether nucleation zones relect local differences in 
lipid composition. Such analyses would beneit from molecular probes speciic for particular lipid 
environments. Several luorescent probes are available that bind to components of the plasma 
membrane, such as annexin for phophatidylserine or cholera toxin which binds the glycolipid 
ganglioside [11]. However, the disadvantage of these probes is that the luorophore may inluence 
the behavior of the lipid leading to changes in the distribution compared to the endogenous 
situation. Therefore, metabolic labeling of lipids is probably the most suitable method for the 
visualization of lipids [12].
Summary and Future directions  |  187
8
Conclusion
In this thesis, we analyzed the requirements for the eficient internalization of cell-penetrating 
peptides from two points of view. First, we identiied the importance of components of the 
plasma membrane at the sugar as well as at the lipid level which are promoting the internalization 
of cell-penetrating peptides. Second, we provided new insights into the structural requirements 
of cell-penetrating peptides. This information may not only contribute to the development of 
more eficient and cell-speciic CPPs but also to drug delivery vehicles and drugs in general. 
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Gedurende de afgelopen decennia is er steeds meer gedetailleerd inzicht verkregen in de 
moleculaire mechanisme van ziekten. Dit heeft in de ontwikkeling van medicijnen tot een 
verandering geleid naar een aanpak gericht op het ziekte veroorzakende molecuul.
Bij de ontwikkeling van medicijnen wordt ernaar gestreefd de medicijnen op een zodanige manier 
te ontwerpen dat ze alleen aangrijpen op het gewenste doelwit om het gewenste therapeutisch 
effect te veroorzaken en om bijwerkingen te voorkomen. Het nadeel van deze aanpak is dat de 
ontworpen medicijnen vaak niet de eigenschappen van een goed medicijn bezitten. Zo is het 
mogelijk dat de fysisch-chemische eigenschappen van het ontworpen medicijn niet geschikt zijn 
voor klinische toepassingen. Een mogelijkheid om dit probleem op te lossen is de combinatie 
met “drug delivery” vectoren, bijvoorbeeld nanopartikelen. Nanopartikelen kunnen zodanig 
gemodiiceerd worden dat ze de barrières kunnen overkomen die het medicijn moet passeren. 
Verder kunnen de nanopartikelen het medicijn beschermen tegen afbraak. De polymeren, die 
de basis van de nanopartikelen vormen, kunnen zodanig worden gekozen dat het mogelijk is 
om verschillende medicijnen in te sluiten en om een gecontroleerde vrijgave van het medicijn te 
bewerkstelligen. Er bestaat de mogelijkheid de “drug delivery” vectoren te functionaliseren met 
“targeting” moleculen om de lokale dosis van het medicijn op de juiste plek te verhogen. Als het 
doelwit binnen in de cellen zit, kunnen opnameverbeteraars gebruikt worden. Op deze manier 
wordt ernaar gestreefd om het therapeutisch effect te verhogen en de bijwerkingen te verlagen.
Dit proefschrift gaat over één type opnameverbeteraars, de cel-penetrerende peptiden (CPPs). 
Dit zijn kleine eiwitten, die door cellen opgenomen kunnen worden en de opname van 
medicijnen en andere moleculen kunnen bevorderen. De eerste stap in de opname van CPPs en 
CPP-geconjugeerde medicijnen is de ontmoeting met het plasmamembraan. Daarom is er veel 
onderzoek gedaan naar de interactie van CPPs met componenten van het plasmamembraan.
Het onderzoek dat in dit proefschrift beschreven staat is erop gericht om de structurele 
voorwaarden van CPPs en de samenstelling van het plasmamembraan die belangrijk zijn voor een 
goede opname van de CPPs beter te begrijpen. In het eerste hoofdstuk wordt een algemene 
inleiding gegeven over CPPs en hun gebruik in de medicijn ontwikkeling. 
De functie van glycosaminoglycanen voor de opname van cel-penetrerende peptiden
Cel-penetrerende peptiden en de meeste andere “drug delivery” vectoren zijn positief geladen. 
Als de cellen in contact komen met deze vectoren, komen ze het eerst een dikke suikerlaag 
tegen die vooral de negatief geladen glycosaminoglycanen (GAGs) bevat. Daarom is het geen 
verassing dat de CPPs interacties aangaan met GAGs. Door een kritische literatuurstudie bleek 
dat het effect op de opname afhankelijk is van de karakteristieken van het CPP (hoofdstuk 2). 
Het belang van de interactie tussen de GAGs en CPPs is vergeleken met andere “drug delivery” 
vectoren en virussen. Het werd duidelijk dat de GAGs niet alleen invloed hebben op de opname-
eficiëntie, maar GAGs blijken als coreceptor te werken. Verder is te vermoeden dat GAG clusters 
andere, nog niet bekende receptoren rekruteren.
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In hoofdstukken 3 en 4 werden verschillende varianten van de CPPs hLF en van de transportan 
analoog TP10 ontworpen en de binding aan GAGs en GAG clustering van de varianten gemeten. 
Het hLF peptide is afkomstig van het humane melk eiwit en heeft een zwavelbrug nodig voor 
een eficiënte opname. Het lineaire hLF peptide heeft de zwavelbrug verloren en wordt niet door 
de cellen opgenomen. In hoofdstuk 3 staat beschreven dat door het toevoegen van arginine 
residuen aan het lineaire hLF peptide de opname hersteld kan worden. Desalniettemin werd de 
circulaire variant met de zwavelbrug en extra arginine residuen beter opgenomen dan de lineaire 
variant. Door het meten van de thermodynamische parameters van de GAG-hLF interactie werd 
een correlatie van de stoichiometrie en de opname-eficiëntie gevonden: hoe minder peptiden 
aan een GAG molecuul waren gebonden, hoe beter was de opname-eficiëntie. Dit resultaat zou 
erop kunnen duiden dat de peptiden met een lage stoichiometrie beter in staat zijn om de GAGs 
bij elkaar de brengen dan de peptiden met een hoge stoichiometrie. Als dit het geval is, is het 
bij elkaar brengen van de GAGs niet hetzelfde als het clusteren, wat in hoofdstuk 4 beschreven 
staat. Grote verschillen in de grootte van de clusters tussen een speciiek GAG en verschillende 
varianten van het amipathische TP10 peptide werden geïdentiiceerd. De vorming van grote 
clusters leidde niet tot een betere opname, waarschijnlijk omdat de clusters te groot waren om 
opgenomen te kunnen worden.
Het effect van de lipide compositie op het opname mechanisme
CPPs worden via verschillende mechanismen in cellen opgenomen. Welke route ze volgen, is 
vooral afhankelijk van de concentratie van het peptide maar ook van het cell type. In hoofdstuk 
5 werden twee verschillende cellijnen (HeLa en HEK cellen) met elkaar vergeleken om uit te 
zoeken waarom een speciiek opname mechanisme alleen plaats vind in het ene celtype (HEK) 
maar niet in het ander (HeLa). Bij dit opname mechanisme komen de arginine-rijke peptiden al 
bij een lage concentratie in het cytoplasma van de cellen terecht. De makkelijkste verklaring zou 
een verschil in de suikercompositie van de cellen zijn geweest want een dikke suikerlaag zou de 
directe interactie met het plasmamembraan kunnen voorkomen. Toch waren er slechts kleine 
verschillen in de suikersamenstelling aanwezig. Ook had het verwijderen van de suikers geen 
invloed op het opname mechanisme van de CPPs. Een lange tijd dacht men dat het membraan 
potentiaal de drijvende kracht is voor de opname van CPPs. We hebben laten zien dat dit niet 
het geval is maar dat de lipidecompositie van de cellen de bepalende factor is voor de beschreven 
opname route. Duidelijke verschillen in de lipidecompositie van de twee cellijnen werden 
aangetoond. Een speciiek lipide, sphingomyeline, was in HeLa cellen aanwezig en nauwelijks in 
HEK cellen. Dit verschil duidde erop dat de aanwezigheid van sphingomyeline de directe opname 
in het cytoplasma negatief beïnvloedt. In HeLa cellen vereist de directe opname de omzetting 
van sphingomyeline in ceramide. Op basis van deze resultaten werd de hypothese opgesteld dat 
HeLa cellen een resistent membraan hebben, veroorzaakt door sphingomyeline, en HEK cellen 
een permeabel membraan. 
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Structurele voorwaarden voor CPPs
In hoofdstuk 6 werd onderzoek gedaan naar structurele principes om bicyclische petiden cell-
penetrerend te maken. Deze bicyclische peptiden, die zijn opgebouwd uit twee ringen, hebben 
een molecuulgewicht van 2-3 kDa en mogen daarom gezien worden als algemeen “scaffold” 
voor bioactieve moleculen. De opname-eficiënties waren in het algemeen afhankelijk van het 
aantal arginine residuen. Het toevoegen van een reeks arginine residuen buiten de ringen leidde 
tot dezelfde opname-eficiënties als het toevoegen van de arginines binnen de ringen. Echter 
waren de varianten met de arginines binnen de ringen stabieler. Een duidelijk voordeel van de 
bicyclische peptiden is dat ze stabieler zijn dan de lineaire varianten. Verder bevorderde het 
toevoegen van histidine en tryptofaan ook de opname.
In hoofdstuk 7 wordt een manier beschreven om korte ketens van arginines, die te kort zijn om 
opgenomen kunnen worden, celpermeabel te maken. In deze strategie worden langere ketens 
van arginines gevormd door een koppeling van de twee korte ketens via een zwavelbrug. Het 
werd duidelijk dat de opname-eficiëntie en het -mechanisme afhankelijk zijn van de positie van 
de zwavelbrug in het peptide. Voor de opname bij hogere peptide concentraties was het vooral 
belangrijk dat even veel arginine residuen aan de twee kanten van de zwavelbrug zaten. Bij 
lagere peptide concentraties hadden alleen heel speciieke rangschikkingen van de arginines een 
negatief effect op de opname-eficiëntie via endocytose. Het vervangen van de zwavelbrug door 
een hydrofobe linker had alleen een positief effect bij hogere peptide concentraties. 
In dit proefschrift staan de voorwaarden voor een eficiënte opname van cel-penetrerende 
peptiden vanuit twee verschillende oogpunten beschreven. Eerst staat beschreven hoe de 
samenstelling van het plasmamembraan, zowel op het suiker- als op het lipideniveau, de opname 
van de CPPs beïnvloedt. Verder zijn nieuwe inzichten voor de structurele voorwaarden van cell-
penetrerende peptiden gegeven. Deze informatie zal niet alleen bijdragen aan de ontwikkeling 
van nieuwe, meer eficiënte en cell-speciieke CPPs, maar ook aan “drug delivery” vectoren en 
medicijnen in het algemeen. 
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DEUTSCHE ZUSAMMENFASSUNG
In den letzten Jahren wurden immer mehr neue Erkenntnisse über die molekularen Mechanismen 
von Krankheiten erworben. Dies hat in der Medikamentenentwicklung dazu geführt, dass neue 
Medikamente jetzt gerichtet auf Zielmoleküle entwickelt werden. 
Bei der Entwicklung von Medikamenten wird beabsichtigt, dass sie ausschließlich am speziischen 
Angriffspunkt wirken, um den gewünschten therapeutischen Effekt zu erzielen. Der Nachteil bei 
dieser Strategie ist, dass die entworfenen Moleküle oft nicht die Eigenschaften von einem guten 
Medikament besitzen. Zum Beispiel kann es sein, dass die physico-chemischen Eigenschaften 
nicht für eine klinische Anwendung geeignet sind. Eine Möglichkeit, um dieses Problem zu lösen, 
ist die Kombination mit “drug delivery“ Vektoren, zum Beispiel Nanopartikeln. Nanopartikel 
können so modiiziert werden, dass sie die Barrieren, die das Medikament überwinden muss, 
überqueren können. Weiterhin können Nanopartikel Medikamente vor dem Abbau schützen. 
Die Polymere, die die Basis für die Nanopartikel bilden, können so ausgewählt werden, dass 
unterschiedliche Medikamente in die Nanopartikel eingeschlossen werden können und eine 
kontrollierte Freisetzung des Medikaments ermöglicht wird. Es besteht die Möglichkeit, “drug 
delivery“ Vektoren mit “targeting“ Molekülen zu funktionalisieren, um die lokale Dosis von dem 
Medikament an dem Zielort zu erhöhen. Wenn der Wirkungsort des Medikaments innerhalb 
der Zellen liegt, können Permeationserhöher verwendet werden, um die Aufnahme in die Zellen 
zu verbessern. Diese Strategie zielt darauf, den therapeutischen Effekt zu erhöhen und die 
Nebenwirkungen zu reduzieren. 
In dieser Doktorarbeit geht es um einen bestimmten Typ von Penetrationserhöhern, die zell-
penetrierenden Peptide (CPPs). Dies sind kleine Eiweiße, die von Zellen aufgenommen werden 
und die Aufnahme von Medikamenten und anderen Molekülen verbessern können. Da der erste 
Schritt bei der Aufnahme von CPPs und CPP-konjugierten Medikamenten die Wechselwirkung 
mit der Plasmamembran ist, wird viel Forschung betrieben, um die Interaktionen zwischen CPPs 
und den Bestandteilen der Plasmamembran besser zu verstehen.
Das Ziel dieser Doktorarbeit war die strukturellen Bedingungen der CPPs und der Bestandteile 
der Plasmamembran zu identiizieren, die für eine gute Aufnahme der CPPs sorgen. Diese 
neuen Kenntnisse werden zu der Entwicklung neuer “drug delivery“ Vektoren beitragen. 
In dem ersten Kapitel wird eine allgemeine Einleitung über CPPs und ihren Einsatz in der 
Medikamentenentwicklung gegeben.
Die Funktion von Glykosaminoglykanen bei der Aufnahme von zell-penetrierenden 
Peptiden
Zell-penetrierende Peptide und die meisten anderen “drug delivery” Vektoren sind positiv geladen. 
Wenn die Zellen mit diesen Vektoren in Kontakt kommen, treffen die Vektoren zuerst auf eine 
dicke Zuckerschicht, die vor allem aus Glykosaminoglykanen (GAGs) besteht. Deshalb ist es nicht 
überraschend, dass die CPPs mit diesen Zuckern interagieren. Eine kritische Literaturstudie hat 
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ergeben, dass der Effekt von den GAGs auf die CPP-Aufnahme von den Eigenschaften der CPPs 
abhängt (Kapitel 2). Die Beteiligung von GAGs bei der Aufnahme von CPPs wurde mit der von 
anderen “drug delivery” Vektoren und Viren verglichen. Es wurde deutlich, dass nicht die GAGs 
alleine die Aufnahme beeinflussen, sondern dass sie wahrscheinlich eher als Korezeptor dienen 
oder dass GAG-Cluster andere, noch unbekannte Rezeptoren, rekrutieren.
In den Kapiteln 3 und 4 wurden verschiedene Varianten der CPPs hLF und des Transportan 
Analogs TP10 entworfen und die Bindung an GAGs sowie die Bildung von GAG Clustern 
untersucht. Das hLF Peptid stammt aus dem humanen Lactoferrin und benötigt eine Disulfidbrücke 
für eine effiziente Aufnahme. Das lineare hLF Peptid, dem die Disulfidbrücke fehlt, wird nicht in 
Zellen aufgenommen. In Kapitel 3 wird beschrieben, dass das Hinzufügen von Argininresten in 
das lineare hLF Peptid die Aufnahme wieder instand setzt. Dennoch wurde das Peptid mit der 
Disulfidbrücke und den zusätzlichen Argininresten noch besser aufgenommen. Die Messung der 
thermodynamischen Parameter der GAG-hLF Interaktion ergab eine Korrelation zwischen der 
Stoichiometrie und der Aufnahmeeffizienz: je weniger Peptide an ein GAG Molekül banden, 
desto besser war die Aufnahme. Dieses Ergebnis deutet darauf hin, dass Peptide mit einer 
geringen Stoichiometrie in der Lage sind, die GAGs nah zueinander zu bringen und unterscheidet 
sich von der Bildung von Clustern, was in Kapitel 4 gezeigt wird. Es wurden große Unterschiede 
in der Größe der Cluster zwischen einem bestimmten GAG und verschiedenen Varianten des 
amphipatischen TP10 Peptides identifiziert. Die Bildung von großen Clustern hat nicht zu einer 
besseren Aufnahme geführt, wahrscheinlich weil die Cluster zu groß waren, um aufgenommen 
zu werden. 
Der Einfluss der Lipidzusammensetzung auf den Aufnahmemechanismus
CPPs werden mittels verschiedener Mechanismen in die Zellen aufgenommen. Welcher 
Mechanismus anzutreffen ist, wird vor allem von der Peptidkonzentration, aber auch von dem Zelltyp 
bestimmt. In Kapitel 5 wurden zwei Zelllinien (HeLa und HEK Zellen) miteinander verglichen, um 
herauszufinden warum ein bestimmter Aufnahmemechanismus nur in einem der zwei Zelltypen 
statt findet, nämlich in HEK Zellen. Bei diesem Aufnahmemechanismus werden argininreiche 
Peptide schon bei einer niedrigen Konzentration in das Zytoplasma der Zellen aufgenommen. Die 
einfachste Erklärung wäre ein Unterschied in der Glycocalyx der Zellen, da eine dicke Glycocalyx 
zum Beispiel die direkte Interaktion mit der Plasmamembran verhindern kann. Allerdings wurden 
keine großen Unterschiede in der Zusammensetzung der Glycocalyx festgestellt und das Entfernen 
der Zucker führte nicht zu einer Änderung des Aufnahmemechanismus. Eine lange Zeit bestand 
die Annahme, dass das Membranpotential die treibende Kraft für die Aufnahme von CPPs ist. 
Hier wurde gezeigt, dass dies nicht der Fall ist, sondern dass die Lipidzusammensetzung der Zellen 
der entscheidende Faktor ist für den genannten Aufnahmemechanismus. Deutliche Unterschiede 
in der Lipidzusammensetzung wurden identifiziert. Ein bestimmtes Lipid, Sphingomyelin, wurde 
in HeLa Zellen ausfindig gemacht und war in HEK Zellen kaum vorhanden. Dieser Unterschied 
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weist darauf hin, dass Sphingomyelin die direkte Aufnahme der Peptide in das Zytoplasma 
beeinträchtigt. Die direkte Aufnahme in HeLa Zellen erfordert die Umsetzung von Sphingomyelin 
in Ceramid. Auf Grund dieser Ergebnisse wurde die Hypothese aufgestellt, dass HeLa Zellen eine 
widerstandsfähige Plasmamembran haben und HEK Zellen eine durchlässige.
Strukturelle Merkmale von zell-penetrierenden Peptide
In Kapitel 6 wurde eine Studie durchgeführt, um strukturelle Prinzipien zu identiizieren, 
bizyklische Peptide zell-penetrierend zu machen. Diese bizyklischen Peptide, die aus zwei Ringen 
aufgebaut sind, haben ein Molekülgewicht von 2-3 kDa und können deshalb als allgemeines 
Gerüst für bioaktive Molekule gesehen werden. Allgemein hing die Aufnahmeefizienz von 
der Anzahl der Argininreste ab. Das Hinzufügen von einer Kette von Argininresten außerhalb 
der Ringe oder Argininresten innerhalb der Ringe ergab die gleiche Aufnahmeefizienz. Die 
Peptide mit den Argininen innerhalb der Ringe waren allerdings stabiler. Ein deutlicher Vorteil 
von bizyklischen Peptiden verglichen zu linearen Peptiden war die höhere Stabilität. Weiterhin 
förderte das Hinzufügen von Histidin und Tryptophanresten die Aufnahme. 
In Kapitel 7 wird eine Methode beschrieben, um kurze Ketten von Argininen, die zu kurz sind, 
um aufgenommen zu werden, zell-penetrierend zu machen. In dieser Strategie wurden mittels 
einer Disulidbrücke lange Argininketten gebildet. Es wurde deutlich, dass die Aufnahmeefizienz 
und der -mechanimus von der Position der Disulidbrücke abhingen. Für die Peptidaufnahme 
bei hohen Konzentrationen war es vor allem wichtig, dass gleich viele Arginine an beiden Seiten 
der Disulidbrücke vorhanden waren. Bei der Aufnahme bei niedrigeren Peptidkonzentrationen 
hatten nur sehr spezielle Anordnungen von den Argininen einen negativen Einluss auf die 
Aufnahmeefizienz. Der Austausch der Disulidbrücke mit einem hydrophoben Linker hatte bei 
hohen Peptidkonzentrationen einen positiven Einluss auf die Aufnahme. 
In dieser Doktorarbeit wurden die Bedingungen für eine efiziente Aufnahme von zell-
penetrierenden Peptiden aus zwei Gesichtspunkten beschrieben. Zunächst wurde die Bedeutung 
der Zusammensetzung der Plasmamembran auf dem Zucker- und Lipidniveau für die Aufnahme 
von CPPs beschrieben. Dann wurden neue Kenntnisse über die strukturellen Bedingungen 
von zell-penetrierenden Peptiden gesammelt. Diese neuen Kenntnisse werden nicht nur zu 
der Entwicklung von neuen, efizienteren und zell-speziischen CPPs beitragen, sondern auch 
allgemein zu neuen “drug delivery” Vektoren und Medikamenten.
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